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Abstract 
 
 
Hume, Patrick S. (Ph.D., Chemical Engineering) 
Department of Chemical and Biological Engineering, University of Colorado 
 
Improvement of the immunoisolation capacity of PEG hydrogels through bioactive 
modifications 
 
Thesis directed by Professor Kristi S. Anseth 
 
 
 
   Cell-based therapies are a promising approach for the treatment of diseases 
such as Type I diabetes mellitus (TIDM), where endogenous insulin production is 
restored via delivery of insulin-producing β-cells or islet of Langerhans clusters.  Tissue 
rejection by the host’s immune system, however, is a major hurdle limiting the broad 
use of transplanted tissues, so β-cell-based therapies require systemic 
immunosuppression. To reduce this requirement, tissues have been encapsulated 
within natural and synthetic barrier materials in a process known as immunoisolation.  
Immunoisolation materials, including poly(ethylene glycol) (PEG) hydrogels, create 
physical barriers between host immune cells and donor tissue while enabling the 
diffusion of small molecules like nutrients and oxygen. Unmodified immunoisolation 
barriers, however, are unable to prevent the diffusion of small cytotoxic molecules, 
including reactive oxygen species (ROS) (e.g., superoxide) and cytokines. 
 This research investigated strategies to introduce immunoactive modifications to 
PEG hydrogels for the purpose of improving their immunoisolation capacity.  Towards 
this, a polymerizable superoxide dismutase mimetic (SODm) was covalently tethered 
within β-cell-laden hydrogels to significantly increase cell survival following challenges 
with superoxide, a major inflammatory mediator of the immune response.  Next, 
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photoiniferter chemistry was employed to polymerize PEG chains co-functionalized with 
an apoptosis inducing factor (anti-fas) and a T cell adhesion ligand (ICAM-1) to locally 
reduce, through apoptosis, the population of T cells, the adaptive immune responder 
cells implicated in islet transplant rejection. Further, conformal, immunoactive coatings 
were formed directly on the surfaces of cell-laden PEG hydrogels using a versatile, 
reactive dip-coating strategy to present a high density of immunoactive signal while 
maintaining encapsulated cell cytocompatibility. Finally, towards preventing the 
development of deleterious adaptive immunity altogether, immunosuppressive 
hydrogels modified with TGF-β1 and IL-10 were introduced, and their capacity to reduce 
dendritic cell maturation was highlighted.  The immunoactive materials developed within 
this thesis suggest innovative strategies for the engineering of future immunoisolation 
barriers to provide localized and targeted protection of transplanted cells. 
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could be derived from cell surface molecules (e.g., MHC molecules), cell 
components (e.g., phospholipids, DNA), cell-specific secreted proteins. In 
the indirect pathway of antigen presentation (B), allo- or xenoantigens shed 
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fragments by host antigen presenting cells before binding to host Class II 
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encapsulated within each a single membrane. Modified from de Vos et al. 
Trends in Mol Med. 2002 [66] ................................................................... 13 
Figure 1.4. (A) Chemical structure of poly(ethylene glycol) diacrylate (PEGDA). In the 
presence of initiator and ultraviolet light, PEGDA may be photopolymerized 
into solid hydrogels (B). Hydrogel shown in (B) appears red in color 
because rhodamine was included for visualization .................................. 17    
Figure 1.5. Immune-mediated destruction of encapsulated islets. Foreign antigens are 
shed from encapsulated islets (1), taken up by host dendritic cells and 
presented to T cells via indirect antigen presentation (2). Activated CD4+ T 
cells (Th2) activate host B cells (3) which mature into plasma cells and 
secrete anti-islet antibodies (Ig). These antibodies bind shed islet proteins 
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triggering the production of inflammatory cytokines. These molecules 
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Weber, et al. Cell Encapsulation Technology and Therapeutics, 1999 .... 19 
Figure 1.6. Strategies to control local inflammatory and immune responses. Islets are 
encapsulated within materials functionalized with various strategies to 
reduce local inflammation. Modified from Wilson, et al. Adv Drug Del Revs. 
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Figure 3.1. (A) The chemical structure of the polymerizable SODm, MnTPPyP-Acryl. 
(B) Schematic of the MnTPPyP-co-PEG immunoisolation barrier. ROS 
diffuse inside the capsule but are broken down by the covalently bound 
SOD mimetic. ROS are indicated as being secreted by activated immune 
cells, as these cells are responsible for ROS secretion in response to 
tissue transplants. For the studies conducted herein, however, superoxide 
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Figure 3.2. Quantification of superoxide generated by the chemical reaction of xanthine 
with xanthine oxidase.  Xanthine (25, 50, 75, & 100 µM) was combined with 
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Figure 3.3. Soluble MnTPPyP-Acryl protects β-cells plated on TCPS from damage. 
Superoxide was generated chemically in the presence of Min6 β-cells with 
or without MnTPPyP-Acryl. (A) Trypan blue staining revealed numerous 
dead (blue) cells in the absence of MnTPPyP-Acryl (left) but fewer dead 
cells with MnTPPyP-Acryl (right). Scale bar denotes 100 µm (B) Exposure 
to superoxide significantly reduced the metabolic activity of plated β-cells 
but the addition of MnTPPyP-Acryl to solution prevented this reduction. * 
denotes p<0.05 difference from other values ........................................... 60 
Figure 3.4. Chemically generated superoxide damages encapsulated β-cells. (A) 
Metabolic activity of encapsulated cells was reduced, compared to 
untreated controls, as the concentration of xanthine added to solution was 
increased. (B) Live/dead confocal imaging enabled the visualization of live 
(green) and dead (red) cells.  Many dead cells were visible when treated 
with 50 & 100 µM xanthine (and 10 nM xanthine oxidase). Scale bar 
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Figure 3.5. Covalently incorporating MnTPPyP-Acryl into the hydrogel protects β-cells 
from ROS damage. (A) Cellular metabolic activity of encapsulated cells 
was monitored following treatment with xanthine (25, 50, & 100 µM) and 10 
nM xanthine oxidase. As the concentration of MnTPPyP-Acryl covalently 
polymerized into the hydrogel was increased, the observed metabolic 
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Live/dead imaging verified that many more live (green) cells were visible 
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following superoxide treatment in the presence of 100 µM MnTPPyP-Acryl 
(right) compared to blank gels (left). Scale bar denotes 100 µm .............. 62 
Figure 3.6. β-cell seeding density effects long-term survival when encapsulated in 
PEGDA hydrogels. (A) Min6 β-cells were encapsulated at 5, 6.7, 10, & 20 
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Figure 3.7. MnTPPyP-co-PEG hydrogels retain enzymatic activity over many days and 
after several superoxide treatments. β-cells were encapsulated with or 
without MnTPPyP-Acryl and cultured for 10 days.  On days 4, 6, & 8 
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Visualization confirmed the presence of many large, live (green) 
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Figure 4.1. Schematic illustrating surface-initiated polymerization of acrylated proteins.  
ACRYL-protein is co-photopolymerized with ACRYL-PEG atop a polymeric 
substrate containing a DTC photoiniferter.  Polymer chains consisting of 
polyacrylate backbones with pendant proteins are formed on the surface, 
and the surface modification is proportional to UV exposure time ........... 83 
 
Figure 4.2. The influence of covalent acrylation on the bioactivity of soluble ACRYL-
DX2.  ACRYL-PEG-NHS was reacted with DX2 in the molar ratios shown 
on the x-axis.  As the reaction stoichiometry was increased, the efficacy 
with which soluble ACRYL-DX2 induced apoptosis was reduced ............ 91 
 
Figure 4.3. Controlled surface-initiated photopolymerization of ACRYL-IgG.  (A) Dry 
graft height, determined by profilometry, increases as a function of surface-
initiated polymerization time.  (B) Surface density of detectable ACRYL-IgG 
increases and then decreases as a function of polymerization time, as 
determined by modified ELISA.  A region of high detectable ACRYL-IgG 
exists between 120 – 180 s fabrication times.  (C) Fluorescein-tagged 
ACRYL-IgG from goat (F-ACRYL-IgG) was photografted for 150 and 500 s.  
Dashed boxes represent a cross-sectional view of the full thickness of each 
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Scale bars = 50 μm.  (D) F-ACRYL-IgG Grafts were stained with 
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rhodamine-tagged donkey anti-goat IgG (R-IgG) to label accessible F-
ACRYL-IgG.  Strong full-thickness R-IgG staining is visible at 150 s but 
only surface staining at 500 s.  Scale bars = 50 μm.  (E) Surface density of 
detectable ACRYL-IgG decreased as a function of TED iniferter 
concentration in the substrate .................................................................. 92 
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Chapter 1 
Introduction 
 
1.1 OVERVIEW 
Cell delivery systems, often consisting of donor tissue embedded within material 
scaffolds, have the potential to cure numerous diseases of the endocrine, 
cardiovascular, neurological and musculoskeletal systems.  The goal of such strategies 
range from the regeneration of functional tissue equivalents to the controlled delivery of 
cell-secreted trophic factors.  One widely investigated cell therapy is the transplantation 
of islets for the treatment of type I diabetes mellitus.  Numerous advancements towards 
improved islet survival and function within biomaterials, as well as in vivo successes, 
continue to highlight the potential of this growing field.  Despite many successes, 
however, several obstacles must be overcome before tissue engineered implants will 
become widely implemented in the clinical setting.  Presently, a major hurdle to tissue 
transplantation is the threat of graft rejection by the host immune system.  As such, 
harsh immunosuppressive medications are a hallmark of islet transplantation.  In this 
introduction, type I diabetes mellitus and the treatment thereof with transplanted tissue, 
is reviewed. Further, strategies to decrease the necessity of systemic 
immunosuppression following islet transplantation, such as those explored in this thesis, 
are highlighted.  
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1.2 TYPE I DIABETES MELLITUS 
 
1.2.1   Disease Overview 
Type I diabeties mellitus (TIDM) is a chronic disease affecting over 3 million 
patients in the US alone [1]. TIDM results from the autoimmune-mediated destruction of 
insulin-producing β-cells, located within the pancreatic islet of Langerhans cell clusters, 
Fig. 1.1. Under normal circumstances, pancreatic β-cells secrete insulin in response to 
the increased blood glucose that follows a meal. Once secreted, insulin circulates 
throughout the body, binds to cells, and triggers the uptake of glucose [2]. Thus, if the 
insulin-producing β-cells are destroyed, as is the case in TIDM, insufficient insulin is 
secreted, so glucose gradually builds up in the bloodstream. The build-up of glucose  
 
Fig. 1.1. Anatomy of the human pancreas. The pancreas contains exocrine and endocrine tissue. The endocrine tissue, 
located within Islets of Langerhans, contain the insulin-producing β-cells which are destroyed during the development of 
TIDM. Adapted from the Encyclopedia of Britannica. 
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results in a condition known as hyperglycemia. Unable to take up glucose, cells turn to 
other energy sources for fuel, particularly fatty acids. Increased fatty acid metabolism, 
however, results in the formation of acidic ketone bodies, which accumulate in the 
bloodstream [3]. Diabetic ketoacidosis (DKA), occurring from the build-up of glucose 
and ketoacids in the blood, is a life threatening emergency. Ketone acids reduce the 
blood pH, and the kidneys begin dumping fluid in an effort to excrete glucose and 
ketones, potentially resulting in severe dehydration. In 1 to 3% of DKA cases, death 
may occur from severe cerebral edema [4, 5]. In the US, It has been  calculated that 
more children die each year from DKA than all cancers [3].  
 
1.2.2  Treatment and complications 
To maintain proper blood glucose levels, TIDM patients manage their blood 
sugar via daily insulin injections. TIDM most commonly presents in young patients, 
under the age of 20, so once afflicted, patients can anticipate a lifetime of insulin 
management. Even with diligent insulin management, though, numerous complications 
are likely when living a lifetime with diabetes [6]. Because it is difficult to maintain 
constant control over serum insulin concentration [7], it is common for TIDM patients to 
maintain higher-than-normal blood glucose levels. After many years with hyperglycemia, 
excess sugar builds up in blood vessels and other tissues in a process known as 
glycation [8]. When glycation occurs, many organ systems may be damaged, including 
the eyes, kidneys, nerves, and vessels, leading to blindness, kidney failure, 
neuropathies, and coronary artery disease [7, 8]. Fortunately, diligent blood sugar 
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monitoring and diabetes control decreases the occurrence of these severe 
complications [9].  
While preventing chronic high blood glucose is important, particular care must 
also be taken to avoid reducing blood glucose levels below the healthy range, by 
properly timing insulin injections and carefully estimating insulin dosages for upcoming 
meals. If excess insulin is administered, blood glucose may fall below healthy levels, 
resulting in hypoglycemia. Severe hypoglycemia is an acute emergency because an 
insufficient amount of glucose is present in the blood to supply the brain. This can result 
in sudden, severe neurologic complications such as dizziness, seizure, coma and death 
[10]. Unfortunately, when patients tightly control blood sugar to minimize long-term 
complications from diabetes, they are at a 3-fold increased risk of experiencing a 
dangerous hypoglycemic episode [11]. Initially, patients are able to feel when his or her 
blood sugar is low and can ingest sugars to correct this. After living many years with 
TIDM, though, it is common for patients to begin to lose the sensation of low blood 
glucose, in a condition known as hypoglycemic unawareness [12]. When TIDM patients 
begin experiencing hypoglycemic unawareness, they are at greatly increased risk of 
experiencing dangerous hypoglycemic episodes [12].         
 
1.3 ISLET & PANCREAS TRANSPLANTATION 
Due to the long-term complications associated with TIDM, the tediousness of daily 
blood sugar management and the dangers of hypoglycemic unawareness, researchers 
have long searched for a means to reduce or eliminate the need for daily blood glucose 
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monitoring and insulin injections for TIDM patients. Many recent efforts towards this 
goal have focused on gene therapy [13, 14], electronic closed-loop glucose monitor / 
insulin pump systems [15, 16], and pancreas and islet transplantation. Herein, organ 
and cell transplants are considered. The rationale for transplantation is simple: replacing 
lost β-cells should re-enable the body to generate insulin.  
 
1.3.1  Early Efforts 
Two years after Minkowski discovered that the removal of the pancreas caused 
diabetes in dogs [17], the first pancreatic transplant was performed in 1894, when 
Williams implanted pieces of sheep pancreas into a boy in a futile effort to cure end-
stage diabetes [18]. Despite relatively constant investigation, it was almost 80 years 
later, 1972, when Lacy et al. successfully reversed diabetes in rodents by islet 
transplantation [19]. While the rodents eventually succumbed to diabetes, this study 
demonstrated the efficacy of islet transplantation.  
 
1.3.2  Success in humans and the Edmonton Protocol 
Progress continued, and in 1988, Ricordi et al. developed a novel, automated 
method for human islet isolation which greatly increased donor cell yields [20]. Using 
this isolation strategy to obtain sufficient islet numbers, in 1989 Sharp et al.  
demonstrated that short-term insulin independence could be achieved in humans 
following allograft islet transplantation [21]. These transplanted islets eventually failed, 
likely due to long-term immune rejection, but researchers successfully demonstrated 
6 
 
that TIDM could be reversed in humans. While steady progress towards successful 
human islet transplantation proceeded throughout the 20th century, large leaps came 
with the introduction of steroid-free immunosuppression regimens to protect islet 
transplants. Chronic steroid use is associated with numerous negative side effects 
including immunosuppression, osteoporosis [22], and hyperglycemia due to increased 
insulin resistance [23]. In 1990, Ricordi et al. reported that the steroid-free agent 
tacrolimus (FK-506) was able to protect human islet transplants up to 5 years. Even 
more encouraging, in 2000 Shapiro, et al. at the University of Edmonton introduced the 
non-steroid rapamycin as an immunosuppressant to prevent islet graft rejection [24]. 
One year following transplantation, all seven patients who received islet transplants and 
chronic rapamycin treatment remained insulin independent [24].  
 
1.3.3  Post-Edmonton Protocol 
The Shapiro et al. approach, now known as the Edmonton protocol, invigorated 
the field of islet transplantation and was initially adopted at multiple sites, yielding 
encouraging results [25-27]. Over time, however, the promise of the Edmonton protocol 
has faded. In 2005, the Edmonton group published a follow-up to their initial report in 
which they documented that 90% of their original islet transplant recipients had become 
insulin-dependent. Further, in 2006, the Edmonton group conducted a multinational, 
nine-site clinical trial to evaluate the efficacy of the Edmonton protocol when conducted 
offsite [28]. In this study, 36 patients received islet transplants; of those, only 58% 
achieved insulin independence at some point in the study, while 76% of patients were 
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back on daily insulin injections within two years [28, 29]. Though insulin-independence 
seems to be unsustainable with present islet transplantation protocols, an important 
finding from these studies was that all patients were protected from dangerous 
hypoglycemic events [28]. This indicates that a significant number of islets are routinely 
lost in the years following a transplant, but enough survive to protect patients from 
hypoglycemia. Therefore, while not yet a cure for diabetes, islet transplantation is able 
to reduce the risk of life-threatening hypoglycemia and improve patient quality of life 
[30].         
 
1.3.4  Pancreas transplantation      
While the progress of islet transplantation has slowed in recent years, over 
30,000 clinical trials with whole pancreas transplants have been conducted worldwide 
[31]. Pancreas transplantation requires a more invasive surgery than islet 
transplantation, but in the US, >75% of transplants survive one year [6, 32]. Further, 
pancreatic transplant recipients have been shown to have a reduced risk of developing 
several diabetic complications, including retinopathy, cardiovascular disease, and 
neuropathy, compared to patients managed with insulin therapy alone [6]. Likewise, the 
transplantation of islets only, though performed in limited numbers, has also been 
shown to improve cardiovascular function [33], retinopathy [34], and renal function [35] 
in TIDM patients. The benefits of receiving a pancreas or islet transplant, however, must 
constantly be measured against the side effects [36]. For example, transplant surgery is 
associated with a risk of bleeding and thrombosis in the portal vein [24, 28, 37]. Further, 
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chronic systemic immunosuppression, while preventing transplant rejection, is 
associated with increased risk of infection, toxicity to numerous organ systems, and 
malignancy [38]. Presently, pancreatic tissue transplants are only indicated for patients 
suffering from severe diabetes, including those with severe hypoglycemic unawareness 
or those undergoing immunosuppression for a second solid organ transplant (typically 
kidney) [39]. Thus, significant hurdles remain before pancreas and islet transplantations 
become viable options for many TIDM patients. Fortunately, there is promising evidence 
that if a tissue transplant can be properly implanted and protected, replacing lost 
pancreatic tissue will cure TIDM.       
 
1.4 IMMUNOLOGICAL CHALLENGES TO ISLET TRANSPLANTATION 
1.4.1  Innate immune responses 
One of the major requirements for successful islet transplantation is the 
prevention of transplant rejection by the host immune system. When islets are 
implanted into the body, the innate and adaptive immune systems play critical roles in 
tissue rejection. Following surgery, innate immune cells, including neutrophils and 
macrophages, migrate to the surgical site and secrete cytokines to promote normal 
wound healing [40]. As Robitaille et al. observed, even minimally-invasive saline 
injections can elicit a large neutrophil infiltrate [41]. In addition to the insult from surgery, 
transplanted islets are known to secrete numerous inflammatory factors including TNF-α 
[42, 43], IL-1β [42, 43], monocyte chemotactic protein-1 (MCP-1) [44, 45], and nitric 
oxide (NO) [46], which further aggravate local inflammatory cells [47]. Activated innate 
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inflammatory cells accumulate over approximately the first 18 hours following a 
transplant [41, 48],  and secrete inflammatory cytokines including IL-1β, IL-6, and TNF-α 
[41], as well as reactive oxygen species (ROS) like superoxide [49]. In addition to 
inducing direct toxicity against transplanted islets [46, 50-53], the presence of these 
inflammatory mediators can initiate the foreign body response, resulting in transplanted 
cells becoming walled off by macrophages [40]. Further, antigen presenting cells 
(APCs), including macrophages and dendritic cells (DCs), proceed to activate the 
adaptive immune response [54].  
 
1.4.2  Adaptive immune responses 
While the innate immune response poses a considerable threat to the initial 
survival of transplanted islets, the response of the adaptive immune system is a primary 
determinant of long-term graft survival. Following the transplantation of naked islets, T 
cells of the host adaptive immune system are exposed to immunogenic antigens from 
the donor tissue via direct and indirect antigen presentation, Fig. 1.2 [54, 55]. Direct 
antigen presentation is the predominant means by which T cells gain immunity to naked 
cell transplants, and occurs when host CD8+ or CD4+ T cells come into direct contact  
with donor APCs expressing major histocompatibility complex class I (MHC I) or MHC II 
proteins, respectively [54]. Once primed against donor tissue, these cytotoxic T cells 
become activated, migrate to foreign cells, and bind them to deliver signals resulting in  
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Fig. 1.2. Antigen presentation via the (A) direct pathway, (B) indirect pathway. In the direct pathway of 
antigen presentation (A), the T cell receptor (TcR) recognizes antigens presented by donor antigen 
presenting cells (APCs) in association with their Class I or II MHC molecules (top). Alternatively, host T 
cells can recognize empty allogeneic MHC molecules (bottom). Ligation of the appropriate co-stimulatory 
molecules is required for T cell activation that will result in T cells specific for the graft antigens presented 
by the APCs. These peptide antigens, of allogeneic (or xenogeneic) sources, could be derived from cell 
surface molecules (e.g., MHC molecules), cell components (e.g., phospholipids, DNA), cell-specific 
secreted proteins. In the indirect pathway of antigen presentation (B), allo- or xenoantigens shed from 
allogeneic or xenogeneic cells are internalized, processed into peptide fragments by host antigen 
presenting cells before binding to host Class II MHC molecules and being presented to host CD4 T helper 
cells. The CD4 molecule of the T cell interacts with the MHC class II molecule and ligation of co-
stimulatory molecules are necessary for efficient T cell stimulation. Modified from Babensee et al. Adv 
Drug Deliv Rev, 1998 [40]. 
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donor cell apoptosis (programmed cell death) [54]. T cells may also become activated 
via indirect antigen presentation, whereby immunogenic proteins and peptides are shed 
from transplanted islets and phagocytosed by host APCs [54]. These host APCs 
process this material and express it within surface MHC II. CD4+ helper T cells bind 
these host APCs and, in turn, become activated against specific islet antigens [54]. 
While unable to induce transplanted cell death directly, CD4+ T cells are involved with 
activating B cells to secrete anti-antigen antibodies. These antibodies bind to 
transplanted cells, targeting them for elimination. While direct and indirect antigen 
presentation are important considerations, Wang et al. demonstrated that CD4+ T cell-
mediated indirect antigen presentation is implicated in the recurrence of diabetes in 
non-obese diabetic (NOD) mice following a transplant [56].        
 
1.4.3  Modern immunosuppression strategies 
To overcome immune-mediated rejection, systemic immunosuppression remains 
a hallmark of whole-organ pancreas transplantation into TIDM patients. Many 
medications have been used to provide chronic immunosuppression, but a particularly 
effective combination includes mycophenolate mofetil (blocks lymphocyte activation & 
proliferation [57]) with either tacrolimus [58] or cyclosporin [59], which are thought to 
reduce T cell IL-2 production, preventing further T cell activation [32, 60, 61]. Unlike 
other organ transplants, one course of T cell depletion therapy prior to pancreas 
transplantation (thymoglobulin) is also used to improve outcome (i.e., 92% graft survival 
after 3 years) [32, 61]. Each of these medications target systemic T cells and the 
associated clinical success highlights the importance of controlling the T cell response 
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to transplanted pancreatic material in TIDM patients. While suppressing the host 
immune system has been shown to allow long-term insulin independence, 
immunosuppression has numerous side effects including infection, malignancy, and 
organ toxicity [38]. Thus, islet transplantation would likely become a desirable option for 
many more TIDM patients if the requirement of systemic immunosuppression was 
reduced or eliminated. 
 
1.5 IMMUNOISOLATION VIA CELL ENCAPSULATION 
Towards the goal of promoting transplant survival in the absence of systemic 
immunosuppression, researchers have long searched for methods to block direct 
antigen presentation by graft tissue. More than 60 years ago, Algire et al. proposed 
isolating cells within diffusion chambers to separate them from the host immune system 
[62]. Since then, researchers have extensively investigated strategies for cell 
encapsulation, or immunoisolation, prior to implantation. In 1975, Chick et al. created 
synthetic capillaries containing immunoisolated islets that were perfused with tissue 
culture media [63].  Five years later, Lim & Sun introduced islets encapsulated in 
semipermeable alginate/poly-L-lysine membranes for the treatment of diabetes in mice 
[64]. Immunoisolation occurs due to the size-exclusion membrane that is characteristic 
of encapsulation materials. Nutrients like glucose and oxygen readily diffuse into the 
capsule, and small, secreted proteins, like insulin, diffuse out. Large molecules and 
cells, however, including immune cells and antibodies, are prevented from diffusing 
through the capsule due to size exclusion [65].  
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1.5.1   Intravascular macroencapsulation 
Three platforms are generally employed for islet encapsulation: intravascular 
macrocapsules (ie. diffusion chamber devices), extravascular microcapsules and 
extravascular macrocapsules, Fig. 1.3 [66]. Intravascular devices consist of cells 
encapsulated in a material structure with a central lumen that may be surgically 
connected to a blood vessel. This architecture allows blood to flow through the capsule, 
 
Fig. 1.3. Types of immunoisolation devices. (Top) Intravascular perfusion device with cells surrounding a central 
lumen with blood flow. (Middle) Extravascular microcapsules are fabricated around individual islets or cell clusters 
and placed near blood flow. (Bottom) Macrocapsules consist of many islets encapsulated within each a single 
membrane. Modified from de Vos et al. Trends in Mol Med. 2002 [66].    
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providing close contact between blood and cells and enabling rapid nutrient transport 
[63].  
The modified diffusion chamber introduced by Chick et al., fabricated from 
polyacrylonitrile and polyvinylchloride copolymer (PAN-PVC), has been studied in 
several animal systems and was shown to provide some degree of islet function [63, 67, 
68]. Unfortunately, these devices were prone to thrombosis, so systemic anticoagulation 
was required for success, ultimately limiting the feasibility of this approach [66].  
 
1.5.2  Extravascular microencapsulation 
During extravascular microencapsulation, materials are formed directly at the 
surface of individual cells or islet clusters to fabricate semi-permeable membranes. 
Islets are then implanted into the peritoneal cavity. While numerous materials have 
been investigated for islet microencapsulation [65, 69-71], the most extensively 
investigated platform utilizes alginate - poly-L-lysine – alginate (APA) microcapsules. As 
pioneered by Lim & Sun, single islets are suspended in alginate droplets and gelation is 
induced by the addition of a divalent cation solution containing Ca2+ [64]. Particles are 
further coated with a polycation, the most commonly utilized one being poly-L-lysine 
(PLL), to stabilize the alginate gel and create the semi-permeable immunoisolation 
membrane. These particles may be modified further with additional alginate to bind free, 
positively-charged PLL to reduce protein adhesion in vivo [72]. Extensive investigations 
with variations of this material have been performed over the last 30 years, including 
numerous in vivo trials [73-78]. Ultimately, however, overwhelming success is yet to be 
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achieved [65]. While some concerns about the biocompatibility of APA microcapsules 
remain, particularly when including PLL [41, 79], recent studies have evaluated specific 
material alternations, including alginate purification, to reduce protein interactions with 
capsules [80, 81].  
Alternatively, another material platform that has been more recently investigated 
for pancreatic microencapsulation utilizes poly(ethylene glycol) hydrogels. PEG 
hydrogels are widely applied for cell encapsulations, as they are hydrophilic materials 
possessing a high internal water content, which often mimics native tissue properties, 
and resists protein adsorption. Further, PEG is easily modified chemically to introduce a 
wide variety of functionalities into capsules. Cruise et al. utilized interfacial 
photopolymerization to coat individual porcine and human islets with thin (<50 µm) 
layers of PEG hydrogel [82-85]. In this approach, the photoinitiator eosin Y was 
adsorbed directly to the surface of islets. In the presence of triethanolamine and light, 
radical polymerization was initiated at the islet surface, resulting in surface mediated gel 
formation and microencapsulation. Using this approach, greater than 90% islet viability 
was achieved [84]. This coating strategy has shown promise in preclinical animal 
studies as well as human trials conducted by Novocell (now known as ViaCyte). 
 
1.5.3  Extravascular macroencapsulation 
While some of the advantages of microencapsulation include a high capsule 
surface area to volume ratio to maximize nutrient transport and the ease of implantation 
via syringe injection, one major limitation to microencapsulation is that the small device 
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size makes transplant retrieval difficult [66]. Macrocapsules, conversely, consist of a 
bulk material with cells suspended throughout. They are larger in size, enabling 
transplant retrieval. While nutrient transport is a concern within macrocapsules, 
mathematical models [86] and experiments [87, 88] indicate that sufficient nutrient 
exchange occurs within macrocapsules as long as proper geometries are selected and 
islet volume does not exceed 5-10 % of device volume [66]. To date, many material 
platforms have been investigated for islet macroencapsulation. For example, Dufrane et 
al. recently encapsulated pig islets within alginate macrocapsules, implanted them into 
primates, and demonstrated 6 month transplant survival in the absence of systemic 
immunosuppression [87].  Likewise, Grundfest-Broniatowski et al. developed a 
synthetic, ampiphilic membrane and demonstrated in vivo survival of 
macroencapsulated islets [88]. Further, Qi et al. used a freeze / thawing technique to 
encapsulate islets within polymer sheets consisting of poly(vinyl alcohol) (PVA) and 
Euro-Collins (EC) solution [89]. These devices were able to provide normal glycemic 
control in diabetic mice for up to 30 days.   
 
1.5.4  Encapsulation within PEG macrocapsules 
Anseth et al. have previously explored the macroencapsulation of islets and β-
cells within PEG hydrogels [90-96]. While many types of PEG hydrogels exist, 
researchers in the Anseth lab have focused on gels formed from PEG diacrylate 
(PEGDA) and PEG dimethacrylate (PEGDMA) monomers (2,000 – 10,000 Da), which 
may be photopolymerized in the presence of long-wave ultraviolet (UV) light and initiator  
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to form a covalently crosslinked polymer network, Fig. 1.4. β-cells and islets are 
suspended within the PEGDA prepolymer solution, and then immobilized upon 
photopolymerization. The photoencapsulation of cells [97] and islets [82] has been 
demonstrated to be highly cytocompatible and efficient, and Weber et al. showed that 
encapsulated β-cell and islet viability and function could be enhanced by the inclusion of 
extracellular membrane (ECM) proteins and peptide mimics in the hydrogel formulation 
[90-92]. Further, Lin et al. showed that the incorporation of glucagon-like peptide 1 
(GLP-1) into hydrogel networks improved β-cell viability and function [94], and illustrated 
the importance of cell-cell contact within hydrogels for β-cell survival [95, 96]. Thus, 
PEG hydrogels provide a versatile platform for the incorporation of functional groups to 
promote healthy β-cell function.  While PEG macrocapsules have been the focus of 
these recent studies, virtually all findings are relevant to PEG microcapsules and other 
encapsulation systems, and are therefore broadly applicable across multiple 
encapsulation platforms.   
A 
 
B
 
 
 
 
 
Fig. 1.4. (A) Chemical structure of poly(ethylene glycol) 
diacrylate (PEGDA). In the presence of initiator and 
ultraviolet light, PEGDA may be photopolymerized into 
solid hydrogels (B). Hydrogel shown in (B) appears red 
in color because rhodamine was included for 
visualization. 
18 
 
1.6 HOST REJECTION OF ENCAPSULATED TISSUE 
1.6.1  Small molecule diffusion 
Conceptually, immunoisolation seems to be a logical choice for protecting 
encapsulated tissue from the host immune system. In practice, however, simple 
encapsulation has been generally inadequate for the long-term protection of 
transplanted tissue. The permeability of barriers may be precisely controlled to limit 
antibodies and immune cells from diffusing within the capsule [65], but it is also crucial 
that small molecules like glucose and insulin remain able to diffuse freely through the 
network to allow donor cell survival and function. Unfortunately, nutrients and cellular 
products are not the only small molecules that pass through the capsule in vivo. Rather, 
low molecular weight cytokines like TNF-α, IL-1β and IL-6, as well as reactive oxygen 
species (ROS), have been demonstrated to pass through the membrane and injure 
encapsulated cells [51, 66]. Therefore, limiting the presence of these inflammatory 
molecules in proximity to a transplant has become a major focus of study.     
 
1.6.2  Indirect antigen presentation 
As discussed above (see 1.4 Immunological challenges to islet transplantation), 
the host’s innate immune system likely becomes activated simply from the insult of 
minor implantation surgery. This activation can result in the production of inflammatory 
cytokines and ROS which are damaging to donor tissue. Further, the adaptive immune 
system of the host may become activated against tissue transplants via indirect antigen 
presentation. Encapsulation has been shown to do an adequate job preventing direct  
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antigen presentation, by limiting direct contact between host tissue and immune cells. 
Indirect antigen presentation, however, still occurs, Fig. 1.5. Even when encapsulated, 
antigens from donor cells continue to be shed into the surroundings. This process can 
occur as cells die and shed protein fragments [70]. Likewise, it is also possible for the 
immune system to become sensitized against cell products, like insulin [70]. These 
antigens are phagocytosed by host dendritic cells (DCs) and presented to CD4+ helper 
T cells. Activated T cells begin secreting inflammatory cytokines and further elicit an 
immune response by activating B cells to secrete anti-islet antibodies. When local 
Fig. 1.5. Immune-mediated destruction of encapsulated islets. Foreign antigens are shed from encapsulated islets 
(1), taken up by host dendritic cells and presented to T cells via indirect antigen presentation (2). Activated CD4+ T 
cells (Th2) activate host B cells (3) which mature into plasma cells and secrete anti-islet antibodies (Ig). These 
antibodies bind shed islet proteins outside of the capsule and bind the macrophage Fc receptor (FcR) (4) triggering 
the production of inflammatory cytokines. These molecules diffuse within the capsule and kill encapsulated islets (5). 
Adapted from Weber, et al. Cell Encapsulation Technology and Therapeutics, 1999.    
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antibodies bind antigen shed from islet-laden capsules, they can bind and activate 
macrophages to secrete additional inflammatory cytokines. Therefore, simple 
encapsulation regimens are likely inadequate for complete islet protection.    
 
1.7 ACTIVE IMMUNOISOLATION BARRIERS 
Given that encapsulation within unmodified immunoisolation barriers is unable to 
provide long-term protection of encapsulated cells, several researchers have recently 
investigated strategies to activate immunoisolation barriers. Active immunoisolation 
barriers are typically formed via the introduction of bioactive molecules within 
immunoisolation barriers. To date, many active immunoisolation barriers have been 
investigated and most fall into the general categories of materials which release anti-
inflammatory molecules or scavenge free radicals and cytokines, Fig. 1.6. In this thesis,  
an immobilized enzyme is investigated to breakdown reactive oxygen species and two 
unique immune cell signaling pathways are mimicked to signal adaptive immune cells.  
 
 
 
 
 
 
 
Fig. 1.6. Strategies to control local 
inflammatory and immune 
responses. Islets are encapsulated 
within materials functionalized with 
various strategies to reduce local 
inflammation. Modified from 
Wilson, et al. Adv Drug Del Revs. 
2008 [70].  
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1.7.1  Limiting the effects of small cytotoxic molecules 
As discussed above, encapsulated cells are thought to be injured by small, 
cytotoxic molecules able to diffuse within the network. To protect cells, researchers 
have investigated methods to sequester cytokines within materials, limiting their 
diffusion. For example, Lin et al. tethered anti-TNF-α affinity peptides within cell-laden 
PEG hydrogels and demonstrated improved cell survival when challenged with TNF-α 
[98]. To influence the cytokine profile around an encapsulation device, Washburn et al. 
conjugated antibodies against IL-1β and TNF-α to hyaluronic acid for cytokine 
sequestration and demonstrated fewer activated macrophages responding to adjacent 
wound sites in vivo [99]. To reduce immune cell activation by encapsulated cells, Lin et 
al. also incorporated an affinity peptide for monocyte chemotactic protein 1 (MCP-1) into 
cell-laden PEG hydrogels and demonstrated decreased antigen release [100]. Reactive 
oxygen species (ROS) also pose a considerable threat to encapsulated tissue. Towards 
protecting cells from ROS damage, erthyrocytes (red blood cells) and hemoglobin have 
been co-transplanted with islets because hemoglobin possesses the capacity to convert 
nitric oxide (NO) to less-reactive nitrate. These systems prolonged normoglycemia 
following islet transplants in mice [53, 101]. Further, Cheung et al. recently introduced a 
covalently crosslink-able superoxide dismutase mimetic (SODm) to catalyze the 
breakdown of superoxide and other ROS within polymeric biomaterials [102]. In this 
thesis, the capacity of this SODm to protect encapsulated cells from ROS damage is 
specifically explored.  
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1.7.2  Anti-inflammatory drug release 
Tailoring implantable biomaterials for drug release has been widely explored, and 
several investigators have recently investigated drug release for the purpose of 
reducing inflammation. Because standard alginate/poly-lysine microcapsules are known 
to produce an inflammatory response [41], most anti-inflammatory release has been 
investigated in the presence of alginate/poly-lysine. For example, Bunger et al. co-
encapsulated the immunosuppressive steroid dexamethasone within alginate capsules, 
to provide drug release over a period of 14 days. After 30 days in vivo, decreased 
fibrous capsule formation and improved islet survival was observed [103]. Giovagnoli, et 
al. incorporated the nonsteroidal anti-inflammatory drug (NSAID) ketoprofen and 
superoxide dismutase (SOD) into degradable poly(D, L-lactide-co-glycolide) (PLGA) 
and poly(D, L-lactide) (PLA) microspheres for controlled release.  Upon incorporation 
within cell-laden alginate microcapsules and implantation into the mouse peritoneum, 
they observed a decrease in the number of macrophages and T cells in proximity to the 
transplantation site [104]. Similarly, Baruch et al. released an alternate NSAID, 
ibuprofen, from PLGA microspheres within alginate and observed increased in vivo 
transplant survival over the period of drug release [105]. Other release platforms have 
recently been explored, as Yu et al. incorporated the NSAIDs ketoprofen [106] and 
acetaminophen [107] into poly(vinyl pyrrolidone) (PVP) nanofibers for controlled 
release. Likewise, Aimetti et al. reported a degradable peptide-based drug release 
platform to deliver payload in response to human neutrophil elastase (HNE), an enzyme 
secreted by activated neutrophils [108].    
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1.7.3  Co-transplantation of immunosuppressive cell types 
While the efficacy of controlled drug release by immunoisolation barriers has 
been demonstrated, these sorts of approaches are only able to function for a finite 
length of time; until all therapeutic has been released. In an effort to provide more long-
term protection, immunosuppressive cells may be co-encapsulated along with donor 
cells. For example, Sertoli cells have been co-transplanted with islet allo- [109, 110] and 
xenografts [111] and significantly improved transplant survival in humans [112]. Sertoli 
cells are normally found within the testes and provide resistance from the autoimmune-
mediated destruction of the developing germ cells [113]. Thus, the co-transplantation of 
Sertoli cells with islet grafts likely mimics the local immunosuppressive environment of 
the testes. This effect is thought to be mediated by the release of the 
immunomodulatory growth factor transforming growth factor beta (TGF-β) [114], the 
expression of Fas ligand (FasL) to deplete local T cells, and the release of clusterin 
[113]. Additionally, human mesenchymal stem cells (MSC) have been co-transplanted 
to promote graft survival [115]. Like Sertoli cells, MSC are thought to provide 
immunomodulatory signals to prevent rejection. For example, MSC have been shown to 
block T cell proliferation [116], likely via the secretion of immunomodulatory factors 
including TGF-β, hepatic growth factors, prostaglandin E2, and IL-10 [117]               
 
1.7.4  Signaling immune cells from material surfaces 
Throughout the field of tissue engineering, many investigators have researched 
interactions between material surfaces and cells. For example, proteins and adhesion 
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ligands are commonly incorporated on the surfaces of biomaterials, including PEG 
hydrogels, to promote cell attachment [118]. Growth factors and other bioactive 
molecules have been patterned on material surfaces to promote cell survival and guide 
development [119]. Conversely, numerous investigations have been made into 
understanding interactions between surfaces and innate immune cells, particularly in 
the settings of reducing macrophage attachment and fibrous capsule formation [40, 
120], as well as characterizing dendritic cell activation by various material surfaces 
[121-123]. Presently, however, few strategies have been investigated whereby 
functionalized surfaces are employed to signal immune-cells [124, 125]. Two material 
platforms to reduce the local concentration of T cells, via surface receptor signaling, are 
considered in this thesis. Additionally, anti-inflammatory molecules are tethered to the 
surfaces of PEG hydrogels to signal dendritic cells and decrease their activation in 
response to immune stimuli in an effort to reduce indirect antigen presentation.    
 
1.8      THESIS APPROACH 
 
 
 
The overall objective of this thesis is to utilize PEG-based materials as modifiable 
platforms to investigate bioactive modifications to reduce immune-mediated 
inflammation toward cell-laden biomaterials. Tissue rejection is a major hurdle to the 
success of implanted cell-delivery devices so strategies to ameliorate or modify the host 
immune response have the potential to significantly improve transplant outcomes.  The 
Specific Aims of this thesis, as well as their rationale, are outlined in Chapter 2.  In 
Chapter 3, results from studies with a polymerizable superoxide dismutase mimetic 
(SODm) are presented.  SODm is covalently incorporated within β-cell-laden hydrogels 
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to demonstrate and evaluate this molecule’s capacity to protect encapsulated cells from 
reactive oxygen species (ROS)-mediated cell death. As described above, ROS are 
known to damage encapsulated tissue and, herein, it is demonstrated that the 
polymerizable SODm provides significant protection from chemically generated 
superoxide. 
In Chapters 4 and 5, methods to signal T cells to undergo apoptosis via 
functionalized biomaterial surfaces are investigated. T cells are a primary mediator of 
the adaptive immune response so methods to reduce the local concentration of T cells 
in proximity to cell delivery devices have the capacity to improve transplant survival. In 
Chapter 4, surface-initiated, photoiniferter-based photopolymerizations are employed to 
fabricate PEG chains with pendant anti-fas antibody on hard plastic substrates. 
Surfaces are shown to induce T cell apoptosis, and this effect is increased by the 
addition of a T cell adhesion ligand, ICAM-1. In Chapter 5, immune cell signaling is  
provided by conformal, PEG-based coatings fabricated directly on the surfaces of PEG 
hydrogels via reactive dip coatings initiated by the glucose oxidase enzyme. This 
coating strategy is demonstrated to create highly-functionalized conformal polymer 
layers of precise thicknesses and with the capacity to induce significant T cell apoptosis. 
In Chapter 6, biologically-functionalized PEG hydrogels are employed to signal 
dendritic cells (DCs). DCs present antigens to the adaptive immune system and play a 
critical role in determining whether or not to initiate an immune response.  Herein, PEG 
hydrogels are functionalized with the anti-inflammatory molecules TGF-β1 and IL-10 to 
reduce the maturation state of bone marrow-derived dendritic cells when challenged 
with immune stimuli. This work furthers understanding of the interactions possible 
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between functionalized PEG materials and the immune system and lays a foundation 
for potential modifications to implantable biomaterials to provide greater 
immunoisolation. Finally, in Chapter 7, general conclusions are drawn from this work 
and future directions are discussed. 
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Chapter 2 
Objectives 
 
Poly(ethylene glycol) (PEG)-based materials, including PEG hydrogels, are 
widely investigated within the field of regenerative medicine for cell encapsulation and 
delivery.  One of the many benefits of encapsulating cells or tissue within PEG 
hydrogels prior to transplantation is the theoretical immunoisolation from the host 
immune system, essentially creating a physical barrier or separation between the host 
immune cells and those of the donor tissue.  As detailed in Chapter 1, however, 
encapsulation alone is often inadequate in providing complete immunoprotection, as 
several small molecules can diffuse into and out of biomaterial capsules and lead to 
corresponding damage of encapsulated cells.  
As a result, recent interest has emerged in creating biofunctional and/or bioactive 
cell delivery vehicles that can locally modulate deleterious effects of the immune 
response.  This strategy is the focus of this thesis research, and the platform of PEG 
hydrogels is readily amenable to introducing bioactive moieties and tailoring their 
presentation.  Harnessing this property of local and controlled presentation of biological 
signals within biomaterial cell carriers, the global aim of this thesis is to explore how 
modifications to PEG hydrogels, through covalent incorporation of bioactive molecules, 
can improve the survival of encapsulated cells and, ultimately, the immunoisolation 
capacity of PEG hydrogels.  Rationally chosen strategies to create bioactive PEG 
hydrogels are evaluated quantitatively in relevant in vitro model systems to determine 
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their utility.  Within this global objective in mind, four specific aims are outlined below to 
demonstrate efficacy of specific formulations in protecting encapsulated beta cells from 
various immune challenges and test corresponding hypotheses.  The specific aims of 
this thesis are as follows: 
 
Specific Aim 1:   Incorporate a polymerizable superoxide dismutase mimetic into 
PEG hydrogels and examine its ability to reduce reactive oxygen species-
mediated damage to encapsulated β-cells 
 One of the significant threats posed by the host inflammatory response towards 
implanted tissue is damage from reactive oxygen species (ROS). ROS are secreted by 
inflammatory cells as an immediate response to device implantation. These ROS are 
small enough to diffuse rapidly through capsules and illicit damage and/or death to 
encapsulated cells. Superoxide, one of the main ROS produced by inflammatory cells, 
poses an immediate threat to delivered cells, but this highly reactive specie also rapidly 
breaks down to form other cytotoxic and more stable species, such as hydrogen 
peroxide (H2O2) and peroxynitrite (ONOO-).  Previously, Cheung et al. synthesized a 
polymerizable superoxide dismutase mimetic (SODm) to catalyze the breakdown ROS 
within hydrogels [1].  Building from this initial work, the primary goal of Specific Aim 1 is 
to demonstrate that this SODm can protect encapsulated β-cells from damage mediated 
by superoxide produced outside of capsules.  
 In accordance, several objectives are considered to evaluate the ability of SODm 
to protect encapsulated cells. First, the cytocompatibility of the SODm is verified in 
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solution, as well as when polymerized into cell-laden hydrogels. Next, an adequate in 
vitro assay system is developed to generate superoxide radicals in solution. For the 
experiments presented herein, a chemical reaction is used to generate superoxide. 
Xanthine and xanthine oxide are reacted to produce uric acid and superoxide and the 
rate of superoxide production in solution is characterized and verified to be 
reproducible.  SODm is then incorporated within cell-laden hydrogels to demonstrate 
bioactivity.  Upon functionalization with various concentrations of SODm, hydrogels are 
treated with superoxide and cell survival is measured via a metabolic activity assay and 
live/dead imaging. Because superoxide and ROS are likely to be secreted by 
inflammatory cells throughout the first several days following transplantation, a 10-day 
study is performed to assess cell survival after many days of encapsulation with multiple 
superoxide challenges.  
      
Specific Aim 2:  Develop and test the ability of a functionalized, PEG-based 
coating to present a high surface density of bioactive ligands to signal T cell 
apoptosis 
 Small cytotoxic molecules, including superoxide, are secreted immediately 
following cell-laden device implantation by cells of the innate immune system. In 
isolation, this inflammatory response runs its course and ceases in a matter of days.  
Often leading to the formation of fibrous capsules surrounding inert biomaterial 
implants; however, the response is much more complex for cell-laden biomaterials.  
Cells of the adaptive immune response can become activated by local inflammation and 
generate specific immunity to shed antigen from encapsulated cells, especially if cell 
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apotosis or necrosis occurs in response to the initial insult. Unchecked, this adaptive 
immune response persists until all antigen is removed (i.e., until all encapsulated cells 
are destroyed). The T cell response by the adaptive immune system has been shown to 
be a significant threat to encapsulated cells and tissues. As such, functionalized 
coatings to suppress the T cell response by inducing local T cell apoptosis have the 
potential to reduce the requirement for immunosuppression (i.e., systemic T cell 
suppression) following the transplantation of many tissue types, including pancreatic 
islets.  
 The focus of Specific Aim 2 is to fabricate functionalized coatings that display a 
high surface density of anti-fas antibody (DX2 clone) to deliver apoptotic signals to T 
cells. Sebra et al. developed a living radical polymerization strategy to incorporate 
antibodies within polymer chains of PEG acrylate to create an ELISA-like biodetection 
platform [2, 3].  Building upon this strategy of controlled, high density presentation of 
antibodies at polymer surfaces, this thesis modifies an anti-fas antibody to render it 
polymerizable via the addition of acrylate groups to free amines using acryl-PEG-NHS 
chemistry. Subsequently, the ability to exploit a dithiocarbamate (DTC) photoiniferter to 
form antibody functionalized polymer chains on hard polymer substrates is examined 
and graft height is studied as a function of light exposure/dose. Next, an ELISA-type 
assay is developed to allow quantification of detectable antibody within the resulting 
polymer. 
 To evaluate the bioactivity of functional coatings, jurkat T cells, a cell line 
previously known to express high levels of fas receptor (comparable to activated T 
cells), are cultured atop functionalized coatings to verify the induction of apoptosis. 
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Because PEG surfaces are resistant to protein and cellular adhesion, we hypothesized 
that increased fas signaling may be observed after the incorporation of adhesion 
ligands. To introduce adhesion with specificity towards T cells and fas-responsive 
leukocytes, inter-cellular adhesion molecule-1 (ICAM-1) is introduced into polymer 
coatings along with anti-fas. These surfaces are seeded with T cells and assayed for 
increased apoptosis.  
 
Specific Aim 3:  Develop cytocompatible fabrication strategies to polymerize 
biofunctional coatings on the external surfaces of cell-laden PEG hydrogels as a 
method to create composite scaffolds to deliver immuno-active signals in a 
spatially regulated manner. 
 Building upon the findings of Specific Aim 2, Specific Aim 3 focuses on 
developing and testing cytocompatible polymerization strategies to functionalize cell-
laden PEG-based hydrogels with biologically functional coatings. Due to technical 
difficulties encountered when translating DTC-mediated photopolymerization for 
modifying hydrogels (e.g., aqueous and cytocompatible conditions), an alternate 
surface-mediated polymerization strategy is investigated.  Johnson et al. recently 
reported on a versatile, reactive dip-coating polymerization mediated by the enzyme, 
glucose oxidase [4, 5].  Glucose oxidase reacts with glucose to form hydrogen peroxide 
(H2O2) which further reacts with iron (Fe2+), yielding hydroxyl radical, which can initiate 
polymerization of vinyl-functionalized macromolecules. When pre-formed hydrogels 
(e.g., those laden with cells) are swollen in glucose (e.g., cell culture media) and then 
43 
 
dipped into glucose-free pre-polymer containing low molecular weight PEG 
(meth)acrylates, glucose diffuses out of the hydrogel to initiate polymerization and 
coating formation at the hydrogel surface.  
 In Specific Aim 3, biomolecules are incorporated within GOx-mediated coatings 
with the goal of signaling external immune cells.  Further, a range of cytocompatible 
conditions are investigated to enable coating formation in the presence of encapsulated 
cells. Biomolecules incorporated within the surface coatings are detected via a modified 
ELISA developed in Specific Aim 2. Using confocal microscopy, the thickness of the 
conformal polymer coating is characterized and related to the dipping time. To 
demonstrate the bioactivity of molecules incorporated using this polymerization 
mechanism, anti-fas antibody and ICAM-1 are covalently incorporated within coatings 
grown from PEG hydrogels. Jurkat T cells seeded atop coatings and the induction of 
their apoptosis are investigated via flow cytometry after 12, 24, and 48 hrs. Finally, 
hydrogels containing encapsulated Min6 β-cells and 3T3 fibroblasts are modified with 
coatings via glucose oxidase polymerization to identify conditions which are compatible 
with high cell survival.  Overall, this GOx-mediated coating strategy has the potential to 
functionalize cell-laden hydrogels with bioactive molecules that remain physically 
separate from the encapsulated cells.  While this thesis specifically evalutes the 
bioactivity of coatings to influence T cell activity, one might easily envision that this 
coating strategy could be readily applied to fabricate coatings with SODm activity, as in 
Specific Aim 1, or to present immunosuppressive molecules, as will be discussed in 
Specific Aim 4.        
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Specific Aim 4:  Explore how PEG hydrogels with modified with 
immunosuppressive proteins can reduce dendritic cell maturation upon exposure 
to immune stimuli 
 T cells of the adaptive immune response pose a significant threat to 
encapsulated tissues. While Specific Aims 2 and 3 explore functionalized polymer-
based strategies to reduce local T cells via apoptosis, a biomaterial able to dampen the 
adaptive immune response and prevent the formation of activated T cells would have 
great utility within the field of cell-based therapies. Dendritic cells (DCs) are one of the 
body’s antigen presenting cells and the only cell type capable of activating naïve T cells. 
When exposed to antigenic material in the presence of immune stimuli, such as an 
implantable biomaterial construct containing live cells, DCs take up shed antigens and 
mature. Upon maturation, DCs present antigen to naïve T cells and elicit an immune 
response. When exposed to antigen under tolerogenic conditions, however, such as in 
the presence of the immunosuppressive proteins TGF-β1 and / or IL-10, DC maturation 
is reduced and the resulting DCs have been shown to induce antigen-specific tolerance. 
Therefore, if a biomaterial surface were to reduce dendritic cell maturation via the 
presentation of bioactive signals (e.g., TGF-β1 and/or IL-10), the ensuing T cell 
response could be dampened. In Specific Aim 4, immunosuppressive proteins are 
presented on the surfaces of PEG hydrogels to signal DCs and their ability to reduce 
DC maturation following immune stimulation. 
 Unlike the biomolecules investigated in Specific Aims 1–3, the 
immunosuppressive proteins TGF-β1 and IL-10 are active in solution at very low (1 to 
10 ng/ml) concentrations and, therefore, commercially available in low quantities (i.e., 5 
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to 10 μg). Further, TGF-β1 is known to be sparingly soluble in biologically relevant 
solutions. Thus, initial work on Specific Aim 4 focuses on developing a strategy to 
chemically modify TGF-β1 in such a manner that it may be polymerized into hydrogels 
without significant loss of bioactivity.  Modification of primary amines with acrylate-PEG-
NHS is initially investigated, but this modification is found to induce the maturation of 
DCs, an unacceptable consequence.  Thiolation with Traut’s reagent is employed with 
improved results, and the bioactivity of thiolated TGF-β1-SH and IL-10-SH are assessed 
in solution via their capacity to reduce DC maturation upon exposure to immune stimuli. 
Further, the solution-phase bioactivity of TGF-β1-SH is verified via the PE-25 TGF-β 
reporter cell assay. 
 After the bioactivity of the immunosuppressive proteins are validated in solution, 
they are conjugated within PEG hydrogels via a thiol-ene reaction, and the resulting 
detectable protein surface density is characterized via the modified ELISA from Specific 
Aim 2. Next, the ability to reduced DC mature following immune stimulation is 
investigated by seeding immature DCs from the JAWSII dendritic cell line on 
functionalized hydrogels.  Bioactivity and reduced DC maturation are assessed by 
ELISA and flow cytometry to measure the secretion of IL-12 and expression of MHCII, 
respectively.  
As further evidence of the efficacy of this approach, immunosuppressive 
hydrogels are evaluated with primary dendritic cells isolated from non-obese diabetic 
(NOD) mice, which are a relevant model for dendritic cells in the context of type I 
diabetes. Based on the observation from Specific Aim 2 that increasing interactions 
between immune cells and PEG surfaces increases signaling, general cell adhesion is 
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promoted on immunosuppressive hydrogels via the incorporation of poly-L-lyine (PLL) 
and extracellular matrix (ECM) proteins, which both facilitate cell binding by increasing 
the adhesion of serum proteins or by directly presenting integrin binding domains, 
respectively. 
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Chapter 3 
 
Polymerizable superoxide dismutase mimetic protects cells encapsulated in PEG 
hydrogels from reactive oxygen species-mediated damage 
 
 
 
A polymerizable superoxide dismutase mimetic (SODm) was incorporated into 
poly(ethylene glycol) (PEG) hydrogels to protect encapsulated cells from superoxide-
mediated damage.  Superoxide and other small reactive oxygen species (ROS) can 
cause oxidative damage to donor tissue encapsulated within size exclusion barrier 
materials.  To enzymatically breakdown ROS within biomaterial cell encapsulation 
systems, Mn(III) Tetrakis[1-(3-acryloxy-propyl)-4-pyridyl] porphyrin (MnTTPyP-acryl), a 
polymerizable manganese metalloporphyrin SOD mimetic, was photopolymerized with 
PEG diacrylate (PEGDA) to create functional gels.  In unmodified PEG hydrogels, a 
significant reduction in metabolic activity was observed when encapsulated Min6 β-cells 
were challenged with chemically-generated superoxide.  Cells encapsulated within 
MnTPPyP-co-PEG hydrogels demonstrated greatly improved metabolic activity 
following superoxide challenge.  To promote encapsulated cell survival throughout a 10 
day period, the effect of cell seeding density on cell survival was characterized in blank 
PEG hydrogels and a significant improvement in viability was observed when seeded in 
excess of 6.7x106 cells/ml.  Finally, cells were encapsulated and cultured for 10 days 
within MnTPPyP-co-PEG hydrogels and challenged with superoxide on days 4, 6, and 
8. At the conclusion of this study, cells in blank PEG hydrogels had no observable 
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metabolic activity but when encapsulated in MnTPPyP-functionalized hydrogels, cells 
retained 60±5% of the metabolic activity compared to untreated controls.      
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3.1     INTRODUCTION 
Cell-based therapies hold the potential to cure numerous diseases resulting from 
the damage or destruction of native tissues.  As cell delivery strategies continue to 
improve, clinical successes [1-5] and new trials [6] have been reported in applications 
ranging from the delivery of dopaminergic neurons to treat Parkinson’s disease to 
autologous chondrocytes to regenerate cartilage to the delivery of β-cells and islets for 
the treatment of type I diabetes.  When considering strategies that rely on allogeneic 
cell delivery, it is crucial to consider adequate protection of donor cells from the host 
immune response.  Generally, systemic immunosuppression is required to facilitate 
transplant survival [7], but this therapy carries several serious side effects that must be 
measured against the benefits of a cell transplant.   
In contrast, cell encapsulation creates a physical barrier between donor tissue and 
host immune cells and has been widely investigated as a means to increase 
immunoisolation [8] for the delivery of cells to treat hepatic [9, 10], central nervous [11], 
and endocrine disorders [12], amongst other diseases.  The encapsulation of pancreatic 
tissue has been the most commonly investigated immunoisolation system[8], and 
numerous materials, natural and synthetic, have been shown to promote cell survival in 
vitro and in vivo [8, 13-15]. As one example, poly(ethylene glycol) (PEG) diacrylate 
(PEGDA) hydrogels offer a desirable cell encapsulation material because PEG itself is 
relatively non-fouling, hydrophilic, and allows facile chemical modification. Our 
laboratory and others have demonstrated that blank and functionalized PEG hydrogels 
readily promote encapsulated cell survival and function [15-18]. 
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The size-exclusion membrane characteristic of an encapsulation barrier blocks 
the passage of immune cells and large molecules like immunoglobulins[8].  However, 
small molecules produced by activated neutrophils and macrophages, such as reactive 
oxygen species (ROS) and cytokines, including tumor necrosis factor (TNF) and 
interleukin 1-beta (IL-1β), can readily diffuse through passive membranes and damage 
donor cells [19, 20].  When reactive oxygen species like superoxide, nitric oxide (NO•), 
hydrogen peroxide (H2O2), and hydroxyl radical (HO•) come into contact with 
transplanted cells, they induce oxidative damage to many cellular molecules including 
DNA, proteins, and membrane lipids, leading to cellular dysfunction and death [21-23].  
Superoxide is also known to combine with NO• to form peroxynitrite (ONOO-), a highly 
reactive nitrogen species able to rapidly induce cells damage and cell death, as well as 
signal additional cytokine secretion [24].  
To provide greater protection from small cytotoxic molecules, researchers have 
previously investigated methods to functionalize passive encapsulation membranes.  To 
highlight recent approaches,  Lin et al. tethered anti-TNF affinity peptides within cell-
laden PEG hydrogels and demonstrated improved cell survival when challenged with 
TNF [25]. Likewise, to influence the cytokine profile around an encapsulation device, 
Washburn et al. conjugated antibodies against IL-1β and TNF to hyaluronic acid 
materials for cytokine sequestration and demonstrated fewer activated macrophages 
responding to adjacent wound sites in vivo [26].  While these approaches limit cytokine 
diffusion in and around capsules, encapsulated cells are also susceptible to damage 
from reactive oxygen species, and a limited number of publications report strategies to 
reduce ROS-mediated cell death.    
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Mammalian cells express several enzymes dedicated to breaking down ROS, 
including superoxide dismutase (SOD), which catalyzes the dismutation of superoxide 
into O2 and H2O2.  Ordinarily, endogenous SOD activity is sufficient to maintain healthy 
levels of superoxide, but during a diseased state or active immune response, the 
concentration of superoxide can exceed that which the SOD enzyme can breakdown 
[27]. In fact, β-cells, such as those delivered from the treatment of type I diabetes, are 
known to express reduced levels of antioxidants as compared to other cell types [28] 
and are at an increased risk of damage from ROS. Delivering SOD directly to cells [29-
32] or cell transplants [33] provides protection from ROS injury.  While SOD protein 
offers a high level of catalytic activity, whole proteins suffer from limited in vivo stability 
and have the potential for immunogenicity.  Thus, SOD mimetics (SODm), small organic 
molecules that recapitulate the enzymatic activity of SOD protein, have gained 
popularity due to their increased half-life and decreased immunogenicity [34]. The most 
popular classes of SODm are the metalloporphyrins, which consist of a carbon-based 
porphyrin ring and redox metal core. Manganese porphyrins exhibit among the highest 
SODm activity [35] and significantly reduce ROS damage [32, 36, 37].  Manganese 
porphyrins also possess catalytic activity to breakdown additional ROS, including H2O2, 
peroxynitrite, and NO•  [27, 38, 39]. 
 While the majority of research delivering SOD focuses on injecting SOD and 
SODm directly into tissues, recent efforts have investigated material platforms for the 
delivery of SOD, including modification of SOD with PEG to improve serum half-life [40, 
41], release of SOD from biomaterials to increase local availability [42, 43] and 
encapsulation of SOD within hydrogels [44]. Each of these approaches has shown 
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promise, but each is limited by the aforementioned problems of using the whole SOD 
protein, rather than SODm.  Additionally, SOD release platforms become inactive once 
the entire payload of SOD is released. Recently, Cheung et al. introduced a modified  
 
Fig. 3.1. (A) The chemical structure of the polymerizable SODm, MnTPPyP-Acryl. (B) Schematic of the 
MnTPPyP-co-PEG immunoisolation barrier. ROS diffuse inside the capsule but are broken down by the 
covalently bound SOD mimetic. ROS are indicated as being secreted by activated immune cells, as these 
cells are responsible for ROS secretion in response to tissue transplants. For the studies conducted 
herein, however, superoxide was generated chemically. 
SOD mimetic, MnTPPyP-Acryl, Fig. 3.1A, with comparable enzymatic activity to 
commercially available SODm [45].  MnTPPyP-Acryl is unique, as it has polymerizable 
acrylate groups that enable covalent incorporation into polymer networks.  Cheung et al. 
co-polymerized MnTPPyP-Acryl with PEG diacrylate (PEGDA) to create hydrogels 
functionalized with SODm, and the MnTPPyP-co-PEG hydrogels exhibited SOD 
enzymatic activity that was sustainable throughout several challenges with superoxide 
[45]. In the present study, we encapsulate Min6 β-cells within MnTPPyP-co-PEG 
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hydrogels to demonstrate the ability of this capsule to increase cell survival following 
treatment with ROS, as summarized in Fig. 3.1B.  
 
3.2  MATERIALS & METHODS 
3.2.1  Synthesis of polymerizable superoxide dismutase mimetic 
The synthesis and characterization of MnTPPyP-Acrl have been previously 
reported in great detail[45] and is briefly summarized herein.  The 4 arms of meso-
Tetra(4-pyridyl)porphine (TPyP) (Frontier Scientific, Logan, UT) were quarternized with 
80-fold molar excess 3-iodopropanol (Trans World Chemicals, Rockville, MD) in DMF 
yielding meso-Tetra[1-(3-hydroxy-propyl)-4-pyridyl] porphine (TPPyP-OH). Product was 
added to chloroform, extracted into water and precipitated with ammonium 
hexafluorophosphate (NH4PF6) (Sigma-Aldrich, St. Louis, MO). TPPyP-OH was 
acrylated in acetone via reaction with 8-fold molar excess acryloyl chloride (Sigma-
Aldrich) and triethylamine (TEA, Sigma-Aldrich), yielding TPPyP-Acryl, and was 
precipitated via the addition of tetrabutylammonium chloride (TBAC, Sigma-Aldrich).  
Next, TPPyP-Acryl was reacted overnight with 20-fold molar excess MnCl2 (Sigma-
Aldrich) in dH2O containing 1 M NaOH, resulting in metallation and the final product, 
MnTPPyP-Acryl.  MnTPPyP-Acryl was precipitated with NH4PF6 and rinsed with 1:1 
isopropanol/diethyl ether.  Product was dissolved in acetone for counterion exchange to 
Cl- and then precipitated by TBAC.  The resulting MnTPPyP-Acryl product was 
desiccated overnight to yield a dry, solid product.          
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3.2.2   Cell culture  
Murine pancreatic β-cells (Min6) were cultured in T-75 tissue culture flasks, 
containing 15 ml cell culture media, consisting of RPMI 1640 supplemented with 10% 
fetal bovine serum, 100 mg/ml Penicillin/Streptomycin, and 0.5 mg/ml Fungizone (all 
from Invitrogen, Carlsbad, CA).  Cells were seeded at 1x106 cells/ml and incubated at 
37 °C in humid conditions with 5% CO2.  Fresh media was added three times per week 
and cells were passaged weekly, by treatment with 0.5 % trypsin EDTA,  (10 ml, 5 min, 
Invitrogen) followed by quenching with 10 ml media.  All cells used were passaged 
between 5 and 20 times. 
 
3.2.3  Superoxide generation & quantification 
Superoxide was generated via enzymatic breakdown of xanthine (Sigma-Aldrich) 
to uric acid, by xanthine oxidase (Sigma-Aldrich)[46].  In cell culture media, Xanthine (0 
to 100 μM) was reacted with xanthine oxidase (10 nM). Superoxide production was 
quantified by measuring the oxidation of cytochrome C (Sigma-Aldrich)[47].  
Xanthine/Xanthine oxidase were reacted in the presence of cytochrome C (100 μM) and 
the change in 550 nm absorbance was measured using UV-vis spectroscopy to 
calculate the superoxide production rate using Eqn. 1, adapted from Choi et al..    
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                                                   (1) 
Here, ΔA is the change in absorbance, v is volume, l is cuvette pathlength, t is time, and 
K is the extinction coefficient for the absorption difference between reduced and 
oxidized cytochrome C (K = 21 x 103 cm-1 M-1)[47, 48] at 550 nm. 
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3.2.4   Cyto-protection with soluble MnTPPyP-acryl 
Min6 β-cells (100 000 cells/ml) were seeded in 96-well plates containing 200 μl 
cell culture media.  After 48 hrs, fresh media was added and superoxide was generated 
via the addition of xanthine (100 μM) and xanthine oxidase (10 nM), with or without the 
addition of soluble MnTPPyP-Acryl (100 μM).  2 hrs following treatment, dead cells were 
visualized by trypan blue (Invitrogen) staining, whereby 180 μl media was gently 
removed from each well (20 μl media/well remained) and 2 μl trypan blue stain (0.4%) 
was added.  Cells were imaged using a Nikon Eclipse TE300 microscope and blue 
staining indicated dead cells.  Metabolic activity of Min6 cells was measured 24 hrs 
following superoxide treatment by adding 22 μl of AlamarBlue reagent (Invitrogen) to 
each condition (yielding a 10% v/v AlamarBlue solution) and incubating for 3 hrs.  
Fluorescence (excitation: 560 nm, emission: 590 nm) represented the metabolic activity 
of living cells. Percentage metabolic activity was calculated by comparing samples to 
untreated controls. 
 
3.2.5   Synthesis of PEGDA 
 The synthesis of poly(ethylene glycol) diacrylate (PEGDA) has been previously 
described[49, 50].   Briefly, hydroxyl-terminated poly(ethylene glycol) (PEG, Mn = 10 
000 g/mol, Sigma-Aldrich) was dissolved in 60 °C toluene and then cooled to room 
temperature.  A 4-fold molar excess of acryloyl chloride and triethylamine (TEA) to PEG 
hydroxyl groups was added to the PEG and reacted overnight at room temperature. The 
PEGDA product was filtered through neutral alumina (Fisher Scientific, Pittsburg, PA) to 
remove TEA-HCl salt.  Excess toluene was removed by rotovap and the resulting 
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product was precipitated in cold diethyl ether and desiccated overnight. The degree of 
acrylation was determined by 1H-NMR to be in excess of 95 %. 
 
3.2.6   Cell Encapsulation 
Min6 β-cells were harvested and suspended (5 to 10 million cells/ml) in PEGDA 
(10 kDa, 10 wt%) macromer solution in phosphate buffered saline (PBS, pH 7.4, 
Invitrogen) with 1-[4-(2-hydroxyethoxy)-phenyl]-2-hydroxy-2-methyl-1-propanone 
(Irgacure 2959, 0.05 wt%, Ciba Specialty Chemicals, Newport, DE) as photoinitiator and 
0 to 100 μM MnTPPyP-Acryl. 30 μl/gel was loaded into 1 ml syringe tips for 
photopolymerization under ultraviolet light (10 mW/cm2, centered at 365 nm), for 10 min.  
Following encapsulation, hydrogel disks of ~ 5 mm diameter x 1 mm height were placed 
in individual wells of a 24-well plate containing 1 ml cell culture media and incubated 
overnight.  Hydrogels were transferred to fresh media the day after encapsulation and 
media was changed every-other day thereafter.  This method of encapsulation has been 
widely investigated and is highly cytocompatible[17, 25, 50, 51]. The intracellular ATP 
content of encapsulated cells was quantified via CellTiter-Glo assay (Promega, 
Madison, WI), where capsules were placed in 300 μl of 50 % CellTiter-Glo reagent / 50 
% cell culture media.  Samples were incubated at room temperature on an orbital 
shaker for 1 h. Next, 200 μL was transferred to white-wall 96-well plate and 
luminescence was detected and compared to ATP standards. 
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3.2.7   Challenging encapsulated β-cells with superoxide and analysis 
Min6 cells were encapsulated in PEGDA with or without the addition of 
MnTPPyP-Acryl. These capsules were exposed to superoxide via the addition of 
xanthine (0 to 100 μM) and xanthine oxidase (10 nM) to 1 ml cell culture media 
containing one hydrogel.  Cell-laden gels were incubated (37 °C, with orbital shaking) 
with xanthine / xanthine oxidase for 2 hrs, as this time point was considered to be 
sufficient for complete superoxide generation (Fig 3.2).  Metabolic activity of 
encapsulated cells was assessed by adding 110 μl AlamarBlue reagent to each 1 ml 
well (yielding 10% v/v AlamarBlue).  Gels were incubated overnight, then 200 μl from 
each well was transferred to individual wells of a 96-well plate and scanned, as 
described above.  Percent metabolic activity was determined by comparing raw 
fluorescence signal to that of untreated, cell-laden, control gels containing equivalent 
concentrations of MnTPPyP-Acryl.  Live and dead encapsulated cells were analyzed by 
fluorescent confocal microscopy using a membrane integrity assay.  Gels were 
incubated 30 min (PBS, 37°C) with green fluorescent calcein AM and red fluorescent 
ethidium homodimer-1 (Invitrogen), to stain live and dead cells, respectively.  A series of 
20 projections at 10 μm intervals were captured on a Zeiss LSM 5 Pascal confocal 
microscope and projected onto a single plane.    
       
3.2.8    Statistical Analysis 
All results are presented as mean ± standard error of the mean.  Statistical 
significance between datasets was determined using a two-tailed, unpaired Student’s t-
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test and differences were considered statistically significant when the p value was less 
than 0.05.  All experiments were replicated at least 3 times. 
 
3.3    RESULTS 
3.3.1  Generation of superoxide 
  Superoxide was generated chemically via the enzymatic breakdown of 
xanthine by xanthine oxidase, as previously described[46].  Cytochrome C was utilized 
to quantify the rate of superoxide generation as a function of xanthine concentration, 
shown in Fig. 3.2. In the presence of 10 nM xanthine oxidase, xanthine concentrations 
ranging from 25 to 100 μM generated superoxide concentrations ranging from 14±4 to 
27 ± 3 nmol/mL, respectively (data shown in Table 3.1).   
 
 
 
 
 
Fig. 3.2. Quantification of superoxide 
generated by the chemical reaction of 
xanthine with xanthine oxidase.  
Xanthine (25, 50, 75, & 100 µM) was 
combined with 10 nM xanthine oxidase 
in cell culture media and cytochrome C 
was used to detect the appearance of 
superoxide anions over time. 
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Table 3.1. Total superoxide generated throughout a chemical reaction of xanthine with xanthine oxidase. 
The change in absorbance of Cytochrome C enabled the detection of the total quantity of superoxide 
produced per reaction, per mL of media. 
 
3.3.2  Solution-phase bioactivity of MnTPPyP-acryl 
 MnTPPyP-Acryl catalyzes the dismutation of superoxide anions in solution[45]. 
To demonstrate that this enzymatic activity is sufficient to protect living cells from 
superoxide damage, β-cells were seeded onto TCPS and exposed to superoxide 
generated by xanthine/xanthine oxidase. After two hours, dead cells were visualized, 
Fig. 3.3A, and cell death was observed following superoxide treatment.  In the presence 
of soluble MnTPPyP-Acryl and superoxide, however, increased cell survival was 
observed.  In Fig. 3.3B, 24 hrs following exposure to superoxide, β-cell metabolic 
activity also decreased significantly, but when MnTPPyP-Acryl and superoxide were 
added, the metabolic activity was rescued, such that comparable activity to non-
superoxide-treated cells was observed.  When added alone, xanthine, xanthine oxidase, 
or MnTPPyP-Acryl did not reduce cellular metabolic activity and were highly 
cytocompatible (data not shown). 
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Fig. 3.3. Soluble 
MnTPPyP-Acryl 
protects β-cells plated 
on TCPS from damage. 
Superoxide was 
generated chemically in 
the presence of Min6 β-
cells with or without 
MnTPPyP-Acryl. (A) 
Trypan blue staining 
revealed numerous 
dead (blue) cells in the 
absence of MnTPPyP-
Acryl (left) but fewer 
dead cells with 
MnTPPyP-Acryl (right). 
Scale bar denotes 100 
µm (B) Exposure to 
superoxide significantly 
reduced the metabolic 
activity of plated β-cells 
but the addition of 
MnTPPyP-Acryl to 
solution prevented this 
reduction. * denotes 
p<0.05 difference from 
other values. 
 
 
3.3.3  Treating cell-laden hydrogels with superoxide 
The metabolic activity of encapsulated cells was assessed following treatment 
with superoxide generated by xanthine/xanthine oxidase.  Min6 were encapsulated at a 
density of 5x106 cells/ml. The following day, hydrogels were treated with xanthine (0 to 
100 μM) in the presence of xanthine oxidase (10 nM) and a decrease in metabolic 
activity related to xanthine concentration was observed, Fig. 3.4A. Live/Dead imaging of 
hydrogels exposed to 0, 50 and 100 μM xanthine and xanthine oxidase (10 nM), Fig. 
3.4B, revealed significant cell death for samples treated with xanthine.          
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Fig. 3.4. Chemically generated superoxide damages encapsulated β-cells. (A) Metabolic activity of 
encapsulated cells was reduced, compared to untreated controls, as the concentration of xanthine added 
to solution was increased. (B) Live/dead confocal imaging enabled the visualization of live (green) and 
dead (red) cells.  Many dead cells were visible when treated with 50 & 100 µM xanthine (and 10 nM 
xanthine oxidase). Scale bar denotes 100 µm. 
  
3.3.4  Copolymerization of MnTPPyP-Acryl and PEGDA to encapsulate β-cells 
 MnTPPyP-Acryl (0 to 100 μM) was covalently incorporated into PEGDA 
hydrogels containing Min6 encapsulated at 5x106 cells/ml and challenged with 25, 50 or 
100 μM xanthine and xanthine oxidase (10 nM).  As shown in Fig 3.5A, a decrease in 
metabolic activity was observed with increased xanthine, similar to the trend highlighted 
in Fig. 3.4A.  However, as the concentration of superoxide dismutase mimetic, 
MnTPPyP-Acryl, polymerized into gels was increased, the metabolic activity of 
encapsulated cells was rescued.  This rescue occurred at a low concentration of 
MnTPPyP-Acryl (10 μM) when challenged with the lowest concentration of xanthine  
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Fig. 3.5. Covalently incorporating MnTPPyP-Acryl into the hydrogel protects β-cells from ROS damage. (A) Cellular 
metabolic activity of encapsulated cells was monitored following treatment with xanthine (25, 50, & 100 µM) and 10 
nM xanthine oxidase. As the concentration of MnTPPyP-Acryl covalently polymerized into the hydrogel was 
increased, the observed metabolic activity of cells was increase following exposure to superoxide. (B) Live/dead 
imaging verified that many more live (green) cells were visible following superoxide treatment in the presence of 100 
µM MnTPPyP-Acryl (right) compared to blank gels (left). Scale bar denotes 100 µm. 
 (25 μM) as metabolic activity was restored to that of untreated controls.  For cell-laden 
gels treated with 100 μM xanthine, the inclusion of MnTPPyP-Acryl (100 μM) resulted in 
over 70 % of the metabolic activity of controls.  Live/dead imaging of encapsulated cells 
verified that the inclusion of polymerizable SOD mimetic, Fig. 3.5B, results in a marked 
increase in cell survival following superoxide treatment.  
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3.3.5   Cell Seeding density and β-cell survival 
 We were interested in studying the cytoprotective capability of polymerized 
MnTPPyP-Acryl in extended in vitro culture.   Previous studies, however, have revealed 
that non-aggregated β-cells encapsulated at low cell seeding density in un-modified 
PEG-based hydrogels exhibit reduced viability after several days of in vitro culture [18, 
51, 52].  Incorporating extracellular matrix proteins (collagen, laminin, etc,) or peptide 
mimetics (RGDS, IKVAV, etc.) only delay the process of cell apoptosis due to the lack 
of cell-cell interactions in PEG hydrogels [18, 52].  To improve the viability of β-cells in 
PEGDA hydrogels, we studied the effects of Min6 β-cell seeding density over the course 
of 10 days.  As shown in Fig. 3.6A, when encapsulated at 5x106 cells/ml in blank 
PEGDA hydrogels, Min6 viability decreased with time, in agreement with prior studies 
[18, 51, 52]. When encapsulated at cell densities equal to or greater than 6.7x106 
cells/ml, however, viability increased with encapsulation time.  Live/dead imaging was 
performed at days 0 and 10 and confirmed an increase in viable cells when 
encapsulated at densities equal to or greater than 6.7x106 cells/ml, Fig. 3.6B.  On day 
10, almost no evidence of viability existed for capsules seeded at 5x106 cells/ml.  For 
higher seeding densities, however, there was visible evidence of intact cell aggregates.  
This simple approach allowed for the maintenance of Min6 viability in PEG hydrogels 
without the addition of ECM components, enabling the protective effects of SODm in 
long term culture to be evaluated.  
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Fig. 3.6. β-cell seeding density effects long-term survival when encapsulated in PEGDA hydrogels. (A) 
Min6 β-cells were encapsulated at 5, 6.7, 10, & 20 million cell/mL and then assayed for viability over a 10-
day period. When seeded at 5 million cells/mL, cellular viability decreased over time.  Cells survived when 
seeded at higher densities. (B) Live/dead imaging confirmed improved viability after 10 days for higher 
seeding densities as larger, live (green), aggregates of β-cells were present when seeded at increased 
densities. Scale bar denotes 200 µm.   
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3.3.6   Long term study of encapsulated β-cells with superoxide 
 To demonstrate the potential of MnTPPyP-Acryl to protect encapsulated cells for 
an extended period of time, a 10 day study was completed with multiple superoxide 
challenges.  Specifically, Min6 β-cells were encapsulated in PEGDA gels, with or 
without MnTPPyP-Acrl (100 μM), at a density of 10x106 cells/ml. As illustrated in Fig 
3.7A, cell-laden gels were treated with superoxide (100 μM xanthine, 10 nM xanthine 
oxidase) on days 4, 6, and 8, and metabolic activity was assayed throughout the study.  
The initial superoxide treatment on day 4 resulted in a 50% reduction in metabolic 
activity for cells within blank hydrogels, while only a 20% reduction was observed for 
gels containing MnTPPyP-Acryl.  Following the second superoxide treatment on day 6, 
the metabolic activity of control gels dropped to only 8 ± 1 % of untreated control gels 
while the gels containing MnTPPyP-Acryl remained at 66 ± 3% of that of untreated 
MnTPPyP-Acryl gels.  Following three superoxide treatments, on day 10, gels 
containing MnTPPyP-Acryl exhibited 60 ± 5% of the metabolic activity of untreated 
MnTPPyP-Acryl gels while no metabolic activity was observed in control gels.  When 
analyzing gels stained for cell viability (i.e, live/dead staining) on day 10 (Fig. 3.7B), 
MnTPPyP-Acryl gels treated 3x with superoxide showed many healthy, cell aggregates.  
Imaging of control gels verified poor viability following three superoxide treatments.         
 
3.4      DISCUSSION 
This study demonstrates that MnTPPyP-Acryl protects cells from superoxide-
mediated ROS damage in vitro. We identified concentrations of xanthine and xanthine  
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Fig. 3.7. MnTPPyP-co-PEG hydrogels retain enzymatic activity over many days and after several 
superoxide treatments. β-cells were encapsulated with or without MnTPPyP-Acryl and cultured for 10 
days.  On days 4, 6, & 8 samples were treated with superoxide (represented by the horizontal dashed 
line) generated by 100 µM xanthine / 10 nM xanthine oxidase. (A) Cells within hydrogels containing 
MnTPPyP-Acryl retained significantly more metabolic activity after repeated superoxide exposure 
compared to control hydrogels. (B) After 10 days in culture with superoxide treatments on days 4,6, & 8, 
cell-laden hydrogels were imaged via live/dead staining.  Visualization confirmed the presence of many 
large, live (green) aggregates in gels contained MnTPPyP-Acryl (right) compared to control gels, which 
contained many dead (red) cells (left). Scale bar represents 100 µm. 
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oxidase to generate superoxide at rates comparable to those generated by activated 
immune cells [48, 53]. When un-encapsulated cells are exposed to the chemically 
generated superoxide, the concentrations of ROS were sufficient to significantly reduce 
overall metabolic activity, but the addition of soluble MnTPPyP-Acryl to the culture was 
found to preserved viability. 
Min6 β-cells were then encapsulated within PEGDA hydrogels and treated with 
superoxide; a loss of metabolic activity was confirmed in the presence of 
xanthine/xanthine oxidase generated superoxide. As others have observed [42], 
superoxide treatment resulted in damage to encapsulated cells and, in our studies, 
rapidly resulted in reduced metabolic activity and cell death.  Further, the extent to 
which cellular metabolic activity was reduced was dependent upon the concentration of 
superoxide generated, as controlled via the xanthine concentration.  When MnTPPyP-
Acryl was immobilized into the hydrogel network through copolymerization, a striking 
cytoprotective effect was observed; when MnTPPyP-Acryl was included at 100 µM, the 
highest concentration investigated, cellular metabolic activity was rescued from 0% to 
over 60%, when treated with 100 µM xanthine. In these studies, the highest 
concentration of MnTPPyP-Acryl was chosen to be 100 μM, because beyond this 
concentration, the polymerization rate of the hydrogel becomes inhibited, as previously 
reported [45], likely due to active radical scavenging by the SODm. 
A major benefit of covalently incorporating MnTPPyP-Acryl into a hydrogel is the 
potential to extend SOD activity over time and localize the SOD activity at the site of the 
transplanted cells.  Thus, we were interested in evaluating the capacity of MnTPPyP-
Acryl to protect encapsulated cells from ROS damage over many days in culture. In 
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performing these studies, it became apparent that, even in the absence of any 
superoxide challenge, Min6 viability declined after several days in culture within 
unmodified PEG hydrogels [18, 51, 52].  In an effort to improve viability, we investigated 
the effect of initial cell seeding density on long-term Min6 survival. We chose to study 
the effects of cell-seeding density, as we hypothesized that increasing cell 
seeding/packing density increases the probability of cell-cell contact paracrine signaling 
that may positively influence β-cells survival when encapsulated in PEG hydrogels.  
Indeed, previous studies have demonstrated the importance of cell-cell contact on the 
proliferation, survival, and function of β-cells [54-57].  We verified this effect, Fig. 3.6, as 
Min6 β-cells had drastically improved viability when seeded at or in excess of 6.7 million 
cell/mL. These results highlight the importance of considering cell seeding density when 
culturing encapsulated β-cells. 
To evaluate the capacity of MnTPPyP-co-PEG hydrogels to protect encapsulated 
cells from multiple ROS exposures over several days, Min6 were seeded at a density of 
10 million cells/mL and exposed to multiple superoxide treatments. We challenged gels 
with a high concentration of superoxide on days 4, 6, and 8. Cheung et al. previously 
demonstrated that a single MnTPPyP-Acryl hydrogel was capable of breaking down 
multiple superoxide challenges with no observable loss in activity [45]. Herein, we have 
shown that these gels are able to protect encapsulated cells from multiple ROS 
challenges. A striking increase in metabolic activity was observed following three 
superoxide challenges within MnTPPyP-co-PEG hydrogels, compared to blank 
capsules. Even with the inclusion of MnTPPyP-Acryl, some loss in metabolic activity 
following superoxide treatment was observed, relative to untreated controls, especially 
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after the first treatment. Because metabolic activity was reduced to a much lesser 
degree following the 2nd and 3rd superoxide exposures, we initially hypothesized that cell 
damage during the first superoxide treatment would be those located in proximity to the 
exterior of the gel and that during the 2nd and 3rd superoxide treatments, ROS 
breakdown would occur prior to diffusing through this space.  Upon analysis of live/dead 
cell images on day 10, however, overwhelming visual evidence of dead cells in the 
periphery of the gel was not observed and live cells seemed to be relatively uniformly 
distributed throughout the network. Thus, it is possible that the β-cell damage during the 
first superoxide treatment simply occurred within cells that tended to be more sensitive 
to ROS.  
While superoxide anions were generated via the reaction of xanthine with 
xanthine oxidase, it was unlikely that superoxide directly elicited the destruction of 
encapsulated β-cells in this study.  Superoxide has a short half-life and others have 
modeled the diffusion of superoxide into hydrogels and predicted that superoxide would 
penetrate only short distances within the capsule [58]. Despite the short half-life of 
superoxide, encapsulated cells experience oxidative damage when challenged with 
superoxide [42]. While superoxide is too short-lived to diffuse into the PEGDA hydrogel, 
the molecule rapidly reacts with NO• to form OONO- and decomposes to H2O2 [21-23].  
Both molecules have significantly longer half-lives and are predicted to diffuse deeply 
into the hydrogel capsule [58, 59]. It is oxidative damage from these ROS that likely 
mediates the reduced metabolic activity observed when cells in blank hydrogels are 
treated with superoxide. Fortuitously, the promiscuity of manganese porphyrin SOD 
mimetics has been previously demonstrated and these molecules are known to possess 
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enzymatic activity to breakdown H2O2 and OONO- [38, 39]. The breakdown of these 
ROS likely explains the mechanism by which MnTPPyP-Acryl preserves encapsulated 
cell viability in this study and further highlights the anti-oxidative benefit of MnTPPyP-
functionalized PEG scaffolds.   
This study showcases the capacity of polymerized MnTPPyP-Acryl to protect 
encapsulated cells from ROS damage, but there are still many hurdles to overcome 
before adequate immunoprotection will be achieved to remove the need for 
immunosuppression following a transplant. Towards this goal, our laboratory and others 
have investigated alternative approaches to reduce the concentration of cytotoxic 
molecules within cell-laden capsules. Peptides and antibodies have been used to 
sequester cytokines or inflammatory molecules within barrier materials and have been 
shown to increase encapsulated cell viability [25, 50]. Likewise, we have reported 
strategies to reduce the local population of inflammatory cells adjacent to transplants 
[60, 61]. We envision that MnTPPyP-Acryl might be used in tandem with these and 
other immunoprotection strategies to improve active immunoisolation barriers and 
increase cell survival. In summary, immunoisolation within MnTPPyP-co-PEG hydrogels 
provides localized protection of encapsulated cells from ROS damage and may provide 
an effective route towards improving long-term survival in future transplantation studies. 
 
3.5      ACKNOWLEDGEMENTS 
 The authors wish to thank Dr. Charles Cheung for training and initial guidance in 
this project, Dr. Alex Aimetti for helpful discussions and Abigail Bernard for assistance 
with β-cell culture. We gratefully acknowledge financial support from the National 
71 
 
Institute of Health (RO1DK076084), the Howard Hughes Medical Institute, and the 
Department of Education’s Graduate Assistance in Areas of National Need fellowship to 
P.S.H.          
72 
 
3.6     REFERENCES 
 
1. Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, et al. 
Transplantation of embryonic dopamine neurons for severe Parkinson's disease. The 
New England journal of medicine 2001 Mar 8;344(10):710-719. 
 
2. Brittberg M, Lindahl A, Nilsson A, Ohlsson C, Isaksson O, Peterson L. Treatment 
of deep cartilage defects in the knee with autologous chondrocyte transplantation. The 
New England journal of medicine 1994 Oct 6;331(14):889-895. 
 
3. Pavlakis M, Khwaja K. Pancreas and islet cell transplantation in diabetes. 
Current opinion in endocrinology, diabetes, and obesity 2007 Apr;14(2):146-150. 
 
4. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, et al. Islet 
transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-
free immunosuppressive regimen. The New England journal of medicine 2000 Jul 
27;343(4):230-238. 
 
5. White SA, Shaw JA, Sutherland DE. Pancreas transplantation. Lancet 2009 May 
23;373(9677):1808-1817. 
 
6. www.clinicaltrails.gov. 
 
7. Bertuzzi F, Ricordi C. Beta-cell replacement in immunosuppressed recipients: old 
and new clinical indications. Acta diabetologica 2007 Dec;44(4):171-176. 
 
8. Wilson JT, Chaikof EL. Challenges and emerging technologies in the 
immunoisolation of cells and tissues. Advanced drug delivery reviews 2008 Jan 
14;60(2):124-145. 
 
9. Nyberg SL, Yagi T, Matsushita T, Hardin J, Grande JP, Gibson LE, et al. 
Membrane barrier of a porcine hepatocyte bioartificial liver. Liver Transpl 2003 
Mar;9(3):298-305. 
 
10. Shi XL, Zhang Y, Han B, Gu JY, Chu XH, Xiao JQ, et al. Effects of Membrane 
Molecular Weight Cutoff on Performance of a Novel Bioartificial Liver. Artificial organs 
2011 Mar 3. 
 
11. Emerich DF, Winn SR. Immunoisolation cell therapy for CNS diseases. Crit Rev 
Ther Drug Carrier Syst 2001;18(3):265-298. 
 
12. Lee MK, Bae YH. Cell transplantation for endocrine disorders. Advanced drug 
delivery reviews 2000 Aug 20;42(1-2):103-120. 
 
73 
 
13. de Vos P, Hamel AF, Tatarkiewicz K. Considerations for successful 
transplantation of encapsulated pancreatic islets. Diabetologia 2002 Feb;45(2):159-173. 
 
14. Cui H, Tucker-Burden C, Cauffiel SM, Barry AK, Iwakoshi NN, Weber CJ, et al. 
Long-term metabolic control of autoimmune diabetes in spontaneously diabetic 
nonobese diabetic mice by nonvascularized microencapsulated adult porcine islets. 
Transplantation 2009 Jul 27;88(2):160-169. 
 
15. Cruise GM, Hegre OD, Lamberti FV, Hager SR, Hill R, Scharp DS, et al. In vitro 
and in vivo performance of porcine islets encapsulated in interfacially photopolymerized 
poly(ethylene glycol) diacrylate membranes. Cell transplantation 1999 May-
Jun;8(3):293-306. 
 
16. Weber LM, Hayda KN, Anseth KS. Cell-matrix interactions improve beta-cell 
survival and insulin secretion in three-dimensional culture. Tissue engineering 2008 
Dec;14(12):1959-1968. 
 
17. Weber LM, Anseth KS. Hydrogel encapsulation environments functionalized with 
extracellular matrix interactions increase islet insulin secretion. Matrix Biol 2008 
Oct;27(8):667-673. 
 
18. Lin CC, Anseth KS. Glucagon-Like Peptide-1 Functionalized PEG Hydrogels 
Promote Survival and Function of Encapsulated Pancreatic beta-Cells. 
Biomacromolecules 2009 Sep;10(9):2460-2467. 
 
19. Jang JY, Lee DY, Park SJ, Byun Y. Immune reactions of lymphocytes and 
macrophages against PEG-grafted pancreatic islets. Biomaterials 2004 
Aug;25(17):3663-3669. 
 
20. de Vos P, Marchetti P. Encapsulation of pancreatic islets for transplantation in 
diabetes: the untouchable islets. Trends Mol Med 2002 Aug;8(8):363-366. 
 
21. Mohseni Salehi Monfared SS, Larijani B, Abdollahi M. Islet transplantation and 
antioxidant management: a comprehensive review. World J Gastroenterol 2009 Mar 
14;15(10):1153-1161. 
 
22. Hadjivassiliou V, Green MH, James RF, Swift SM, Clayton HA, Green IC. Insulin 
secretion, DNA damage, and apoptosis in human and rat islets of Langerhans following 
exposure to nitric oxide, peroxynitrite, and cytokines. Nitric Oxide 1998;2(6):429-441. 
 
23. Di Matteo MA, Loweth AC, Thomas S, Mabley JG, Morgan NG, Thorpe JR, et al. 
Superoxide, nitric oxide, peroxynitrite and cytokine combinations all cause functional 
impairment and morphological changes in rat islets of Langerhans and insulin secreting 
cell lines, but dictate cell death by different mechanisms. Apoptosis 1997;2(2):164-177. 
 
74 
 
24. Delaney CA, Tyrberg B, Bouwens L, Vaghef H, Hellman B, Eizirik DL. Sensitivity 
of human pancreatic islets to peroxynitrite-induced cell dysfunction and death. FEBS 
letters 1996 Oct 7;394(3):300-306. 
 
25. Lin CC, Metters AT, Anseth KS. Functional PEG-peptide hydrogels to modulate 
local inflammation induced by the pro-inflammatory cytokine TNFalpha. Biomaterials 
2009 Oct;30(28):4907-4914. 
 
26. Sun LT, Bencherif SA, Gilbert TW, Farkas AM, Lotze MT, Washburn NR. 
Biological activities of cytokine-neutralizing hyaluronic acid-antibody conjugates. Wound 
Repair Regen  May-Jun;18(3):302-310. 
 
27. Muscoli C, Cuzzocrea S, Riley DP, Zweier JL, Thiemermann C, Wang ZQ, et al. 
On the selectivity of superoxide dismutase mimetics and its importance in 
pharmacological studies. British journal of pharmacology 2003 Oct;140(3):445-460. 
 
28. Lenzen S, Drinkgern J, Tiedge M. Low antioxidant enzyme gene expression in 
pancreatic islets compared with various other mouse tissues. Free radical biology & 
medicine 1996;20(3):463-466. 
 
29. Grankvist K, Marklund S, Taljedal IB. Superoxide dismutase is a prophylactic 
against alloxan diabetes. Nature 1981 Nov 12;294(5837):158-160. 
 
30. Piganelli JD, Flores SC, Cruz C, Koepp J, Batinic-Haberle I, Crapo J, et al. A 
metalloporphyrin-based superoxide dismutase mimic inhibits adoptive transfer of 
autoimmune diabetes by a diabetogenic T-cell clone. Diabetes 2002 Feb;51(2):347-355. 
 
31. Thiruchelvam M, Prokopenko O, Cory-Slechta DA, Buckley B, Mirochnitchenko 
O. Overexpression of superoxide dismutase or glutathione peroxidase protects against 
the paraquat + maneb-induced Parkinson disease phenotype. The Journal of biological 
chemistry 2005 Jun 10;280(23):22530-22539. 
 
32. Pedulla M, d'Aquino R, Desiderio V, de Francesco F, Puca A, Papaccio G. 
MnSOD mimic compounds can counteract mechanical stress and islet beta cell 
apoptosis, although at appropriate concentration ranges. Journal of cellular physiology 
2007 Aug;212(2):432-438. 
 
33. Nomikos IN, Wang Y, Lafferty KJ. Involvement of O2 radicals in 'autoimmune' 
diabetes. Immunology and cell biology 1989 Feb;67 ( Pt 1):85-87. 
 
34. Salvemini D, Riley DP, Cuzzocrea S. SOD mimetics are coming of age. Nature 
reviews 2002 May;1(5):367-374. 
 
35. Pasternack RF, Banth A, Pasternack JM, Johnson CS. Catalysis of the 
disproportionation of superoxide by metalloporphyrins. III. Journal of inorganic 
biochemistry 1981 Nov;15(3):261-267. 
75 
 
36. Haskins K, Bradley B, Powers K, Fadok V, Flores S, Ling X, et al. Oxidative 
stress in type 1 diabetes. Annals of the New York Academy of Sciences 2003 
Nov;1005:43-54. 
 
37. Benov L, Batinic-Haberle I. A manganese porphyrin suppresses oxidative stress 
and extends the life span of streptozotocin-diabetic rats. Free radical research 2005 
Jan;39(1):81-88. 
 
38. Szabo C, Day BJ, Salzman AL. Evaluation of the relative contribution of nitric 
oxide and peroxynitrite to the suppression of mitochondrial respiration in 
immunostimulated macrophages using a manganese mesoporphyrin superoxide 
dismutase mimetic and peroxynitrite scavenger. FEBS letters 1996 Feb 26;381(1-2):82-
86. 
 
39. Day BJ, Fridovich I, Crapo JD. Manganic porphyrins possess catalase activity 
and protect endothelial cells against hydrogen peroxide-mediated injury. Archives of 
biochemistry and biophysics 1997 Nov 15;347(2):256-262. 
 
40. Nakaoka R, Tabata Y, Yamaoka T, Ikada Y. Prolongation of the serum half-life 
period of superoxide dismutase by poly(ethylene glycol) modification. J Control Release 
1997 Jun;46(3):253-261. 
 
41. Kojima Y, Akaike T, Sato K, Maeda H, Hirano T. Polymer conjugation to Cu,Zn-
SOD and suppression of hydroxyl radical generation on exposure to H2O2: Improved 
stability of SOD in vitro and in vivo. J Bioact Compat Polym 1996 Jul;11(3):169-190. 
 
42. Li Z, Wang F, Roy S, Sen CK, Guan J. Injectable, highly flexible, and 
thermosensitive hydrogels capable of delivering superoxide dismutase. 
Biomacromolecules 2009 Dec 14;10(12):3306-3316. 
 
43. Chiumiento A, Dominguez A, Lamponi S, Villalonga R, Barbucci R. Anti-
inflammatory properties of superoxide dismutase modified with carboxymetil-cellulose 
polymer and hydrogel. Journal of materials science 2006 May;17(5):427-435. 
 
44. Chiumiento A, Lamponi S, Barbucci R, Dominguez A, Perez Y, Villalonga R. 
Immobilizing Cu,Zn-superoxide dismutase in hydrogels of carboxymethylcellulose 
improves its stability and wound healing properties. Biochemistry (Mosc) 2006 
Dec;71(12):1324-1328. 
 
45. Cheung CY, McCartney SJ, Anseth KS. Synthesis of Polymerizable Superoxide 
Dismutase Mimetics to Reduce Reactive Oxygen Species Damage in Transplanted 
Biomedical Devices. Advanced Functional Materials 2008 Oct;18(20):3119-3126. 
46. McCord JM, Fridovich I. Superoxide dismutase. An enzymic function for 
erythrocuprein (hemocuprein). The Journal of biological chemistry 1969 Nov 
25;244(22):6049-6055. 
76 
 
47. Cohen HJ, Chovaniec ME. Superoxide generation by digitonin-stimulated guinea 
pig granulocytes. A basis for a continuous assay for monitoring superoxide production 
and for the study of the activation of the generating system. The Journal of clinical 
investigation 1978 Apr;61(4):1081-1087. 
 
48. Choi SY, Ha H, Kim KT. Capsaicin inhibits platelet-activating factor-induced 
cytosolic Ca2+ rise and superoxide production. J Immunol 2000 Oct 1;165(7):3992-
3998. 
 
49. Cruise GM, Scharp DS, Hubbell JA. Characterization of permeability and network 
structure of interfacially photopolymerized poly(ethylene glycol) diacrylate hydrogels. 
Biomaterials 1998 Jul;19(14):1287-1294. 
 
50. Lin CC, Boyer PD, Aimetti AA, Anseth KS. Regulating MCP-1 diffusion in affinity 
hydrogels for enhancing immuno-isolation. J Control Release 2010 Mar 19;142(3):384-
391. 
 
51. Weber LM, Hayda KN, Haskins K, Anseth KS. The effects of cell-matrix 
interactions on encapsulated beta-cell function within hydrogels functionalized with 
matrix-derived adhesive peptides. Biomaterials 2007 Jul;28(19):3004-3011. 
52. Su J, Hu BH, Lowe WL, Jr., Kaufman DB, Messersmith PB. Anti-inflammatory 
peptide-functionalized hydrogels for insulin-secreting cell encapsulation. Biomaterials  
Jan;31(2):308-314. 
 
53. Gabler WL, Creamer HR, Bullock WW. Modulation of the kinetics of induced 
neutrophil superoxide generation by fluoride. Journal of dental research 1986 
Sep;65(9):1159-1165. 
 
54. Luther MJ, Davies E, Muller D, Harrison M, Bone AJ, Persaud SJ, et al. Cell-to-
cell contact influences proliferative marker expression and apoptosis in MIN6 cells 
grown in islet-like structures. American journal of physiology 2005 Mar;288(3):E502-
509. 
 
55. Hauge-Evans AC, Squires PE, Persaud SJ, Jones PM. Pancreatic beta-cell-to-
beta-cell interactions are required for integrated responses to nutrient stimuli: enhanced 
Ca2+ and insulin secretory responses of MIN6 pseudoislets. Diabetes 1999 
Jul;48(7):1402-1408. 
 
56. Konstantinova I, Nikolova G, Ohara-Imaizumi M, Meda P, Kucera T, Zarbalis K, 
et al. EphA-Ephrin-A-mediated beta cell communication regulates insulin secretion from 
pancreatic islets. Cell 2007 Apr 20;129(2):359-370. 
 
57. Lin CC. Cell-cell communication mimicry with PEG hydrogels for enhancing Beta-
cell function. Proc Natl Acad Sci USA 2010 2011. 
 
77 
 
58. Kavdia M, Lewis RS. Free radical profiles in an encapsulated pancreatic cell 
matrix model. Annals of biomedical engineering 2002 May;30(5):721-730. 
 
59. Uchiyama T, Kiritoshi Y, Watanabe J, Ishihara K. Degradation of phospholipid 
polymer hydrogel by hydrogen peroxide aiming at insulin release device. Biomaterials 
2003 Dec;24(28):5183-5190. 
 
60. Cheung CY, Anseth KS. Synthesis of immunoisolation barriers that provide 
localized immunosuppression for encapsulated pancreatic islets. Bioconjug Chem 2006 
Jul-Aug;17(4):1036-1042. 
 
61. Hume PS, Anseth KS. Inducing local T cell apoptosis with anti-Fas-functionalized 
polymeric coatings fabricated via surface-initiated photopolymerizations. Biomaterials 
2010 Apr;31(12):3166-3174. 
 
 
78 
 
Chapter 4 
 
Inducing local T cell apoptosis with anti-Fas-functionalized polymeric coatings 
fabricated via surface-initiated photopolymerizations 
 
 
(As appears in Biomaterials, 31:3166-74. 2010) 
 
 Cell encapsulation has long been investigated as a means to achieve transplant 
immunoprotection as it creates a physical barrier between allograft tissue and host 
immune cells.  Encapsulation with passive barrier materials alone, however, is generally 
insufficient to protect donor tissue from rejection, because small cytotoxic molecules 
produced by activated T cells can diffuse readily into the capsule and mediate allograft 
death.  As a means to provide bioactive protection for polymeric encapsulation devices, 
we investigated a functionalized polymeric coating that mimics a natural T cell 
regulation pathway.  T cells are regulated in vivo via Fas, a well-known ‘death receptor,’ 
whereby effector cells express Fas ligand and elicit T cell apoptosis upon binding the 
Fas receptor on a T cell surface.  Anti-Fas antibodies are capable of replicating this 
effect and induce T cell apoptosis in solution.  Here, an iniferter-based living radical 
polymerization was utilized to fabricate surface-anchored polymer chains containing 
poly(ethylene glycol) with covalently-incorporated pendant anti-Fas antibody.  Using this 
reaction mechanism, we demonstrate fabrication conditions that yield surface densities 
in excess of 1.5 ng/cm2 of incorporated therapeutic, as detected by ELISA.  Additionally, 
we show that coatings containing anti-Fas antibody induced significant T cell apoptosis, 
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21±2 % of cells, after 24 hours.  Finally, the incorporation of a T cell adhesion ligand, 
intracellular adhesion molecule-1, along with anti-Fas antibody, yielded even higher 
levels of apoptosis, 34±1% of T cells, compared to either signal alone. 
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4.1      INTRODUCTION 
 
Cell transplantation has the potential to cure numerous diseases of the 
endocrine, cardiovascular, and central nervous systems [1-3].  However, clinical 
prevalence of allogeneic cell transplantation is limited due, in part, to the side effects of 
immunosuppressants administered systemically for suppressing host immune rejection 
[4].  Encapsulating donor cells within immunoisolation barrier materials has been widely 
explored as a means to decrease the necessity of systemic immunosuppression, 
because the barrier materials can block direct contact between the transplanted grafts 
and the host immune cells [4].  For example, the encapsulation of pancreatic β-cells for 
the treatment of type I diabetes mellitus has been extensively studied over the last 30 
years [5,6].  An important criterion of designing materials for immunoisolation is that the 
capsule should block immune cell contact, but must not restrict the diffusion of small 
molecules such as nutrients, glucose, and insulin, as they are necessary for maintaining 
β-cell survival and transplant function.  While maintaining permeability of the capsule is 
critical, it has been shown that small cytotoxic molecules produced by activated, 
autoreactive T lymphocytes are capable of infiltrating the capsule and inducing donor 
cell apoptosis [7-9].  These cytotoxic molecules include reactive oxygen species (ROS), 
interleukin 1β (IL-1β), and tumor necrosis factor alpha (TNF-α), etc.  While the material 
properties of the encapsulation systems are improving [10], systemic 
immunosuppression remains necessary for the long-term (>1 yr) survival of 
encapsulated β-cells [11,12].   
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Recently, efforts have been made to fabricate bioactive encapsulation barriers 
capable of regulating the local immune environment.  For example, a polymerizable 
superoxide dismutase mimetic has been described which catalyzes the dismutation of 
superoxide into hydrogen and oxygen when co-photopolymerized with poly(ethylene 
glycol)-diacrylate (PEGDA) [13].  Likewise, methods to conjugate antibodies or peptides 
which sequester TNF-α within encapsulation materials have been developed to slow 
cytokine diffusion and improve encapsulated cell viability [14,15].  Unlike these 
approaches, which regulate the capsule’s internal cytokine environment, we report an 
alternate strategy to functionalize the surface of polymeric encapsulation materials, 
such as PEGDA hydrogels, to modulate the immune reactions by inducing local T 
lymphocyte apoptosis.   
Previously, research has investigated strategies to induce T lymphocyte 
apoptosis utilizing Fas signaling [16].  Fas, a cell surface receptor in the TNF-α 
superfamily, induces apoptosis upon Fas ligand (FasL) binding.  The Fas pathway plays 
two important roles in normal lymphocyte regulation.  First, autoreactive T cells undergo 
negative selection via clonal deletion mediated by Fas/FasL signaling [17].  Second, T 
cells strongly upregulate Fas expression upon activation, and FasL-expressing cytotoxic 
lymphocytes induce T cell apoptosis to clear a completed immune response [18].  To 
initiate the signal transduction cascade resulting in cell apoptosis, pre-associated Fas 
receptors on the cell membrane must bind multiple FasLs [19].  Therefore, 
oligomerization of FasL improves the efficacy with which apoptosis is induced [20].   
DX2, an anti-Fas monoclonal antibody of the IgG1 subclone, induces apoptosis 
upon cross-linking the T cell Fas receptor [21].  Cheung and Anseth [16] previously 
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demonstrated that DX2 induces nearly 20% T cell apoptosis when covalently 
conjugated to the surface of gels formed from 7.5 wt% PEGDA and 2.5 wt% N-
hydroxysucinimide-PEG-acrylate (NPA) hydrogel.  Others have shown a local anti-
inflammatory effect mediated by IgM-class anti-Fas antibodies adsorbed to polyester 
membranes [22,23].  While coating anti-Fas antibody directly onto biomaterial surfaces 
preserves some biological activity, these strategies yield a relatively low protein surface 
density and limited accessibility of functional groups to the surroundings.  Herein, a 
living radical photopolymerization (LRP)-based strategy was exploited to graft PEG 
chains with pendant DX2 antibodies from a polymeric surface.  As illustrated in Fig. 4.1, 
an LRP mechanism is mediated by a photoiniferter specie, containing a 
diethyldithiocarbamate (DTC) group able to reversibly initiate photopolymerization from 
a surface.  DTC-mediated LRP yields uniform, highly mobile polymer chains whose 
length is proportional to photopolymerization time [24].  As previously reported [25,26], 
upon covalent modification with a polymerizable acrylate group, antibodies may be 
copolymerized onto these surface anchored polymer chains.  This architecture provides 
several benefits, including improved protein accessibility to the surroundings due to high 
chain mobility and increased antibody surface density due to the incorporation of 
multiple antibodies per chain.  In addition, the natural DX2 clustering that occurs as 
antibodies are incorporated on polymer chains may provide the added benefit of 
increasing the likelihood that multiple DX2 binding events occur at one T cell Fas 
receptor.  This multimerization could improve the chance that an apoptotic signal is 
delivered.   
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Fig. 4.1. Schematic illustrating surface-initiated polymerization of acrylated proteins.  ACRYL-protein is 
co-photopolymerized with ACRYL-PEG atop a polymeric substrate containing a DTC photoiniferter.  
Polymer chains consisting of polyacrylate backbones with pendant proteins are formed on the surface, 
and the surface modification is proportional to UV exposure time. 
Herein, the fabrication, characterization and evaluation of surface-initiated 
polymer chains is reported for chains consisting of PEG monoacrylate (400 Da) with a 
high surface density of pendant acrylated IgG.  Further, cell studies were performed to 
evaluate the effects of DX2-conjugating polymer coatings on inducing T cell apoptosis.  
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Finally, a T cell adhesion ligand, Inter-Cellular Adhesion Molecule 1 (ICAM-1), was 
incorporated in the polymer coating to increase the interaction between T cells and the 
material surface.  Our group has previously demonstrated that iniferter-mediated LRP 
allows for the fabrication of multifunctional grafts [25], and here, we report dually-
functionalized polymeric coatings, containing DX2 and ICAM-1, which yield a significant 
increase in T cell apoptosis. 
 
4.2 MATERIALS & METHODS 
4.2.1  Materials 
Mouse anti-human Fas monoclonal IgG (DX2), goat anti-Fas receptor IgG, and 
ICAM-1/Fc chimera fusion protein (ICAM-1) were obtained from R&D Systems.  All 
other IgGs were obtained from Jackson Immunoresearch.  Soluble Fas receptor was 
purchased from Peprotech.  Monoacrylated poly(ethylene glycol)-N-hydroxysuccinimide 
(ACRYL-PEG-NHS, MW=3400) was purchased from Laysan Bio Inc.  Slide-a-Lyzer 
dialysis cassettes (10,000 MWCO), fluoraldehyde Reagent Solution, and TMB ELISA 
Substrate were obtained from Thermo Fisher Scientific.  Aromatic urethane diacrylate 
(UDA) was a generous gift donated by UCB Chemicals Corp.  Triethylene glycol 
diacrylate (TEGDA) was purchased from Polysciences Inc. Tetraethylthiuram disulfide 
photoiniferter (TED) was obtained from Sigma-Aldrich.  2,2-dimethoxy-2-
phenylacetophenone initiator (DMPA) was purchased from Ciba Specialty Chemicals.  
Monoacrylated poly(ethylene glycol) (ACRYL-PEG, MW=400) was purchased from 
Monomer-Polymer & Dajac Labs.  Vybrant apoptosis assay kit #3, AlamarBlue reagent, 
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and Trypan Blue stain were obtained from Invitrogen.  Vector VIP stain was obtained 
from Vector Labs. 
      
4.2.2  Protein acrylation and characterization 
Goat IgG (IgG), fluorescein-conjugated goat IgG (F-IgG), DX2 and ICAM-1 were 
acrylated by reacting proteins (2 mg/ml) with 3400 Da ACRYL-PEG-NHS at defined 
molar ratios in 50 mM sodium bicarbonate buffer, pH 8.4.  The reactions proceeded for 
3 h at room temperature under constant stirring.  The percentage of protein acrylation 
was determined immediately following reaction using Fluoraldehyde regent to compare 
the concentration of free amine groups prior to and following reaction.  Unreacted 
ACRYL-PEG-NHS was removed by dialysis against deionized water for 24 hrs using a 
10 000 MWCO Slide-a-Lyzer dialysis cassette.  Solutions were lyophilized to yield solid 
acrylated IgG (ACRYL-IgG), acrylated F-IgG (F-ACRYL-IgG), acrylated DX2 (ACRYL-
DX2), or acrylated ICAM-1 (ACRYL-ICAM-1). 
 
4.2.3   Preparation of the polymer substrate 
The polymeric grafting substrate used in these studies consisted of 49.125 wt% 
UDA, 49.125 wt% TEGDA, 0.25 wt% TED iniferter, and 1.5 wt% DMPA initiator.  This 
pre-polymer solution was sonicated and stirred intermittently for >1 hr and was purged 
with argon for 2 min prior to polymerization.  The base layer was photopolymerized by 
exposing mixed pre-polymer solution to 35 mW/cm2 ultraviolet, collimated light 
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generated by a mercury arc-lamp centered at 365 nm for 500 s.  Sebra et al. [25] has 
previously demonstrated that these conditions yield a polymeric network with greater 
than 90% double bond conversion.  Polymerized UDA-TEGDA substrates were 
immersed in methanol for 15 min with stirring to remove unreacted monomers and 
excess DMPA.       
  
4.2.4  Surface-initiated photopolymerization of acrylated proteins 
Acrylated proteins where covalently incorporated on polymer chains using a 
living radical photopolymerization-based chemistry as previously described [25].  Briefly, 
acrylated protein, including 250 μg/ml ACRYL-IgG, 250 μg/ml ACRYL-DX2, or 25 μg/ml 
ACRYL-ICAM-1, was dissolved in 50% v/v 400 Da ACRYL-PEG in phosphate buffered 
saline (PBS, pH=7.4).  This solution was applied onto the DTC-containing substrate 
surface prepared as described earlier and exposed to 35 mW/cm2 collimated ultraviolet 
light centered at 365 nm for 0 – 900 s.  Following polymerization, devices were 
immersed in deionized water for 1 hr, followed by rinsing in 70% ethanol overnight.  
Then, the devices were washed in sterile-filtered 30% ethanol for 1 hr and finally rinsed 
in sterile PBS overnight.  All washing steps were carried out at room temperature with 
mixing.          
 
4.2.5   Detection of polymerized ACRYL-IgG 
The surface density of polymerized ACRYL-IgG was assessed using a modified 
ELISA.  ACRYL-IgG coatings were incubated at room temperature for 8 min with 8 
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μg/ml horse radish peroxidase (HRP)-conjugated donkey anti-goat detection antibody 
(HRP-DAG-IgG), and then rinsed 4 times with PBS.  HRP-treated coatings were either: 
1) Incubated 15 min with Vector VIP reagent to stain HRP, or 2) Dissected with a biopsy 
punch into 6 mm diameter disks and placed in the bottom of a 96-well plate.  These 
HRP-treated samples were incubated with 100 μl TMB ELISA substrate for 20 min with 
mixing to allow color change, and the reaction was quenched with the addition of 100 μl 
2N H2SO4.  The 450 nm absorbance of each sample was measured and converted to 
ACRYL-IgG surface density by comparing sample absorbance to that of TMB-treated 
control solutions with known HRP-DAG-IgG mass. 
Fluorescein-conjugated ACRYL-goat IgG (F-ACRYL-IgG) was polymerized, as 
described above, and incubated 30 min with 8 μg/ml rhodamine-conjugated donkey 
anti-goat IgG (R-DAG-IgG) prior to fluorescent imaging with confocal microscopy 
(Axioplan 2, Zeiss).  Height of dry coatings was determined using profilometry (Stylus 
Profiler, Dektak 6M, force = 1 mg, radium = 12.5 mm, and range = 1 mm). 
 
4.2.6   Characterization of ACRYL-DX2-containing coatings 
ACRYL-DX2 was photografted at a concentration of 250 μg/ml, as described 
above.  Grafted ACRYL-DX2 was detected and quantified by Vector VIP staining and 
the modified ELISA described above, where an HRP-conjugated goat anti-mouse IgG 
(HRP-GAM-IgG) was used as the detection antibody.  In addition, a modified sandwich 
ELISA was performed where devices containing polymerized ACRYL-DX2 were 
incubated for 1 hr with 1 μg/ml soluble Fas receptor, followed by 1 μg/ml goat anti-Fas 
88 
 
receptor IgG, and incubated 8 min with 5 μg/ml HRP-DAG-IgG.  Samples were rinsed 
and stained with Vector VIP for 15 min to verify ACRYL-DX2 maintained the capacity to 
bind the Fas receptor following incorporation in the surface graft.   
4.2.7   Cell culture 
Jurkat T cell lymphoma cells and I9.2 Fas-insensitive Jurkats (ATCC, Manassas, 
VA) were cultured in RPMI 1640 supplemented with 10% fetal bovine serum, 100 u/ml 
Penicillin/Streptomycin, and 0.5 μg/ml Fungizone.  Cells were incubated at 37 °C in 
humid conditions with 5% CO2.  The biological activity of soluble ACRYL-DX2 was 
assessed by incubating Jurkat T cells (50 000 cells/ml, 200 μl media) with ACRYL-DX2 
at a concentration of 5 μg/ml.  After 6, 12, 24, and 48 hrs, the percentage of T cells 
undergoing apoptosis was analyzed using an Annexin assay, as described below. 
Maximum T cell apoptosis was detected after 24 hrs of culture with ACRYL-DX2, so this 
time point was used for all subsequent studies.  The biological activity of functionalized 
polymer coatings containing ACRYL-DX2 was also evaluated by incubation with T cells.  
Disks of functionalized substrate were dissected using a 6 mm diameter biopsy punch 
and placed in the bottom of a 96-well plate.   Jurkat and I9.2 T cells were seeded atop 
coatings at 50 000 cells/ml in 200 μl media and cultured for 24 hrs, prior to analysis for 
apoptosis.   
 
4.2.8  T cell assays 
T cells were stained for apoptosis using the Vybrant apoptosis assay kit #3.  
Cells were stained with fluorescein-labeled Annexin V and counterstained with 
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propidium iodide (PI) to differentiate apoptotic and necrotic cells, respectively.  Cells 
were imaged using a Nikon Eclipse TE300 fluorescent microscope and counted in 4 
random fields of view per sample.  Each field contained approximately 100-200 cells.  
The fraction of apoptotic cells was calculated by dividing the number of fluorescein-
positive (but PI-negative) T cells by the cell number.  Bulk T cell metabolic activity was 
also analyzed after 24 hrs by adding 22 μl of AlamarBlue reagent to each condition 
(resulting in a 10% v/v AlamarBlue solution) and incubating for 3 hr.  Fluorescence 
(excitation: 560 nm, emission: 590 nm) represented the metabolic activity of the living 
cells.  All cell data is shown as the mean of 4 replicates and each experiment has been 
repeated at least twice. 
 
4.2.9  T Cell Adhesion Studies 
 T cells were seeded atop coatings functionalized with ACRYL-ICAM-1, ACRYL-
DX2, ACRYL-ICAM-1 / ACRYL-DX2, or control, in 96-well plates, as described above.  
At 6 hr, 12 hr, and 24 hr time points, media was removed from each well and gently 
washed three times with 200 μl PBS.  50 ul of 50% Trypan Blue Stain (0.4%), 50% 
media was added to denote dead cells and incubated 5 minutes.  Bright field 
microscopy was used to count the number of live cells remaining on the polymer 
surface and the percentage of adherent cells was calculated by dividing the number of 
cells remaining on the polymer surface by the total number of cells seeded. 
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4.2.10  Statistical analysis   
 Statistical significance was determined using a two-tailed, unpaired Student’s t-
test.  Differences between datasets were considered statistically significant when the p 
value was less than 0.05.  All results are presented as mean ± standard error of the 
mean. 
   
 
4.3 RESULTS 
 
4.3.1   Acrylation of IgG 
 IgG was acrylated prior to surface grafting by reacting primary amine groups with 
ACRYL-PEG-NHS.  Degree of acrylation was controlled by varying the molar ratio of 
ACRYL-PEG-NHS to IgG from 0:1 to 25:1.    While increasing the number of acrylate 
groups per IgG increases the likelihood that the protein will be incorporated into graft 
polymer chains, over-modification can reduce the biological activity of the molecule.  To 
verify the biological activity of ACRYL-DX2 (acrylated anti-Fas IgG) post modification, 
ACRYL-DX2 was added to Jurkat T cell cultures for 24 hours to induce apoptosis.  As 
shown in Fig. 4.2, a 25-fold, but not 10-fold, molar excess of ACRYL-PEG-NHS to DX2 
resulted in a significant reduction in biological activity.  Thus, a reaction ratio of 10 
moles ACRYL-PEG-NHS per mole IgG was used for all future studies.  A Fluoraldehyde 
assay indicated these reaction conditions yielded 2.2±0.6 % acrylation of this 150 kDa 
IgG.    
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4.3.2  Surface grafting of acrylated IgG 
As illustrated in Fig. 4.1, ACRYL-IgG was dissolved in 50% ACRYL-PEG 
 
(400 
Da) in PBS and photopolymerized from an iniferter-containing UDA-TEGDA substrate 
for controlled polymerization times ranging from 0 – 900 s.  Because of the LRP nature 
of this system, one expects the polymer thickness and ACRYL-IgG incorporation to 
increase proportionally to light exposure time.  As shown in Fig. 4.3A, profilometry of dry 
grafts revealed increasing dry polymer height with UV exposure time.  Fig. 4.3B 
illustrates the relationship between detectable ACRYL-IgG surface density with 
photopolymerization time.  Unlike dry graft height, detectable ACRYL-IgG did not 
consistently increase with time.  Instead, a peak in detectable ACRYL-IgG existed 
between 120 and 180 s.  ACRYL-IgG surface density was determined by a modified 
ELISA, so incorporated protein was only observable if bound by a detection antibody 
(150 kDa).  We postulate that the surface-initiated chains become cross-linked for  
 
Fig. 4.2.  The influence of covalent acrylation on 
the bioactivity of soluble ACRYL-DX2.  ACRYL-
PEG-NHS was reacted with DX2 in the molar ratios 
shown on the x-axis.  As the reaction stoichiometry 
was increased, the efficacy with which soluble 
ACRYL-DX2 induced apoptosis was reduced.       
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Fig. 4.3.  Controlled surface-initiated 
photopolymerization of ACRYL-IgG.  (A) Dry graft 
height, determined by profilometry, increases as 
a function of surface-initiated polymerization time.  
(B) Surface density of detectable ACRYL-IgG 
increases and then decreases as a function of 
polymerization time, as determined by modified 
ELISA.  A region of high detectable ACRYL-IgG 
exists between 120 – 180 s fabrication times.  (C) 
Fluorescein-tagged ACRYL-IgG from goat (F-
ACRYL-IgG) was photografted for 150 and 500 s.  
Dashed boxes represent a cross-sectional view 
of the full thickness of each coating.  Fluorescein 
is visible throughout the thickness of both 
samples.  Scale bars = 50 μm.  (D) F-ACRYL-IgG 
Grafts were stained with rhodamine-tagged 
donkey anti-goat IgG (R-IgG) to label accessible 
F-ACRYL-IgG.  Strong full-thickness R-IgG 
staining is visible at 150 s but only surface 
staining at 500 s.  Scale bars = 50 μm.  (E) 
Surface density of detectable ACRYL-IgG 
decreased as a function of TED iniferter 
concentration in the substrate.   
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polymerization times greater than 180 s due to chain transfer and other non-idealities, 
so the detection antibody was unable to penetrate deeply into the coating.  Further 
evidence of this phenomena is presented below. 
 
4.3.3  Surface grafting of fluorescent ACRYL-IgG 
Fluorescein-tagged ACRYL-IgG (F-ACRYL-IgG) was photografted for either 150 
or 500 s.  As seen in the cross-sectional images of surface-initiated coatings, shown in 
Fig. 4.3C, fluorescein was visible throughout the full thickness for 150 and 500 s 
polymerization times.  Swollen coatings were approximately 10 μm and 25 μm thick, 
respectively.    Following fabrication, surfaces were incubated with rhodamine-tagged 
donkey anti-goat IgG (R-IgG) to selectively label the accessible F-ACRYL-IgG.  As seen 
in Fig. 4.3D, strong rhodamine fluorescence is visible throughout the full thickness of the 
150 s graft but only observed near the top of the 500 s graft.  Control coatings lacking F-
ACRYL-IgG revealed no significant fluorescein or rhodamine fluorescence (data not 
shown), demonstrating that the presence of fluorescence is due to F-ACRYL-IgG and 
specific antibody binding, and not the result of physical entrapment of the antibodies.  
Coupled with the spike in detectable antibody observed between 120 – 180 s, we 
believe that the 150 and 500 s fluorescence profiles provide insight into the architecture 
of this surface-initiated polymer network.  We postulate that non-idealities in polymer 
chain formation, likely due to chain transfer events, result in chain crosslinking during 
longer polymerization times (>300 s).  This cross-linking prevents the diffusion of 150 
kDa R-IgG through graft chains and indicates that ACRYL-IgG incorporated early during 
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the surface modification is inaccessible to the outside environment.  To ensure a high 
surface density of accessible ACRYL-IgG, a photopolymerization time of 150 s was 
used for all future studies.       
 
4.3.4 Iniferter concentration affects detectable ACRYL-IgG surface density 
Surface modification and coating properties are further controlled by the density 
of surface grafting sites.  The effect of iniferter concentration on detectable ACRYL-IgG 
was studied by varying the initial concentration of TED in the pre-polymer solution from 
0.25 to 1.0 wt% and subsequent grafting of ACRYL-IgG for 150 s.  As shown in Fig. 
4.3E, maximum detectable ACRYL-IgG surface densities were observed at the lowest 
TED concentration, 0.25 wt%.  Because TED concentration correlates with the surface 
bound DTC concentration, lowering the concentration of TED in the substrate reduces 
the total number of polymer chains initiated from the surface.  By decreasing the total 
surface density of polymer chains, it is likely that the resulting polymer chains gain 
greater mobility, increasing the overall accessibility of incorporated ACRYL-IgG, and 
minimizes network formation via crosslinking.  Minimal polymer chain initiation occurred 
for TED concentrations below 0.25 wt%, so lower TED concentrations were not 
investigated.     
 
4.3.5   Polymerization of ACRYL-DX2 induces T cell apoptosis from a surface 
ACRYL-DX2 was incorporated into surface-anchored polymer chains using the 
photopolymerization conditions identified to yield a high protein surface density (150 s 
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photopolymerization, 0.25 wt% TED).  Polymers were washed > 36 hrs, as described 
above, to remove any unconjugated ACRYL-DX2.  Incorporation of ACRYL-DX2 was 
verified using an ELISA-type assay and was consistently found to be between 1.4 and 
1.7 ng/cm2
The biological activity of polymerized ACRYL-DX2 was assessed by its ability to 
induce apoptosis in T-cells.  Jurkat T-cells were seeded onto surfaces with or without 
ACRYL-DX2 for 24 hrs.  Apoptotic cells were stained with fluorescein-conjugated 
Annexin V.  Fig. 4.4B shows representative fluorescent images of apoptotic Jurkat T-
cells on a control surface, while Fig. 4.4C illustrates an increase in Jurkat apoptosis 
when seeded on a surface containing ACRYL-DX2.  As shown in Fig. 4.4D, ACRYL-
DX2 surfaces induced significant apoptosis, 21±2% of Jurkat T cells.  When I9.2 T cells 
(Jurkats rendered insensitive to Fas-mediated apoptosis [27,28]) were exposed to 
ACRYL-DX2 grafts, no significant increase in apoptosis was observed.  This indicates 
that the apoptosis induced by grafted ACRYL-DX2 is specific and mediated through 
DX2/Fas signaling. 
.  Additionally, Vector VIP staining was performed prior to each ACRYL-DX2 
cell experiment to verify the presence of anti-Fas IgG.  The staining of circular-patterned 
ACRYL-DX2 grafts, shown in Fig. 4.4A, confirms the presence of ACRYL-DX2 (left) and 
that grafted ACRYL-DX2 remains specific binding ability to Fas receptor (right).   
 
4.3.6  ACRYL-ICAM-1 increases the efficacy of ACRYL-DX2 
We chose to incorporate a 70 kDa ICAM-1/Fc fusion protein because its structural 
similarity to IgG allowed predictable acrylation using the same conditions identified for  
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Fig. 4.4.  Grafted ACRYL-DX2 induces T cell apoptosis.  (A)  ACRYL-DX2 was incorporated in 6 mm 
diameter grafts and incubated with HRP-conjugated GAM IgG (left) or soluble Fas receptor, goat anti-Fas 
IgG, and HRP-conguated DAG IgG (right).  Both (left) and (right) were stained with Vector VIP to stain 
HRP.  Vector VIP staining indicates (left) high ACRYL-DX2 surface density and (right) ACRYL-DX2 
retains the ability to bind the Fas receptor.   (B & C) Representative brightfield (right) and 480 nm 
fluorescent (left) images of Jurkat T cells seeded for 24 hrs on grafted (B) control and (C) ACRYL-DX2 
surfaces for 24 hrs followed by staining with fluorescein-conjugated Annexin V.  Apoptotic T cells are 
visible at 480 nm.  Scale bars = 100 μm (D) Jurkat and Fas-insensitive I9.2 T cells were seeded on 
grafted surfaces for 24 hours and assayed for apoptosis.  A statistically significant increase in apoptosis 
was observed for Jurkat T cells incubated on ACRYL-DX2 surfaces.  Asterisks indicates a statistically 
significant difference (p<0.05) from all other values.  
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ACRYL-IgG.  ACRYL-ICAM-1 and ACRYL-DX2 were simultaneously co-polymerized 
from the iniferter-containing substrates, as Sebra et al. [25] has previously 
demonstrated that multiple acrylated proteins may be simultaneously polymerized with 
the LRP grafting technique.  As shown in Fig. 5.5A, seeding T cells on grafted polymer 
surfaces functionalized with ACRYL-DX2 and ACRYL-ICAM-1 resulted in ~34±1% 
Jurkat T cell apoptosis, an improvement of nearly 50% when compared to ACRYL-DX2 
alone.  Surfaces functionalized with only ACRYL-ICAM-1 did not yield a significant 
increase in apoptosis relative to controls, demonstrating a synergistic effect between 
ACRYL-ICAM-1 and ACRYL-DX2.  Culturing Jurkats on ACRYL-DX2/ACRYL-ICAM-1 
functionalized surfaces demonstrated more than a 50% reduction in metabolic activity 
when compared to control surfaces (Fig. 4.5B), likely indicating a reduction in T cell 
number.  A statistically significant reduction in metabolic activity was not observed for T  
 
Fig. 4.5.  ACRYL-ICAM-1 improves the efficacy of grafted ACRYL-DX2.  (A) Grafted ACRYL-ICAM-1, 
when incorporated with ACRYL-DX2, increases the percentage of Jurkat T cells signaled to undergo 
apoptosis after 24 hrs.  (B) Metabolic activity studies of Jurkat T cells seeded on control or dually-
functionalized grafted surfaces for 24 hrs.  Jurkat T cells show an over 50% reduction in metabolic activity 
when cultured on ACRYL-DX2 / ACRYL-ICAM-1 grafts.  Asterisks indicates a statistically significant 
difference (p<0.05) from all other values. 
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cells cultured on polymeric surfaces functionalized singularly with either ACRYL-DX2 or 
ACRYL-ICAM-1, highlighting the importance of the synergistic effect between ACRYL-
ICAM-1 and ACRYL-DX2 in reducing the population of T cells.  No increase in 
apoptosis or decrease in metabolic activity was observed for I9.2 cells, indicating these 
effects were Fas-mediated.   
 
4.3.7  Probing the T cell / material interaction 
When incorporating ACRYL-ICAM-1, we considered the possibility that this 
ligand could enable T cells to form sustained adhesions with the functionalized surface.  
This behavior might be deleterious to the end goal of immunoprotection, as lymphocyte 
recruitment could increase the local concentration of inflammatory cytokines.  T cell 
adherence was analyzed at 6 hr, 12 hr, and 24 hr following seeding on polymers 
functionalized with ACRYL-ICAM-1 and/or ACRYL-DX2.  At all time points, less than 1% 
of cells seeded upon the polymer surface remained following a wash to remove non-
adherent cells.   
 
 
4.4 DISCUSSION 
Towards protecting allograft tissue from rejection, cell encapsulation strategies 
continue to improve.  Despite improvements, however, T cell-mediated rejection 
continues to pose a considerable hurdle to transplant acceptance.  This work aimed to 
fabricate biomaterial coatings to reduce the local concentration of T cells.  Towards that 
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end, we utilized an iniferter-based LRP to fabricate functionalized coatings, which mimic 
in vivo T cell signaling events.   
IgG was covalently modified with acrylate groups and subsequently polymerized 
into surface-imitated polymer chains of poly(ethylene glycol).  Using this polymer 
chemistry, maximum detectable IgG concentrations were identified for 
photopolymerization times ranging from 120-180 s, indicating that polymer networks 
became cross-linked for polymerization times greater than 180 s, and therefore, were 
less accessible to the surrounding environment.  This notion was supported by the 
observation that fluorescently-labeled secondary antibody was able to penetrate 
throughout a ~20 μm coating generated by 150 s UV light exposure, but was unable to 
diffuse deeply within a ~50 μm coating generated by a 500 s exposure.  Network cross-
linking was likely the result of polymer chain transfer, and other non-idealities, which 
become more apparent with increased photopolymerization time.  Even though 
polymerized fluorescent IgG was visible throughout polymer coatings grafted for 150 
and 180 s, it is reasonable to assume that polymerized IgG which was not detectable 
by 
Utilizing the appropriate fabrication conditions indentified for grafting ACRL-IgG, 
Anti-Fas IgG (ACRYL-DX2) was incorporated into the polymer network.   When T cells 
were seeded atop ACRYL-DX2-functionalized coatings for 24 hrs, significant apoptosis 
(21±2 % of cells) was observed.  Prior to incubation with T cells, coatings were rinsed 
for 36 hrs, as described earlier, to allow for the complete removal of non-covalently 
a secondary IgG would also be inaccessible to T cells.  Thus, in keeping with the 
goal of fabricating a coating that allows bioactive molecules to be highly accessible to 
nearby cells, a polymerization time of 150 s was used for all future studies. 
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incorporated ACRYL-DX2.  Therefore, the observed increase in apoptosis is due to 
surface-bound ACRYL-DX2, and not soluble DX2.  While T cell apoptosis induced by 
this ACRYL-DX2-functionalized surface represents only a modest increase over the 
level of apoptosis induced by a previously described system, consisting of a hydrogel 
coated with DX2 [16], it is critical to note that our LRP grafting approach requires 80% 
less DX2 than the previously-investigated hydrogel coating.              
While PEG is an important component of the surface-mediated polymerization, 
PEG is also known as a chemistry that resists non-specific protein interactions, thereby 
rendering it minimally adhesive for most cell types.  Thus, we postulated that increased 
T cell apoptosis might be achieved by introducing an Inter-cellular Adhesion Molecule-1 
(ICAM-1), a member of the immunoglobulin superfamily, into an ACRYL-DX2-
functionalized polymeric surface.  ICAM-1 is expressed by selected cell types, including 
endothelial cells and antigen presenting cells (APCs), and is known to bind a β2-
integrin, Leukocyte Functional Antigen-1 (LFA-1), expressed on the T cell surface [29].  
ICAM-1 binding is essential to initiating several T cell attachment mechanisms, including 
adhesion to endothelial cells for transmigration through blood vessel wall in addition to 
the formation of the immune synapse with an APC [29].  Furthermore, ICAM-1 binding 
has been shown to enhance the activity of membrane-bound FasL.  Sieg et al. blocked 
ICAM-1 on the surface of FasL-expressing effector cells and observed a significant 
decrease in T cell apoptosis induction, suggesting that LFA-1/ICAM-1 binding stabilizes 
the adhesion between target and effector cells during Fas/FasL signaling [30].   
Fig. 4.5 shows that the addition of acrylated ICAM-1 significantly increases (> 
50%) the apoptosis induced by an ACRYL-DX2 functionalized coating and significantly 
101 
 
decreased (< 50 %) the overall T cell metabolic activity.  Further, T cell adhesion studies 
indicate that this effect was possible without long-term, stable adhesion between T cells 
and the biomaterial surface.  This is likely possible because the interaction between T 
cells and ICAM-1 is short lived.  Others have investigated the transient nature of the 
interaction between T cells and ICAM-1-coated surfaces.  For example, Somersalo et 
al. reported that T cells formed stable adhesions to ICAM-1 coated surfaces for 
approximately 15 minutes before releasing [31].  Fortuitously, the induction of Fas-
mediated apoptosis occurs quickly [32], and our results indicate that the transient 
increase in adhesion afforded by ICAM-1 is sufficient to significantly increase ACRYL-
DX2-mediated apoptosis.  Further, the observed lack of sustained adhesion provides 
encouragement that this coating could avoid significant lymphocyte recruitment, 
minimizing the local concentration of inflammatory cytokines.    
As with any biomaterial developed towards the eventual goal of implantation, it is 
important to consider the competing effects that this coating might have upon cell types 
not investigated herein.  This is particularly important because, in addition to T cells, 
ICAM-1 is known to bind several classes of leukocytes.  For example, ICAM-1 is 
implicated in neutrophil transendothelial migration [33,34] and macrophage adherence 
[35,36].  While the interaction that neutrophils and macrophages might have with an 
ICAM-1-coated biomaterial surface has not been well studied, some interaction between 
these cells and a coating functionalized with ACRYL-DX2/ACRYL-ICAM-1 might 
ultimately be beneficial toward the goal of immunoprotection.  This is because, like T 
cells, neutrophils and macrophages have been shown to undergo apoptosis in response 
to Fas receptor stimulation [22,23,37-39].  Thus, the anti-inflammatory benefits of an 
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ACRYL-DX2/ACRYL-ICAM-1-functionlized surface could extend beyond T cells, offering 
greater promise that this coating may provide an active barrier against transplant 
rejection.             
 
 
4.5 CONSLUSIONS 
A surface-initiated polymerization was utilized to grow polymer chains containing 
anti-Fas antibody and ICAM-1 from a polymeric substrate to induce significant T cell 
apoptosis.  Appropriate surface-mediated photopolymerization conditions were 
identified to polymerize a high density of detectable acrylated protein.  Surfaces with 
polymerized ACRYL-DX2 were shown to illicit Fas-mediated T cell apoptosis, and the 
addition of a T cell adhesion ligand, ACRYL-ICAM-1, enhanced this pro-apoptotic affect.  
These findings indicate that dually functionalized (DX2 & ICAM-1) surfaces are capable 
of significantly reducing the local T cell population.  In summary, this study introduces a 
new methodology to functionalize polymeric surfaces with immunosuppressive proteins 
and this graft architecture offers potential as a bioactive coating for future cell 
encapsulation devices. 
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Chapter 5 
 
Functionalized PEG hydrogels through reactive dip-coating for the formation of 
immunoactive barriers 
 
 
(As appears in Biomaterials, in press. 2011) 
 
 
Influencing the host immune system via implantable cell-delivery devices has the 
potential to reduce inflammation at the transplant site and increase the likelihood of 
tissue acceptance.  Towards this goal, an enzymatically-initiated, dip-coating technique 
is adapted to fabricate conformal hydrogel layers and to create immunoactive polymer 
coatings on cell-laden poly(ethylene glycol) (PEG) hydrogels.  Glucose oxidase (GOx)-
initiated dip coatings enable the rapid formation of uniform, PEG-based coatings on the 
surfaces of PEG hydrogels, with thicknesses up to 500 μm where the thickness is 
proportional to the reaction time.  Biofunctional coatings were fabricated by thiolating 
biomolecules that were subsequently covalently incorporated into the coating layer via 
thiol-acrylate copolymerization.  The presence of these proteins was verified via 
fluorescent confocal microscopy and a modified ELISA, which indicated IgG 
concentrations as high as 13±1 ng / coated cm2 were achievable. Anti-Fas antibody, 
known to induce T cell apoptosis, was incorporated into coatings, with or without the 
addition of ICAM-1 to promote T cell interaction with the functionalized coating.  Jurkat T 
cells were seeded atop functionalized coatings and the induction of apoptosis was 
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measured as an indicator of coating bioactivity.  After 48 hours of interaction with the 
functionalized coatings, 61±9% of all cells were either apoptotic or dead, compared to 
only 18±5% of T cells on non-functionalized coatings.  Finally, the cytocompatibility of 
the surface-initiated GOx coating process was confirmed by modifying gels with either 
encapsulated β-cells or 3T3 fibroblasts within a gel that contained a PEG methacrylate 
coating. 
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5.1 INTRODUCTION 
Strategies to encapsulate donor tissues within biomaterials prior to 
transplantation have been extensively investigated to reduce immune-mediated damage 
and promote cell survival. Encapsulated tissue transplants hold the potential to cure 
numerous diseases resulting from the loss of endocrine, cardiovascular, and 
neurological tissues [1]. One of the most widely studied diseases treatable with 
transplanted tissues is type I diabetes mellitus (TIDM). TIDM results from the 
autoimmune destruction of insulin-producing β-cells, located within the pancreatic islet 
of Langerhans cell clusters. The number of successful pancreatic tissue transplants 
continues to increase [2, 3] and transplant recipients experience fewer complications 
resulting from diabetes, compared to patients treated with daily insulin injections alone 
[4]. Despite continued improvements in transplantation regimens, most transplant 
recipients require systemic immune suppression to prevent graft rejection [2], which can 
lead to undesirable side effects including an increased risk of infection. Researchers 
have hypothesized that cell encapsulation within semi-permeable barriers prior to 
implantation may reduce or eliminate the requirement for systemic immunosuppression 
by reducing contact between donor tissue and the host immune system[1, 5]. Thus, 
strategies to encapsulate cells within natural and synthetic biomaterials have been 
extensively investigated [6]. Unfortunately, in the absence of systemic 
immunosuppression, encapsulated cell transplants are still likely to fail, in part because 
small cytokines and reactive oxygen species (ROS) are secreted by nearby immune 
cells, and these species remain able to diffuse into the capsule [1, 5] where they 
damage or destroy encapsulated cells [5, 7, 8]. 
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To improve semi-permeable encapsulation barriers, researchers in our 
laboratory, as well as others, have investigated methods to functionalize biomaterials to 
actively modulate the local immune environment.  For example, antibodies and peptides 
have been incorporated within capsules to bind and sequester damaging cytokines [9, 
10].  Enzymes may be incorporated to breakdown ROS, like superoxide, and promote 
cell survival [11-14].  Further, materials have been tuned to elute anti-inflammatory 
molecules for localized immune suppression [14-17].  Each of these strategies has 
shown potential to provide protection for encapsulated cells, but no method of immune 
modulation has been sufficient to allow long-term transplant survival in the absence of 
systemic immunosuppression.  Towards reducing the local concentration of activated 
immune cells responding to a transplant, we have recently reported a polymeric coating 
that induces apoptosis in T cells [18, 19], the adaptive immune cells implicated in 
mediating the long-term rejection of encapsulated cell transplants [20].  This coating 
utilized immobilized anti-fas antibody, known to induce T cell apoptosis upon 
engagement of the T cell fas receptor [21], and an adhesion ligand, ICAM-1 [22].  A 
dithiocarbamate (DTC) photoiniferter was incorporated on a hard, plastic substrate to 
initiate poly(ethylene glycol) (PEG) polymer chain formation with pendant anti-fas and 
ICAM-1 [23].   Using this chemistry, polymeric surfaces were coated with precise 
thicknesses and a high surface density of available biomolecules.  These functionalized 
coatings induced T cell apoptosis and demonstrated the potential of functionalized 
PEG-based polymer coatings to interact with local immune cells [18].  While this 
previously-investigated photoiniferter-based photopolymerization enabled the formation 
of bioactive polymer chains, coating of cell-laden biomaterials was hindered by limited 
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chemical reactivity in aqueous conditions, as well as technical difficulties in forming a 
conformal coating on an arbitrarily shaped 3D hydrogel.  Thus, an alternate strategy is 
investigated herein. 
Many biomaterials promote encapsulated cell viability and function [6], including 
PEG diacrylate (PEGDA) hydrogels [24-26].  PEG hydrogels have several 
characteristics which make them desirable for cell encapsulation and transplantation, 
including a high water content which can mimic native tissue, the potential for simple 
chemical modifications to incorporate biomolecules, and limited immunogenicity in vivo.  
Thus, PEG hydrogels were selected as the model encapsulation material for this study.  
To signal apoptosis in a local population of T cells, simple approaches like the co-
encapsulation of anti-fas antibody within the cell-laden hydrogel are inadequate 
because fas signaling is damaging to many cell types, including β-cells, and anti-fas 
must be physically separated from encapsulated cells [27].  Therefore, it is necessary to 
selectively modify the exterior of the cell-laden hydrogel with anti-fas to prevent contact 
with the encapsulated β-cells.  Several strategies have been previously employed to 
functionalize the surfaces of PEG hydrogels.  For example, Weber et al. fabricated 
layer-by-layer (LBL) hydrogels by immersing islet-laden PEG hydrogels into PEGDA 
precursor solution and photopolymerizing [28]. Likewise, Hahn et al. adapted traditional 
photolithography to pattern 3D structures and biomolecules onto the surfaces of PEG 
hydrogels [29, 30].  Microcontact printing, or soft lithography, has also been employed 
to stamp biomolecular patterns onto hydrogel surfaces [31].  While each of these 
modification methods provide specific advantages, it remains difficult to apply these 
techniques to fabricate uniform conformal coatings on 3D, cell-laden hydrogels.  Though 
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traditional photolithography allows patterning on 2D surfaces, light attenuation prevents 
the simultaneous formation of uniform coatings on all facets of a 3D hydrogel.  Likewise, 
soft lithography allows for versatile transfer of 2D patterns, but functionalizing multiple 
faces of a 3D object would be quite complex with this method and edges would 
inevitably be different in their coating as compared to the surfaces.  
Recently, Johnson et al. introduced an innovative strategy for fabricating uniform 
and sequential layers of hydrogel coatings [32]. They demonstrated the formation of 
polymer coatings via radicals generated by the reaction of glucose with glucose oxidase 
(GOx) at a hydrogel surface [32].  When glucose diffuses out of a pre-swollen gel and 
reacts with GOx, hydrogen peroxide (H2O2) is generated and further reacts with Fe2+ to 
form a hydroxyl radical (HO•) capable of initiating polymerization [33].  As Johnson et al. 
demonstrated, when a PEG hydrogel was swollen in a glucose solution and then dipped 
into a glucose-free pre-polymer solution (PEGDA, GOx and Fe2+), glucose diffuses out 
of all faces of the hydrogel, reacts with GOx and initiates polymerization at the surface, 
as summarized in Figs. 5.1A-C [32].  This reaction results in the rapid formation of 
polymer coatings with tunable thicknesses ranging from approx 100 to 800 µm, with the 
thickness proportional to the reaction time and dependent on the glucose concentration 
[32].  Further, this chemistry is possible in the presence of encapsulated cells [33].  
Thus, the simplicity, cytocompatibility and ability to fabricate coatings of precisely 
controlled thicknesses on 3D hydrogels makes GOx-mediated dip-coating desirable for 
functionalizing β-cell-laden hydrogels for immune cell signaling.  
In our present report, we modify the previously-reported GOx-initiated polymer 
coating strategy to coat cell-laden hydrogels with conformal coatings functionalized with  
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anti-fas antibody and ICAM-1 to induce T cell apoptosis.  We demonstrate this 
polymerization strategy allows for the rapid formation of thin polymer coatings with a 
high density of available bioactive molecules.  Further, we demonstrate the induction of 
T cell apoptosis atop bioactive coatings and verify that cell viability is maintained within 
GOx-coated capsules.  Finally, we examine the range of cytocompatible reaction 
conditions.  Ultimately, we highlight the capacity for GOx-mediated polymerizations to 
create multifunctional hydrogels with spatially defined signals to create cell-laden 
hydrogels with the potential to signal and regulate external cells. 
 
Fig. 5.1. Schematic illustrating the formation of polymer coatings initiated by 
glucose oxidase (GOx). (A) Cell-laden PEG hydrogels are swollen in a 
glucose-containing media and then (B) dipped into a pre-polymer solution 
containing acryl-PEG, GOx, Fe2+, and thiolated signaling molecules. Glucose 
diffuses out of the gel, reacts with GOx and initiates polymerization at the 
surface of the hydrogel. (C) Reactive coating results in conformal PEG layers. 
Schematic not to scale. (D) Confocal micrograph of PEG hydrogel (green) with 
GOx-mediated polymer coating (red). Scale = 200 μm. 
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5.2     MATERIALS & METHODS 
5.2.1 Materials 
 Poly(ethylene glycol), poly(ethylene glycol) monomethacrylate, triethyl-amine, 
acryloyl chloride, glucose oxidase enzyme, Fe2+, catalase, bovine serum albumin, 
EDTA, and D-glucose were obtained from Sigma-Adrich, St. Louis MO. All cell culture 
media, trypsin EDTA, fetal bovine serum, penicillin/streptomycin, fungizone, and 
live/dead staining assay were obtained from Invitrogen, Carlsbad, CA.  Anti-fas antibody 
(DX2 clone) and ICAM-1/Fc chimera were obtained from R&D Systems, Minneapolis, 
MN.  All other antibodies were obtained from Jackson ImmunoResearch, West Grove, 
PA.  Traut’s reagent, Zeba Spin filtration columns, Ellman’s reagent, fluoraldehyde 
reagent solution, and TMB ELISA substrate were each obtained from Thermo Fisher 
Scientific, Rockford, IL.  2-hydroxy-4′-(2-hydroxyethoxy)-2-methylpropiophenone 
(Irgacure 2959) was obtained from Ciba Specialty Chemicals, Basel, Switzerland.  Cell 
Titer Glo viability assay was obtained from Promega, Madison, WI. All compounds were 
used as received without additional purification steps.  
 
5.2.2  Cell culture 
 All cells were cultured at 37°C, in 5% CO2 and humid conditions.  Min6 β-cells 
and Jurkat T cells were maintained in RMPI 1640 media supplemented with fetal bovine 
serum (FBS, 10%), penicillin/streptomycin (1%) and fungizone (0.5 μg/ml).  Jurkat T 
cells were passaged every other day and seeded at 2.5x105 cell/ml.  Min6 β-cells were 
passaged once per week by treatment with 0.5 % trypsin EDTA (10 ml, 5 min) and 
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seeded at 1x106 cells/ml.  Fresh Min6 media was exchanged every other day.  3T3 
fibroblasts were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented 
with fetal bovine serum (FBS, 10%), penicillin/streptomycin (1%) and fungizone (0.5 
μg/ml).  3T3s were passaged every 4 days by treatment with 0.5 % trypsin EDTA (10 
ml, 5 min) and seeded at 1x105 cell/ml.   
    
5.2.3  Synthesis of poly(ethylene glycol) diacrylate (PEGDA) and formation of hydrogels 
 The synthesis of PEGDA has been described elsewhere [24, 34] and will be 
summarized herein.  Briefly, hydroxyl-terminated PEG (10 kDa) was dissolved in 
anhydrous toluene at 60ºC and then allowed to cool to room temperature (RT).  A 4-fold 
molar excess (per hydroxyl group) of triethylamine (TEA) and acryloyl chloride was 
added and the reaction was allowed to proceed overnight at RT. The following day, 
PEGDA was filtered through neutral alumina to remove TEA and then placed on the 
rotavap to remove excess toluene.  Finally, PEGDA was precipitated in diethyl ether 
and desiccated to dryness overnight.  A PEGDA (10 wt%, 10 kDa) hydrogel was used 
as the underlying substrate for all coating studies.  Hydrogels were formed from pre-
polymer solution containing PEGDA (10 kDa, 10 wt%) and 0.5 wt% 2-hydroxy-4′-(2-
hydroxyethoxy)-2-methylpropiophenone (Irgacure 2959, as a photoinitiator) in 
phosphate buffered saline (PBS, pH = 7.4). 30 µl pre-polymer was added to the tip of a 
1 ml syringe and polymerized for 9 minutes under ultraviolet light (centered at 365 nm, 6 
mW/cm2).  Following polymerization, solid hydrogel disks were ejected from the syringe 
tips into >3 ml cell culture media (RPMI 1640 supplemented with 10 % fetal bovine 
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serum (FBS), 100 mg/ml penicillin/streptomycin, and 0.5 mg/ml Fungizone) and 
incubated overnight at 37°C, with 5% CO2 and humid conditions. 
 
5.2.4  Thiolation of IgG, anti-Fas, & ICAM-1 
To covalently incorporate proteins within polymer coatings, proteins were modified via 
the addition of thiol groups.  As previously demonstrated in our laboratory, proteins and 
peptides with free thiol groups may be photopolymerized via the radical-mediated thiol-
acrylate polymerization [35].  Free thiol groups were added to IgGs, anti-Fas (IgG, DX2 
clone), and ICAM-1 (1 mg/ml) by reacting with Traut’s reagent (5 mol Traut’s reagent / 1 
mol protein), in PBS containing 5 mM EDTA for 1 hr with mixing.  Unreacted Traut’s 
reagent was removed via filtration through Zeba™ Spin Desalting Columns (7K 
MWCO).  Protein solutions were diluted to a final concentration of 1 mg/ml in PBS 
containing bovine serum albumin (BSA, 2 mg/ml) and EDTA (5 mM) and frozen at -
80°C.  Thiolated proteins were thawed immediately prior to polymerization into polymer 
coatings. 
 
5.2.5  Formation of GOx-mediated Polymer coatings 
 After swelling overnight in cell culture media, a polymer coating was formed on 
hydrogels using the reaction of glucose oxidase with glucose, in the presence of Fe2+, to 
generate radicals capable of initiating polymerization. Hydrogels swollen overnight (>12 
hrs) in cell culture media (containing 11.1 mM glucose) were dipped in pre-polymer 
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solutions containing either PEG acrylate (acryl-PEG, 25 wt%, Mn=400 Da) or PEG 
methacrylate (methacryl-PEG, 25 wt%, Mn=525 Da), with Fe2+ (4 mM) and GOx (0 to 50 
µM) in phosphate buffered saline (PBS, pH=7.4) for subsequent coating formation.  
Methacrylated Rhodamine (methacryl-Rhod, 300 uM) was included in some coatings for 
visualization purposes, but did not significantly affect the polymerization or polymer film 
growth rate.  Thiolated IgGs (from goat, blank and FitC-conjugated) and anti-Fas were 
incorporated into coatings at 250 µg/ml.  Thiolated ICAM-1 was incorporated at 100 
µg/ml.  Gels were dipped in 50 µl pre-polymer in individual wells of a 96-well plate for 0 
to 60 s to study varying times of coating formation. After dipping, coated hydrogels were 
removed and immersed in either cell culture media or PBS for further study. 
 
5.2.6   Characterization of coatings 
 The thickness of the polymer coatings as a function of dipping time was 
measured via laser-scanning confocal microscopy (LSM 500 microscope, Zeiss).  
Methacryl-Rhod was co-polymerized into PEG coatings for visualization and a series of 
images were taken at 10 µm increments throughout the full thickness of coated 
hydrogels.  Images were reconstructed into a 3D model of each coated hydrogel and 
coating thicknesses were measured via software analysis (MetaMorph, Molecular 
Devices, Sunnyvale, CA).  A modified ELISA was employed to quantify the 
concentration of accessible IgG incorporated within the coatings, as we have previously 
described [18].  Briefly, IgG (from goat) was polymerized into coatings as described 
above and incubated overnight in PBS to ensure complete removal of unconjugated 
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proteins.  Coated gels were incubated for 30 min with donkey-anti-goat secondary IgG 
(horse-radish peroxidase (HRP)-conjugated, 5 µg/ml) in PBS with 0.5% BSA.  Gels 
were rinsed 4x with PBS and transferred to PBS with 0.5% BSA for an additional 30 min 
to remove unconjugated secondary IgGs.  Gels were rinsed an additional 4x in PBS and 
transferred to individual wells of a 96-well plate in 70 µl PBS.  TMB ELISA substrate 
was added to each well for 60s with frequent pipetting to mix and subsequently 
transferred to H2SO4 (2M) to quench the reaction.  The absorbance was read at 450 nm 
and compared to signals of a calibration curve generated by known concentrations of 
HRP-conjugated secondary IgG.  For dual-color imaging, samples were stained per the 
modified ELISA, except FitC-IgG (from goat) was incorporated into polymer coatings 
and samples were incubated in rhodamine-conjugated donkey-anti-goat secondary IgG.  
Coated gels were imaged via confocal microscopy and z-direction images were 
constructed to visualize FitC-IgG throughout the entire coating and Rhod-IgG secondary 
IgG that bound accessible, polymerized IgGs.          
 
5.2.7  T cell Apoptosis studies and flow cytometry 
 The biological activity of anti-fas-functionalized coatings was assessed via Jurkat 
T cell apoptosis studies.  Coatings functionalized with thiolated anti-fas antibody (DX2 
clone) and/or ICAM-1-Fc chimera were formed as described above and incubated 
overnight (>12 hrs) in catalase-containing media with at least 3 media changes.  After 
24 hrs, coated gels were placed in individual wells of a 96-well plate and 100 000 T cells 
/ well were seeded atop coatings in 200 µl media.  T cells were incubated for 12, 24, or 
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48 hours and then analyzed for apoptosis and necrosis via Vybrant #3 apoptosis assay.  
T cells were stained with FitC-Annexin V and propidium iodide (PI) to label apoptotic 
and dead cells, respectively.  Cells were analyzed using a CyAn flow cytometer 
(Beckman Coulter, Brea, CA).  T cells were considered apoptotic if they stained positive 
for FitC-Annexin V and negative for PI.  All cells staining positive for PI were considered 
dead.      
 
5.2.8  Cell encapsulation, coating & analysis 
Min6 β-cells (15 x106 cells/ml) or 3T3 fibroblasts (5 x106 cells/ml) were 
encapsulated within PEG hydrogels by suspension in pre-polymer solutions containing 
PEGDA (10 kDa, 10 wt%), 1-[4-(2-hydroxyethoxy)phenyl]-2-hydroxy-2-methyl-1-propan-
1-one (I2959, 0.05 wt%) as a photoinitiator, and catalase (100 nM).  The peptide 
CRGDS (1mM) was also added when 3T3 cells were encapsulated to avoid anoikis.  30 
µl of cell-containing pre-polymer suspensions were transferred into 1 ml syringe tips and 
photopolymerized for 10 min, under 6 mW/cm2 UV light centered at 365 nm, yielding 
hydrogel disks of ~2 mm thickness and ~5 mm in diameter.  Cell-laden hydrogels were 
transferred to cell culture media and incubated overnight at 37°C.  Coatings were 
formed via a GOx-mediated surface polymerization from the cell-laden gels as 
described above.  Following the coating process, gels were transferred to cell culture 
media containing catalase (100 nM) and media was changed 3 times per hour for at 
least the first 2 hours following coating.  Then, gels were incubated overnight at 37°C.  
Cell viability was assessed via a Live/Dead staining assay in which calcein AM labels 
live cells green and propidium iodide labels dead cells red.  Cell-laden gels were 
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imaged via confocal microscopy whereby 20 images were taken at 10 µm intervals and 
projected into a single plane.  The CellTiter glo assay was used to quantify cellular 
viability as follows: Cell-laden hydrogels were transferred to 50% cell titer glo solution in 
PBS (200 μl /sample) and incubated 40 min with orbital shaking.  100 μl / sample was 
transferred to an opaque-walled, white 96-well plate and luminescence was recorded 
and compared to that of ATP standards. 
 
5.2.9   Statistical Analysis 
   Results presented herein are expressed as mean ± standard error of the mean.  
Two-tailed, unpaired Student’s t-tests were used to determine statistical significance 
between datasets. Differences were considered statistically significant when the p value 
was less than 0.05.  All experiments were replicated at least 3 times.  
 
5.3    RESULTS 
5.3.1 Glucose oxidase-mediated polymer coatings 
 The GOx enzyme was utilized to initiate polymerization on the surfaces of 
hydrogels as described above and illustrated in Figs. 5.1A-C.  Uniform coatings, such 
as the one shown in Fig. 5.1D, were polymerized on the surfaces of PEG hydrogels by 
dipping glucose-swollen hydrogels into glucose-free pre-polymer containing GOx 
enzyme, Fe2+ and either PEG monoacrylate (acryl-PEG) or PEG monomethacrylate 
(methacryl-PEG).  Coating thicknesses were controlled by varying the dipping time, and 
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a pseudo-linear relationship was observed between dipping time and the resulting 
coating thickness, as shown in Fig. 5.2.  Coating thicknesses up to 450±50 μm were 
fabricated for dipping times ranging 0 to 60 s.  As shown in Fig. 5.2, conformal coatings 
are formed using either acryl-PEG or methacryl-PEG. Further, 3D visualization via 
confocal microscopy confirmed that a conformal layer is formed on all faces of the 
hydrogel. 
 
 
 
Fig. 5.2. Polymer coating thickness as 
a function of dipping-time. Fluorescent 
molecules were incorporated within 
polymer coatings and then visualized 
and measured via confocal 
microscopy.  Coatings were formed 
from dipping solutions containing 25 
wt% of either acryl-PEG (black line) or 
methacryl-PEG (dashed red line) with 
50 μM GOx and 4 mM Fe2+.   
 
 
5.3.2   Incorporating proteins & signaling molecules into polymer coatings 
 IgGs, anti-Fas, and ICAM-1 were rendered polymerizable via the addition of thiol 
groups to free amines by reaction with Traut’s reagent.  The extent of protein 
modification was controlled by varying the molar excess of Traut’s reagent relative to 
protein.  Protein modification was confirmed in two different manners: the appearance of 
thiol groups on purified protein was monitored via Ellman’s reagent, and the 
disappearance of free amines was observed using Fluoraldehyde reagent.  Both 
measures confirmed that the extent of thiolation was proportional to the molar excess of 
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Traut’s reagent (data not shown).  Once thiolated, IgG-SH, anti-Fas-SH and ICAM-1-SH 
were incorporated into polymer coatings via GOx-initiated thiol-acrylate polymerization, 
as we have previously demonstrated that proteins and peptides containing free thiol 
groups may be incorporated into polymer networks via mixed mode thiol-acrylate 
polymerizations [35].  Briefly, the thiol acts as a chain transfer agent, having its 
hydrogen abstracted by the propagating radical of the growing (meth)acrylic coating.  
The new thiyl radical that is formed reinitiates a new (meth)acrylic polymer chain which, 
due to the multifunctional nature of the (meth)acrylate monomers, becomes crosslinked 
into the original coating, thus uniformly incorporating the peptide into the coating.   
 
5.3.3  Characterization of proteins within polymer coatings 
A previously reported modified ELISA was utilized to detect available proteins 
incorporated within the polymer network [18].  Thiolated IgGs from goat were 
incorporated at concentrations ranging from 0 to 250 μg/ml into polymer coatings and 
incubated with donkey anti-goat secondary antibodies with conjugated HRP or 
fluorophore to detect or visualize, respectively, IgGs incorporated within polymer 
coatings.  FitC-labeled IgG-SH was polymerized into polymer coatings and then 
incubated with rhodamine-conjugated secondary IgG. As shown in Fig 5.3A, a green 
polymer coating containing FitC-IgG was visible on both faces of a coated hydrogel.  
Red secondary IgG (IgG-Rhod) was incubated with coatings and staining was most 
evident at the surface of the coating.  Some staining with secondary IgG was visible 
within the polymer coatings (indicated by yellow). Control coatings lacking FitC-IgG-SH 
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were fabricated and exposed to IgG-Rhod secondary IgG and no green or red staining 
was visible (data not shown), indicating that the secondary IgG staining in Fig 5.3A was 
specific for IgGs polymerized into the coating.  
 
Fig. 5.3. Incorporation of biomolecules within polymer coatings. (A) z-stack confocal image of coatings on 
the top and bottom of a PEG hydrogel. FitC-labeled goat IgG was covalently incorporated within polymer 
coating (green). When incubated with rhodamine-conjugated donkey-anti-goat IgG, accessible goat IgG is 
fluorescently labeled (red). For simplicity, illustration shows coatings only on top and bottom of the 
hydrogel; actual samples were coated on all sides. (B) Concentration of accessible IgG in polymer 
coatings, per cm2 of hydrogel coated, as a function of the concentration of IgG-SH loaded into the pre-
polymer. (C) Concentration of accessible IgG in polymer coating as a function of dip-coating time. 
Coatings were formed with 25 wt% of either acryl-PEG (black line) or methacryl-PEG (dashed red line) 
with 50 μM GOx and 4 mM Fe2+. 
 
To quantify the amount of IgG-SH within coatings that remained accessible to the 
surroundings, samples were incubated with HRP-conjugated secondary IgG, reacted 
with TMB ELISA substrate, and the substrate absorbance change was compared to a 
standard curve [18].  The amount of detectable IgG was found to increase as the 
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concentration of IgG-SH in the coating pre-polymer solution was increased, Fig. 5.3B, 
and surface concentrations in excess of 10 ng IgG per coated cm2 were achieved.  The 
amount of detectable IgG as a function of coating formation time was also analyzed, 
Fig. 5.3C.  For the first 20 s of coating, the amount of detectable IgG increased with 
time; however, the amount of detectable IgG remained constant for longer 
polymerization times, Fig 5.3C. This relationship suggests that IgGs were accessible to 
secondary IgG within approximately the outermost 100 - 150 μm of the coating (the 
thicknesses achieved for coating times of 20 s or 30 s for acryl-PEG or methacryl-PEG, 
respectively).  While the overall coating thickness increases for longer reaction times, it 
is likely that the additional polymer formation of a thicker coating limits the accessibility 
of IgG near the original surface.  Thus, a relatively constant amount of IgG-SH remained 
accessible to the surroundings for coating times in excess of ~20 to 30 s. 
  
5.3.4  Inducing T cell apoptosis with functionalized dip coatings 
 Thiolated anti-Fas and ICAM-1 were incorporated into GOx-initiated polymer dip-
coatings as described above.  A 30 s reaction time was used for all T cell studies to 
allow a high concentration of accessible protein.  Coated hydrogels were swollen 
overnight in catalase-containing cell culture media to ensure removal of unconjugated 
signaling proteins.  The following day, Jurkat T cells were seeded atop functionalized 
coatings and cultured for 24 hrs.  Following 24 hrs, T cells were harvested by PBS rinse 
and analyzed for apoptosis by FitC-Annexin V staining and flow cytometry.  Samples 
were counter-stained with propidium iodide to label dead cells so that only live cells 
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were included in analysis.  Flow cytometry of T cells 24 hrs following seeding atop 
functionalized coatings revealed significant apoptosis when cultured on coatings 
containing co-polymerized anti-fas, Figs. 5.4A & 5.4B.  As shown in Fig. 5.4B, for T cells 
seeded atop blank or ICAM-1-only coatings, a low level of apoptosis was observed, 
2±1% and 4±2% (for PEG acrylate-based coatings), respectively.  Coatings  
functionalized with anti-fas induced significantly higher levels of apoptosis, 13±2%.  
Coatings fabricated with acryl-PEG that were dually-functionalized with anti-Fas and the 
ICAM-1 adhesion ligand induced the highest percentage of T cell apoptosis, 22±2%.          
  
 
Fig. 5.4.  Induction of T cell apoptosis atop functionalized PEG coatings. (A) Flow cytometry of T cells 
harvested from functionalized coatings fabricated with acryl-PEG. Live cells (PI neg) stained with FitC-
Annexin V are shown and the percentage of cells positive for apoptosis increased with the incorporation 
of anti-fas and anti-fas/ICAM-1. (B) Summary of findings for functionalized coatings composed of 25 wt% 
of either acryl-PEG (solid bar) or methacryl-PEG (slashed red bar). * denotes p<0.05 difference. $ 
denotes p<0.05 difference from -/- acryl-PEG control. # denotes p<0.05 difference from -/- methacryl-PEG 
control. 
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5.3.5  Apoptosis time course 
 To assess the impact that functionalized coatings have on the local T cell 
population over time, a 48 hr time course experiment was conducted.  T cells seeded 
atop dually-functionalized (anti-Fas & ICAM-1) coatings fabricated with acryl-PEG were 
analyzed for apoptosis and cell death, via staining and flow cytometry, at 12, 24, and 48 
hrs.  For T cells seeded atop blank coatings, Fig. 5.5A, a low level of apoptosis and cell 
death was observed for all time points. When seeded atop dually-functionalized (anti- 
 
Fig. 5.5. T cells were seeded atop control (A) or dually-functionalized (anti-Fas + ICAM-1) (B) coatings 
composed of 25 wt% acryl-PEG for 12, 24, or 48 hrs and then analyzed via flow cytometry. The fraction of 
dead and apoptotic cells for each condition was measured. Functionalized coatings induced a significant 
increase in the number of T cells undergoing apoptosis. 
Fas and ICAM-1) coatings, Fig. 5.5B, increased apoptosis was observed for all time 
points.  The number of cells undergoing apoptosis increased from 12 to 24 hrs but 
remained similar from 24 hrs to 48 hrs. Interestingly, the number of dead cells increased 
dramatically from 24 to 48 hrs, from 17±2% to 37±4%, respectively.  This observation 
was attributed to the likelihood that cells undergoing apoptosis eventually die, and dead 
cells accumulate on the gel surface over time.  Following seeding atop anti-fas / ICAM-1 
coatings, apoptosis was monitored over 48 hrs, and 61±9% of all cells were either 
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apoptotic or dead, compared to only 18±5% of T cells on non-functionalized coatings.  
This result indicates that anti-fas-functionalized polymer coatings formed via GOx-
initiated surface-mediated polymerizations were able to significantly reduce the local T 
cell population in culture. 
 
5.3.6 GOx coating of cell-laden hydrogels 
 A critical aspect of functionalizing cell-laden carriers is the cytocompatibility of the 
coating process.  To assess the cytocompatibility of coatings formed via GOx-mediated 
polymerization on cell-laden hydrogels, Min6 β-cells and 3T3 fibroblasts were 
encapsulated in PEG hydrogels and then reactively dip-coated.  Interestingly, low 
molecular weight PEG acrylates (Mn= 400 Da) were found to be highly toxic to 
encapsulated cells, show in Fig. 5.6, even at the shortest coating times.  When 
immersed in low molecular weight PEG methacrylates (Mn= 525 Da), however, high cell 
viability was maintained.  Viability was assessed 24 hrs following GOx-mediated coating 
via live/dead staining and confocal microscopy as well as ATP viability assay.  As 
shown in Fig. 5.6A, high cell viability was visualized for both Min6 and 3T3-laden 
hydrogels dipped for 30s in methacryl-PEG-containing pre-polymer solutions containing 
either 0 or 50 μM GOx enzyme.  Of note, immersion in the 50 μM GOx solution resulted 
in significant coating formation.  Hydrogels containing either Min6 β-cells (Fig. 5.6B) or 
3T3 fibroblasts (Fig. 5.6C) were coated via dipping in acryl-PEG or methacryl-PEG and 
subsequently cultured in catalase-containing cell culture media for 24 hrs before viability 
was quantified.  As shown in Figs. 5.6B & C, high cell viability remained after 24 hrs for  
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Fig. 5.6. Cytocompatibility of GOx-initiated polymer coatings toward encapsulated cells (A) Live/dead 
confocal microscopy of cell-laden hydrogels containing (top) Min6 β-cells or (bottom) 3T3 fibroblasts. 
Samples were dipped for 30 s in a pre-polymer solution containing (left) 0 μM or (right) 50 μM GOx 
enzyme with 25 wt% methacryl-PEG and then analyzed at 24 hrs. The 50 μM GOx condition resulted in 
coating formation.  Green and red staining denotes live and dead cells, respectively. Scale = 100 μm. (B-
C) Viability of encapsulated Min6 β-cells (B) or 3T3 fibroblasts (C) 24 hours after coating. Coatings were 
fabricated with 25 wt% of either acryl-PEG acrylate (solid bar) or methacryl-PEG (slashed red bar).  
Virtually no metabolic activity remained after 24 hrs with hydrogels dipped in acryl-PEG coating solutions. 
 
coatings fabricated with methacryl-PEG, but essentially no viability remained after 
dipping in acryl-PEG.    
 
5.4     DISCUSION 
 Strategies to form multi-layer hydrogel structures offer the ability to spatially 
regulate biological and cellular functions within biomaterials systems.  Here, glucose-
swollen hydrogels were dipped into pre-polymer solutions containing the glucose 
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oxidase enzyme to form conformal coatings on cell-laden structures and introduce 
biologically relevant functionalities that manipulate the local immune response.  While 
conceptually straightforward, two critical design parameters relate to the thickness and 
bioactivity of the coating, combined with the cytocompatibility of the processing 
conditions.  Many concentrations of GOx enzyme and Fe2+ were investigated (data not 
shown), but concentrations of 50 μm and 4 mM, respectively, were used for all reported 
studies, unless otherwise stated, as they enabled the rapid formation (0 to 60 s) of 
coatings (approximately 0 to 500 μm). The thicknesses of fluorescently-labeled coatings 
were measured via confocal microcopy and a pseudo-linear relationship was found 
between immersion times and coating thickness, Fig. 5.2.  This relationship agreed well 
with that previously observed by Johnson et al. [32].  PEG monoacrylate (acryl-PEG, 
Mn=400 Da) and PEG monomethacrylate (methacryl-PEG, Mn=525 DA) were used as 
the base monomers for coatings in this study because we have previously 
demonstrated immune-cell signaling by functionalized coatings fabricated from 
monoacrylated PEGs [18].  While mono-(meth)acrylated PEGs were evaluated herein, 
di(meth)acrylated PEGs have also been shown to be suitable for GOx-mediated dip 
coatings [32].  
 Proteins were rendered reactive for copolymerization via covalent modification 
with free thiol groups.  As previously investigated in our laboratory, thiolated peptides 
and proteins may be covalently conjugated into polymer networks via radical-mediated 
thiol-acrylate polymerizations [35, 36].  Thiolated IgGs were incorporated into coatings 
atop the surfaces of hydrogels via GOx-mediated dip coatings.  Incorporation was 
verified by fluorescent confocal microscopy and ELISA-type assays, Fig. 5.3.  High 
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concentrations of proteins were detectable within polymer coatings, exceeding 10 ng 
per coated cm2 of hydrogel.  These concentrations were over 7-fold greater than those 
that we have previously observed for functionalized, polymeric coatings fabricated via 
surface-initiated photopolymerizations [18].  This increase in detectable, incorporated 
IgG is likely due to the increased coating thickness and the higher density of initiating 
sites that are formed by the GOx-mediated polymerization.  Previous coating 
thicknesses achieved by grafted photoinitiators ranged from 0 to approximately 50 μm 
[18].       
 To signal immune cells in proximity to hydrogels, thiolated anti-fas IgG was 
incorporated within coatings.  We previously investigated the induction of T cell 
apoptosis by PEG-based polymer coatings and observed that significant apoptosis was 
induced by surfaces functionalized with anti-fas IgG [18]. Additionally, we determined 
that incorporating the ICAM-1 adhesion protein further improved fas signaling [18], likely 
by increasing the interaction between T cells and the PEG surface [37] and promoting 
fas signaling [38]. Because of these previous findings, we chose to incorporate anti-fas 
IgG and ICAM-1 into the GOx-mediated PEG coatings investigated herein.  Jurkat T cell 
studies verified that anti-fas retained significant bioactivity when incorporated into 
coatings, as apoptosis was successfully induced.  When analyzed for apoptosis at 12, 
24 and 48 hrs, it was clear that the dually-functionalized anti-Fas / ICAM-1 coatings had 
a significant impact on the local T cell population.  After 48 hrs atop functionalized 
coatings, less than 40% of cells remained healthy.  
 To verify the cytocompatibility of this coating process, cell-laden hydrogels were 
coated and subsequently cultured overnight.  When dipped in pre-polymer solutions 
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containing acryl-PEG, interestingly, poor cell viability was observed.  In fact, in the 
absence of any other factors, dipping in 10 wt% acryl-PEG (Mn=400 Da) for very short 
times (e.g., 10 s) was sufficient to result in almost complete cell death to encapsulated 
cells (data not shown).  Coating with methacryl-PEG, however, was better-tolerated by 
encapsulated cells and resulted in high viability after 24 hrs.  Because higher surface 
concentrations of detectable signaling molecules were observed on hydrogels 
fabricated with acryl-PEG, this coating formulation may be superior to methacryl-PEG-
based coatings for the singular purpose of signaling nearby cells.  If it is desirable to 
coat cell-laden hydrogels, however, methacryl-PEG-based coatings are clearly superior 
due to drastically-improved cytocompatibility of the compounds evaluated here.   
Following 24 hrs, coated gels retained high viability when cultured in media 
containing catalase.   In the absence of catalase, however, low cell viability was 
observed.  Because the addition of catalase, a commercially available enzyme which 
breaks down H2O2, was sufficient to provide high cell viability, H2O2 formation likely 
continued after dip-coating.  This observation might be attributed to the encapsulation of 
GOx enzyme within the polymer coatings, which may subsequently continue to react 
with glucose in cell culture media. Once entrapped with PEG coatings, the large (160 
kDa [39]) GOx molecule is unlikely to diffuse out of the PEG network [40].  In the 
presence of catalase, however, high β-cell and 3T3 viability were observed.  Ultimately, 
as previously described [33], the glucose oxidase chemistry can be highly 
cytocompatible.    
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5.5     CONCLUSIONS 
We have demonstrated a cytocompatible dip-coating technique for modifying 
cell-laden hydrogels and for the purpose of fabricating immunoactive coatings.  GOx 
enzyme allows for the initiation and formation of uniform, PEG-based polymer coatings 
with thicknesses controlled via the reaction/dipping time.  Thiol-acrylate polymerization 
enabled thiolated biomolecules to be covalently and efficiently incorporated into the 
coatings, and a modified ELISA verified that a high density of incorporated protein was 
accessible to the surroundings. To form an immunoactive coating around PEG 
hydrogels, anti-fas antibody and ICAM-1 adhesion molecule were incorporated into the 
surface layer.  Studies with T cells verified that functionalized coatings induced 
significant fas signaling, as over 60% of all T cells were apoptotic or dead after 48 hrs 
atop the coatings.  Finally, the cytocompatibility of methacryl-PEG-based coatings was 
studied and verified in the presence of catalase.  In summary, GOx-mediated dip 
coatings are an attractive technique for functionalizing cell-laden biomaterials with 
biologically active molecules to signal external cells, including immune cells. 
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Chapter 6 
 
Strategies to reduce dendritic cell maturation and promote tolerance through 
functional biomaterial design 
 
 
Dendritic cells play a key role in determining adaptive immunity, so the 
interaction between biomaterials and dendritic cells has the potential to shape whether 
immunity or tolerance results. Accordingly, there is growing interest in characterizing the 
interactions between dendritic cells and biomaterial surfaces. While contact with several 
common biomaterials has been shown to induce the maturation of immature dendritic 
cells, substrates that reduce dendritic cell maturation are particularly desirable within the 
field of tissue engineering, where it is often preferable to reduce the immune response 
to cell-laden material carrier. Towards this goal, a novel strategy was examined 
whereby poly(ethylene glycol) hydrogel were functionalized with immobilized 
immunosuppressive factors (TGF-β1 and IL-10) to reduce the maturation of immature 
dendritic cells.  TGF-β1 and IL-10, as soluble factors, are commonly employed to 
program dendritic cells in vitro, and herein it is demonstrated these proteins retain 
bioactivity towards dendritic cells when immobilized on hydrogel surfaces. Following 
stimulation with lipopolysaccharide and/or cytokines, immature dendritic cells interacting 
with the surfaces of immunosuppressive hydrogels demonstrated reduced markers of 
maturation, including IL-12 production and MHCII, which was comparable to dendritic 
cells treated with soluble or immobilized TGF-β1 and IL-10. Further, the bioactivity of 
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these immunomodulatory hydrogels was confirmed towards immature dendritic cells 
isolated from non-obese diabetic (NOD) mice, a cell type relevant to type I diabetes. 
Finally, the addition of general adhesion to immunomodulatory hydrogels is explored 
and demonstrated to improve the extent to which BMDC maturation is reduced. 
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6.1     INTRODUCTION 
Dendritic cells (DCs) bridge the innate and adaptive immune systems and are 
crucial to initiating and guiding the adaptive immune response. Immature dendritic cells 
(iDCs) survey the body’s periphery in search of foreign and self antigens [1]. Upon 
antigen uptake, DCs present antigen to lymphocytes, but have the unique capacity to 
induce either immunity or tolerance to antigen [1, 2]. For example, when iDCs encounter 
antigen in the presence of stimulatory factors such as “danger signals” or pathogen 
associated molecular patterns (PAMPs), iDCs undergo maturation into mature DCs and 
initiate an adaptive immune response [3]. Upon maturation, DCs increase expression of 
MHC stimulatory molecules, B7 family co-stimulatory molecules (i.e., CD80 and CD86), 
and inflammatory cytokines, including IL-12, which enable the activation of naïve CD4+ 
helper T cells to initiate an immune response [1]. Conversely, if iDCs encounter antigen 
under conditions which prevent full DC maturation, they may become tolerogenic DCs 
with decreased expression of the aforementioned maturation markers, preventing an 
adaptive immune response [2, 4].  
Because of their critical importance in dictating the fate of the adaptive immune 
response, understanding interactions between iDCs and implanted biomaterial surfaces 
has gained considerable interest in recent years [5]. For example, several commonly-
used biomaterials including poly(lactic-co-glycolic acid) (PLGA) and chitosan [6], as well 
as surface modifications with common extracellular matrix (ECM) proteins [7] and 
integrins [8], have been identified as regulators that can induce iDC maturation and 
initiate an adaptive immune response.  The induced maturation of iDCs by biomaterials, 
or adjuvant effect, is desirable for biomaterial vaccines against infection and tumors 
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where an immune response is favorable [9]. When designing biomaterials for tissue 
engineering applications, such as the transplantation of tissues encapsulated within 
biomaterials for the treatment of diseases like type I diabetes mellitus (TIDM), however, 
optimal biomaterial cell carriers would minimize the adjuvant effect or even prevent the 
full maturation of iDCs and form tolerogenic DCs. To date, few research groups have 
investigated strategies to limit iDC maturation via controlled modification of biomaterial 
surfaces. As a result, a great potential exists for development in this area, and as one 
example, Babensee and coworkers recently demonstrated that hyaluronic acid and 
agarose have the capacity to limit immunogenicity compared to surfaces with known 
adjuvant effect [6, 10].  
 In previous work, tolerogenic DCs have been generated in vitro by culturing iDCs 
in the presence of one or more soluble factors [11].  A particularly well known method to 
generate tolerogenic DCs involves culturing iDCs in the presence media additives such 
as transforming growth factor β-1 (TGF-β1) and/or interleukin 10 (IL-10)  [11-14]. 
Culturing iDCs with these immunosuppressive proteins has been shown to yield 
tolerogenic iDCs that undergo incomplete maturation upon immune stimulation and can 
promote T cell anergy or, alternatively, the formation of regulatory T cells [2]. Immature 
DCs primed with TGF-β1 and IL-10 in this manner have been widely investigated. For 
example, Torres-Aguilar et al. recently cultured iDCs with IL-10 and TGF-β1 in the 
presence of insulin to generate tolerogenic DCs, which induced antigen-specific insulin 
tolerance in humans [15]. 
 In this contribution, a biomaterial surface is modified with the tethered 
immunosuppressive proteins TGF-β1 and / or IL-10 to create immunomodulatory 
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surfaces that signal iDCs and reduce maturation upon stimulation with LPS. Specifically, 
a poly(ethylene glycol) (PEG) hydrogel platform, which limits immunogenicity and allows 
facile modification to incorporate proteins, was chosen as a basis from which anti-
inflammatory molecules could be tethered for iDC signaling. Numerous proteins, 
peptides and other molecules of interest have been previously incorporated onto 
biomaterial surfaces and remained bioactive for cell signaling [16, 17]. Notably, Mann et 
al. tethered TGF-β1 within PEG hydrogels to signal vascular smooth muscle cells and 
demonstrated that immobilized TGF-β1 maintained bioactivity and increased ECM 
protein synthesis [18]. In our group, we have previously investigated PEG-based 
surfaces for the purposes of immune signaling, and demonstrated that PEG coatings 
containing immobilized anti-fas are capable of interacting with T cells and inducing 
apoptosis [19, 20]. Further, it is known that DCs have the capacity to receive biological 
cues from tethered signaling proteins, as Leclerc et al. immobilized granulocyte-
macrophage colony stimulating factor (GM-CSF) upon surfaces to promote the 
development of iDCs from isolated bone marrow tissue [21].  
 Herein, bone marrow-derived mDCs are employed to characterize the 
immunomodulatory capacity of PEG hydrogels modified with immunosuppressive 
proteins. Initial studies were conducted with the cytokine-dependent, immortalized 
immature dendritic cell line, JAWSII. The JAWSII dendritic cell line was originally 
isolated from the bone marrow of p53-/- C57BL/6 mice and has been previously shown 
to mimic the capacity of primary iDCs to undergo maturation in response to immune 
stimuli [22-25]. Additionally, primary bone marrow-derived DCs (BMDCs) generated 
from bone marrow isolated from non-obese diabetic (NOD) mice were evaluated with 
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immunomodulatory hydrogels. Immature DCs from NOD mice are previously known to 
have impaired maturation [26, 27]. Therefore, exploring the immunosuppressive 
capacity of functionalized PEG hydrogels towards iDCs generated from NOD mice 
provides greater insight into the capacity of selectively functionalized material to target 
cells of the adaptive immune response as related to disease models relevant to the 
treatment of type I diabetes mellitus. 
 
6.2  MATERIALS & METHODS 
6.2.1   Dendritic cell culture 
JAWSII cells, an immortalized dendritic cell line of murine bone marrow origin 
(ATCC, Manassas, VA), were cultured in α-MEM media (Invitrogen, Carlsbad, CA) 
supplemented with 20% heat inactivated FBS (Invitrogen), 1% penicillin/streptomycin 
(Invitrogen, and 5 ng/ml GM-CSF (Peprotech, Rocky Hill, NJ). JAWSII were cultured in 
tissue culture flasks and media was changed weekly. Primary bone marrow-derived 
dendritic cells (BMDCs) were harvested from femurs isolated from NOD mice. The ends 
of femurs were cut and the marrow was rinsed with 10 ml RPMI media 1640 (Invitrogen) 
with a 27 gauge syringe needle. Freshly isolated samples were mixed with an 18 gauge 
syringe to dissociate clumps. Following isolation, samples were cultured in cell culture 
media consisting of RPMI 1640 medium supplemented with 1.5% mouse serum 
(Invitrogen), 20 ng/ml GM-CSF, and 1% penicillin/streptomycin. BMDCs were seeded 
onto TCPS in 6-well plates or hydrogels in 96-well plates and 50% fresh media volume 
was changed daily.       
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6.2.2  Thiolation of proteins 
To incorporate TGF-β1 and IL-10 as covalent pendant functional groups within 
hydrogels, proteins were rendered polymerizable via modification by Traut’s reagent 
(Thermo Scientific, Rockford, IL), which conjugates to free amines to create thiols.  In 
brief, proteins were reconstituted in phosphate buffered saline (PBS, pH 7.4, Invitrogen) 
containing 2 mM EDTA (Sigma) and a 5-fold molar excess Traut’s reagent per mol 
protein.  Samples were mixed and reacted at room temperature for 1 hr. Following 
thiolation, unreacted Traut’s reagent was removed via filtration through Zeba™ Spin 
Desalting Columns (7K MWCO, Thermo Scientific), yielding the final thiolated product of 
TGF-β1-SH or IL-10-SH. Samples were diluted to a final concentration of 25 μg/ml in 
PBS with 2 mM EDTA and immediately placed in a  -80°C freezer. Prior to use, protein 
solutions were rapidly thawed and added to pre-polymer solutions in concentrations 
ranging from 0 to 1 μg/ml for gel formation via photopolymerization.          
 
6.2.3   PEG hydrogel formation  
The synthesis of poly(ethylene glycol) (PEG) diacrylate (PEGDA, 10 kDA) 
macromolecular monomers from hydroxyl-PEG (Sigma) has been described in detail 
elsewhere [28].  Briefly, hydroxyl PEG was dissolved in anhydrous toluene by heating to 
60ºC with mixing. After the dissolved PEG was allowed to cool to room temperature 
(RT), triethylamine (TEA, 4-fold molar excess per hydroxyl group) and acryloyl chloride 
were added and reacted overnight at RT with stirring.  Next, TEA was removed via 
filtration through neutral alumina. PEGDA was precipitated in cold diethyl ether and 
desiccated to dryness overnight. To ensure high levels of purity, PEGDA was dialyzed 
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against deionized water overnight (1 kDa MWCO membrane) with >3 dialysis volume 
changes.  
Pre-polymer solutions were prepared consisting of 10 wt% PEGDA in PBS with 
0.05 wt% of the photoinitiator 2-hydroxy-4′-(2-hydroxyethoxy)-2-methylpropiophenone 
(Irgacure-959, Ciba Specialty Chemicals) and thiolated proteins (0 to 1 µg/ml).  For 
selected studies, poly-L-lysine (PLL, 10 μM, Sigma), laminin (200 μg/ml, BD 
Biosciences, Bedford, MA) or fibronectin (200 μg/ml, BD Biosciences) were also 
included in pre-polymer solutions.  Pre-polymer solutions were loaded into the tips of 1 
ml syringes (30 µl) and polymerized for 10 min under ultraviolet light (6 mW/cm2, 
centered at 365 nm) for gel formation. Following polymerization, hydrogels were 
incubated overnight in either PBS or cell culture media (4°C, with orbital shaking) with at 
least two solution changes to ensure complete removal of residual photoinitiator and 
untethered proteins.  The final, swollen hydrogels were disks with a diameter of ~5.5 
mm and height of ~2 mm.  
   
6.2.4 Measurement of incorporated proteins 
TGF-β1 was added to pre-polymer solutions in concentrations ranging from 0 to 
1 μg /ml. Following photopolymerization, functionalized hydrogels were rinsed overnight 
in 3 ml PBS with >2 solution changes to ensure complete removal of non-covalently 
bound protein. The following day, a modified ELISA was employed to quantify the 
concentration of protein on the gel surface. Hydrogels were incubated with anti-TGF-β1 
monoclonal antibody from mouse (5 μg/ml, Peprotech) in ELISA buffer (sterile filtered 
PBS with 0.1% BSA and 0.05% TWEEN-20) for 1.5 hrs and then rinsed three times with 
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ELISA buffer. Next, samples were incubated with horseradish peroxidase-conjugated 
goat anti-mouse secondary antibody (100 ng/ml, Jackson ImmunoResearch, West 
Grove, PA) for 30 min, followed by three rinses with PBS. Samples were then incubated 
for 60 minutes in ELISA buffer, rinsed three times, and incubated another 15 min in 
ELISA buffer to ensure complete removal of unbound antibodies. Hydrogels were 
distributed into individual wells of a 96-well plate containing 70 μl PBS (30 μl hydrogel 
plus 70 μl PBS resulted in roughly 100 μl total volume / well), and the TMB ELISA 
substrate (100 μl/well, Thermo Scientific) was added for 20 minutes. Finally, the 
reaction was quenched via the addition of 100 μl H2SO4 100 μl combined TMB /H2SO4 
and the absorbance was measured at 450 nm and compared to that of standards 
prepared from known quantities of secondary antibody, TMB, and H2SO4.          
 
6.2.5 PE-25 TGF-β reporter cell assay 
The presence of biologically active TGF-β1 on hydrogel surfaces was verified 
using a PE-25 TGF-β reporter cell line (i.e., mink lung epithelial cells (Mv1Lu or CCL-
64)) containing a stably transfected luciferase reporter gene for TGF-β which were 
generously donated by Dr. Xuedong Liu [29]). PE-25 cells were seeded atop 
functionalized hydrogels at a density of 1x105 cells/ml for 24 hrs in 200 μl Dulbecco's 
Modified Eagle Medium (Invitrogen). The following day, the media was gently removed 
and samples were lysed via the addition of 200 μl passive lysis buffer (Promega, 
Madison, WI) and incubated for 10 min at 37°C, with shaking, and finally stored at -80°C 
for >2 hr.  Next, the samples were thawed, transferred to microcentrifuge tubes and 
centrifuged for 10 min (13,000 rpm, 4°C).  The lysate was transferred to white, opaque-
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walled 96-well plate (100 μl per well), and 50 μl luciferase substrate (Promega) was 
added to each well for 5 min and then luminescence was quantified.   
 
6.2.6 JAWSII DC studies 
JAWSII DCs were seeded into 96-well plates on either empty wells (TCPS) or 
atop hydrogels at a density of 3.0x105 cell/ml in 200 μl JAWSII cell culture media. Cells 
were cultured atop blank and functionalized (TGF-β1-SH and/or IL-10-SH) hydrogels or 
on TCPS with or without the addition of soluble TGF-β1 and/or IL-10-SH for three days. 
On day 4, DCs were activated via the addition of lipopolysaccharide (LPS, 1 μg/ml, 
Sigma), with interferon gamma (IFN-γ, 10 ng/ml), tumor necrosis factor alpha (TNF-α, 
10 ng/ml) and interleukin 4 (IL-4, 10 ng/ml), each obtained from Peprotech.  On day 6, 
100 μl of each sample was analyzed for IL-12p70 production via an ELISA kit 
(eBioscience, San Diego, CA) per the manufacturer’s instructions. For flow cytometry 
analysis, JAWSII were removed from TCPS and hydrogels via incubation in cold PBS 
(10 min on ice). For flow cytometry analysis, samples were rinsed in PBS + 10% FBS 
and then incubated for 10 min at 4°C with Fc Block (anti-mouse CD16/CD32, Fcγ III/II 
Receptor, BD Pharmingen, San Diego, CA). FitC-rat anti-mouse I-A/I-E (clone 2G9, BD 
Pharmingen) and PE-rat anti-mouse CD86 (clone GL1, BD Pharmingen); antibodies 
were added and allowed to stain for 60 min at 4°C. Fluorescently labeled antibody 
isotypes were included as controls. Following staining, samples were rinsed and then 
analyzed using a CyAn Flow Cytometer and Summit software (Beckman Coulter) and 
more than 25,000 events were collected per sample. 
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6.2.7 BMDC studies 
BMDCs were harvested and then seeded in 6 well plates at 5x106 cells/ml, in 4 
ml BMDC media for four days. Half of the BMDC media was exchanged after 2 days.  
BMDCs were harvested via cell lifter on day 5 and transferred to either blank or 
functionalized PEG hydrogels or onto TCPS in 96-well plates at a density of 2x105 
cells/ml in 200 μl BMDC media. Cells were cultured for an additional 3 days atop blank 
or functionalized gels or on TCPS in the presence or absence of soluble TGF-β-SH and 
or IL-10.  Half of the media volume was exchanged with fresh media each day. On day 
8, samples were activated via the addition of LPS (1 μg/ml). On day 9, 100 μl of 
supernatant per sample was harvested and the IL-12p70 concentration was quantified 
via ELISA. Cells were lifted for flow cytometry by incubation in PBS with 5 mM 
Na2EDTA (Sigma) for 20 min at 37°C. Cells were rinsed with 1% BSA in PBS and 
stained with Fc block (anti-mouse CD16/CD32, Fcγ III/II Receptor, BD Pharmingen) for 
10 min on ice. Next, samples were stained with FitC-anti-MHCII (Clone: RI1B, Ox-6, BD 
Pharmingen), FitC-anti-CD86 (Clone: GL1, BD Pharmingen), PE-anti-CD11b (Clone: 
M1/70, BD Pharmingen), PE-anti-CD80 (Clone: 16-10A1, BD Pharmingen), APC-Anti-
CD11c (Clone: N418, BD Pharmingen), PerCP-anti-CD11b (Clone: M1/70, BD 
Pharmingen) were incubated for 30 min on ice. Finally, cells were rinsed 3 times and re-
suspended for flow cytometry. Samples collected using a FACScan flow cytometer (BD 
Biosciences). 
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6.2.8 T cell activation studies 
T cell cones, 6.9 TG.C6/T2, were derived from spleen cells harvested from 6.9 
TCR-Tg/NOD.C6.scid mice as previously described [30, 31].  Cells were maintained in 
complete medium (CM) consisting of Dulbecco’s modified Eagle’s minimal essential 
medium (Life Technologies, Gaithersburg, MD) supplemented with IL-2 (0.5% 
supernatant of phytohaemagglutinin stimulated EL-4 cells), 10 % fetal bovine serum.  
Cells were maintained at 1x106 cells/ml and every two weeks, T cells were stimulated 
via incubation with antigen (10 µg granule membrane protein from β-cell tumor cells) 
and antigen presenting cells (irradiated NOD spleen cells).  At the conclusion of a two 
weeks cycle, T cells (2.5x105 cells/ml) were added to BMDCs (1.88x105 cells/ml) 
generated as described above and harvested from either TCPS, or PEG hydrogels with 
our without LPS stimulation and / or immunomodulation (TGF-β and IL-10) by 
incubating with 5 mM Na2EDTA.  T cells and BMDCs were co-cultured in CM for 72 
hours.  Finally, media supernatant from co-cultures was collected and analyzed by 
ELISA for interferon gamma (INF-γ) as a measure of T cell activation by BMDCs.       
 
6.2.9 Statistical Analysis 
Statistical significance was determined using a two-tailed, unpaired Student’s t-
test.  Differences between datasets were considered statistically significant when the p 
value was less than 0.05.  All results are presented as mean ± standard error of the 
mean. Each experiment, excepting CD80 expression of BMDCs atop 
immunomodulatory hydrogels, was repeated at least twice. 
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6.3 RESULTS 
6.3.1 Bioactivity of thiolated TGF-β1 
TGF-β1 was rendered polymerizable via thiolation with Traut’s reagent [32], as 
schematically illustrated in Fig. 6.1A. To confirm that TGF-β1-SH remained bioactive, 
PE-25 (TGF-β reporter) cells were incubated overnight with 0, 1.0 and 10 ng/ml of 
soluble and unmodified TGF-β1 as compared to TGF-β1-SH. The following day, 
luciferase activity was quantified as a marker of TGF-β bioactivity. As shown in Fig. 
6.1B, a slight reduction in TGF-β1-SH bioactivity was observed, as compared to 
unmodified TGF-β1, at a concentration of 1.0 ng/ml. When added at 10 ng/ml, however, 
both thiolated and unmodified TGF-β1 resulted in high levels of luciferase activity. Some 
reduction in bioactivity is to be expected following thiolation, as the nonspecific 
chemistry likely modifies the active site of some percentage of proteins. Despite some 
loss of function, though, significant bioactivity was preserved. Bioactivity was also 
verified via activity towards JAWSII DCs. Dendritic cells were incubated with thiolated 
and unmodified TGF-β1 for 24 hrs (10 ng/ml) and then activated via stimulation with 
LPS and IFN-γ. As presented in Fig. 6.1C, both forms of TGF-β1 were able suppress 
DC IL-12 production when challenged with LPS, indicating bioactivity of TGF-β1-SH 
was preserved. This effect was also observed for soluble IL-10-SH, shown in Fig. 6.1D. 
Further, the surface expression of MHCII (Fig. 6.1E) and CD86 (Fig. 6.1F) was 
characterized for JAWSII iDCs cultured with both soluble TGF-β1-SH and/or IL-10-SH 
and then stimulated. As anticipated, stimulation resulted in a large increase in MHCII 
expression. Pretreatment with either TGF-β or IL-10, however, resulted in DCs with 
decreased MHCII expression, compared to stimulated controls. Stimulation also  
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Fig. 6.1. Soluble bioactivity of modified growth factors. (A) Schematic for the thiolation of free amine groups on 
proteins via Traut’s reagent. Circles represent one protein molecule (B) Comparison of bioactivity for thiolated and 
unmodified TGF-β1 via PE-25 TGF-β reporter assay. (C) IL-12 produced by JAWSII DCs cultured with soluble, 
thiolated and unmodified TGF-β1. (D) IL-12 produced by JAWSII cultured in the presence of TGF-β1-SH or IL-10-SH 
following immune stimulation with LPS and cytokines. (E) MHCII and (F) CD86 expression of JAWSII DCs cultured 
with or without soluble TGF-β1-SH and/or IL-10-SH. * denotes p<0.05 difference. # denotes p<0.05 difference from 
all other values. 
increased the expression of CD86 by DCs but pre-treatment with immunosuppressants 
did not influence the expression of CD86 by JAWSII DCs.  
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6.3.2 Formation of immunomodulatory PEG hydrogels 
 To create functional material systems, PEGDA (10 kDa, 10 wt%) hydrogels were 
photopolymerized with or without the addition of thiolated proteins, Fig. 6.2A. Free thiols 
on proteins are covalently incorporated within hydrogel networks via a mixed-mode, 
radical-mediated, thiol-acrylate polymerization, as previously described [33]. A modified 
ELISA was employed to characterize the concentration of TGF-β1 available on the 
hydrogel surface. As illustrated in Fig. 6.2B, an increase in detectable surface TGF-β1 
was observed relative to the concentration of TGF-β1-SH included in the pre-polymer 
solution. When 1.0 µg/ml TGF-β1-SH was included in the pre-polymer solution, 18±2 
pg/cm2 TGF-β1 was detected on the gel surface. To verify the bioactivity of 
functionalized TGF-β1 hydrogels, PE-25 TGF-β reporter cells were seeded atop gels  
                       A 
 
B 
 
C
 
Fig. 6.2. Formation of functionalized PEG hydrogels. (A) Schematic of hydrogel formation in which thiolated proteins 
are covalently polymerize within PEG hydrogels via thiol-acrylate photopolymerization. (B) Detectable surface density 
of TGF-β1 on hydrogel surfaces, as detected by modified ELISA. (C) Bioactivity of TGF-β1 incorporated on 
functionalized hydrogels, as assessed by PE-25 TGF-β reporter cell assay. * denotes p<0.05 difference from all other 
values. 
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and allowed to interact for 24 hours. Luciferase activity was quantified, and significant 
TGF-β bioactivity was provided by the hydrogel surfaces fabricated with 1 µg/ml TGF-β-
SH, shown in Fig. 6.2C.         
 
6.3.3 JAWSII DCs on immunomodulatory hydrogels 
JAWSII iDCs were seeded atop hydrogels functionalized with or without the 
immunosuppressive proteins TGF-β1 and or IL-10 and cultured for 3 days.  As shown in  
A 
 
B 
   
C 
 
D 
 
Fig. 6.3. JAWSII DCs with immunomodulatory hydrogels. (A) IL-12 production of JAWSII DCs stimulated with LPS 
and cytokines following cell culture atop hydrogels functionalized with various concentrations of TGF-β1. (B) IL-12 
production of DCs cultured atop hydrogels polymerized with 1 μg/ml TGF-β1 and / or IL-10. (C) MCHII and (D) CD86 
expression of JAWSII DCs cultured atop functionalized hydrogels. * denotes p<0.05 difference. # denotes p<0.05 
difference from all other values. 
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Fig. 6.3A, JAWSII iDCs were seeded on hydrogels substrates fabricated with 0, 0.1, and 
1.0 µg/ml TGF-β1-SH in the pre-polymer solution. Following stimulation, JAWSII 
cultured atop hydrogels with 1.0 µg/ml TGF-β1-SH secreted less IL-12, compared to 
stimulated controls. A marked reduction in IL-12 in response to stimulation was also 
observed for DCs seeded on hydrogel surfaces containing IL-10, as well as for surfaces 
dually-functionalized with TGF-β1 and IL-10, as shown in Fig. 6.3B. Stimulated JAWSII 
DCs atop dually-functionalized gels secreted 63% less IL-12 than DCs cultured on 
unmodified control hydrogels, providing evidence that the immobilized 
immunosuppressant biological signals remained active and signaled the DCs.  
Flow cytometric analysis was performed on JAWSII DCs harvested after seeding 
on functionalized hydrogels. The increase in surface expression levels of the stimulatory 
protein MHCII and co-stimulatory protein CD86 are commonly observed markers of DC 
maturation, and their expression on JAWSII DCs has been previously observed to 
correlate with activation state [23]. In brief, JAWSII DCs upregulated MHCII (Fig. 6.3C) 
and CD86 (Fig. 6.3D) expression in response to stimulation. Seeding JAWSII atop TGF-
β1, IL-10, or dually-functionalized gels, however, significantly decreased the percentage 
of MHCII+ DCs following stimulation, Fig. 6.3C. Like the result observed when JAWSII 
were incubated with soluble immunosuppressants (Fig. 6.1F), CD86 expression was not 
affected by hydrogel functionalization (Fig. 6.3D). In all, culturing JAWSII with either 
soluble or immobilized immunosuppressants generated DCs with similar IL-12, MHCII, 
and CD86 expression, demonstrating the bioactivity of immunomodulatory hydrogels.  
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6.3.4 Treating BMDCs with soluble TGF-β1 and IL-10 
As further evidence of localized immune modulation, we examined bone marrow-
derived dendritic cells (BMDCs) harvested from NOD mice.  BMDCs were first treated 
with soluble TGF-β1-SH and IL-10-SH, and selected samples were stimulated with LPS 
to induce BMDC maturation and the media supernatant was assayed for IL-12. Further, 
the level of surface expression of MHCII, CD80 and CD86 was assayed via flow 
cytometry. All samples were co-stained for the dendritic cell marker CD11b, and a high 
percentage of all samples were found to be CD11b+. The expression of MHCII (Fig. 
6.4A), CD80 (Fig. 6.4B) and CD86 (Fig. 6.4C) were each reduced amongst CD11b+ 
DCs cells by treatment with soluble immunomodulatory factors. Upon stimulation with 
LPS, all samples had a higher percentage of DCs positive for stimulatory and co-
stimulatory markers, but pre-treatment with the soluble immunosuppressive factors 
reduced the extent to which the expression of each marker was increased by 
stimulation, relative to stimulated controls. As shown in Fig 6.4D, control BMDC cultures  
treated with LPS secreted dramatically higher levels of IL-12. When pre-treated with 
soluble TGF-β1-SH and IL-10-SH, however, significantly lowered levels of IL-12 were 
detected, indicating a less mature phenotype.  
 
6.3.5 Culturing BMDCs with immunomodulatory PEG hydrogels 
BMDCs were cultured on the surfaces of functionalized and unfunctionalized gels 
(Fig. 6.5 A) and then stimulated via the addition of LPS.  IL-12 production was 
quantified, as shown in Fig. 6.5B, and, as before, a significant increase in cytokine 
production was observed for LPS-stimulated samples. The presence of  
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immunomodulatory factors on the surfaces of otherwise blank the hydrogels, however, 
only slightly reduced iDC maturation, as evident by a small but significant decrease in 
IL-12 production with TGF-β1 and IL-10 on the hydrogel surface. We hypothesized that 
this effect might be due to limited interaction between the immature BMDCs and the 
PEG surface, as PEG is well documented to resist cell and protein adhesion.  
To increase interaction between BMDCs and PEG surfaces, two strategies were 
explored to promote adhesion: introduction of poly-L-lysine (PLL) and the ECM proteins,  
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Fig. 6.4. Immunomodulation of primary BMDCs with soluble proteins. (A) CD11b / MHCII, (B) CD11b / CD80, and (C) 
CD11b/CD86 expression of BMDCs treated with or without soluble immunomodulation (10 ng/ml TGF-β1-SH and IL-10-SH) 
and with or without stimulation with LPS (1 μg/ml). Numbers are % of cells. Experiment performed by Jing He (D) IL-12 
production by BMDCs treated with soluble TGF-β1-SH and IL-10-SH. * denotes p<0.05 difference. 
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Fig. 6.5. BMDCs on immunomodulatory hydrogels. (A) Brightfield microscopy of BMDCs seeded atop PEG hydrogels 
that contain (top) no functionalization (middle) poly-L-lysine, and (bottom) the ECM proteins laminin and fibronectin. 
Scale = 60 μm (B-D) IL-12 production by BMDCS cultured on immunomodulatory hydrogels functionalized with (B) 
unmodified, (C) +PLL, (D) +ECM proteins. * denotes p<0.05 difference, # denotes p<0.05 difference from all values     
fibronectin and laminin, on the surfaces of PEG hydrogels to promote cellular 
interactions.  Visually, these surfaces seemed to effect iDC/surface interaction, as 
depicted in Fig. 6.5A. On unmodified PEG hydrogels, BMDCs had a tendency to 
aggregate together, while PLL hydrogels promoted single-cell attachment to the 
surface. Aggregation occurred for cells seeded on ECM-modified gels, but to a lesser  
159 
 
 Control PLL ECM 
M
H
C
II 
   
C
D
80 
   
C
D
86 
   
Fig. 6.6. Surface marker expression of BMDCs seeded atop control or immunomodulatory (+TGF-β1 and IL-
10) hydrogels, with or without immune stimulation. Hydrogels were seeded on control hydrogels, or gels co-
functionalized with either poly(L-lysine) (PLL) or hydrogels containing laminin and fibronectin (ECM). The 
percentage shown represents the fraction of CD11c+ dendritic cells which stained positive for surface markers 
(MHCII, CD80, or CD86), as compared to isotype controls.   
extent than observed on PLL hydrogels. BMDCs were cultured atop PLL and ECM 
hydrogels functionalized with TGF-β1 and IL-10, and then stimulated with LPS. When 
seeded atop hydrogels co-functionalized with PLL and immunosuppressive factors, the 
IL-12 measured post-stimulation was decreased by more than 50%, Fig. 6.5C. Further, 
the expression of the surface maturation markers MHCII, CD80 and CD86 were 
generally reduced prior to and following immune stimulation on immunomodulatory 
hydrogels, as shown in Fig. 6.6.  Immunosuppressive hydrogels provided strong 
evidence of reduced maturation, as evident by drastic reductions in IL-12 secretion, Fig. 
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6.5D, as well as reduced expression of MHCII stimulatory molecules and CD80 and 
CD86 co-stimulatory molecules, Fig. 6.6.   
 
6.3.6 Co-culture of BMDCs with T cells 
Following culture atop immunosuppressive hydrogels, BMDCs were harvested 
and co-cultured with T cells to assess the functional capacity of dendritic cells to 
activate T cells.   As illustrated in Fig. 6.7A, unstimulated dendritic cells lacked the 
capacity to activate T cells, characteristic of an immature dendritic cell phenotype.  
Upon LPS stimulation, however, BMDCs were found to have matured, as they 
possessed the capacity to activate T cells, shown via increased T cell IFN-γ secretion (a 
marker of T cell activation).  When BMDCs were pre-treated with soluble TGF-β and IL-
10 prior to stimulation, T cell IFN-γ production was significantly reduced, indicating 
reduced T cell activation by dendritic cells.  This finding further highlights the  
  
Fig. 6.7. Interferon γ (IFN-γ) production by T cells following culture with BMDCs.  BMDCs were cultured 
on (A) TCPS or (B) PEG hydrogels functionalized with PLL.  BMDCs were treated with or without (A) 
soluble TGF-β1 and IL-10 or (B) covalently immobilized TGF-β1 and IL-10 for two days.  Then, + stim 
samples were treated with LPS overnight to induce DC maturation.   
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immunosuppressive capacity of these biomolecules towards iDCs.  This effect was also 
observed when dendritic cells were cultured atop hydrogels functionalized with PLL to 
promote cell / material interactions, shown in Fig. 6.7B.  In the absence of 
immunomodulatory factors, stimulated dendritic cells signaled T cells to secrete high 
levels of IFN-γ, while DCs culture atop hydrogels co-functionalized with PLL and 
possessed a drastically reduced capacity to activate T cells.   
 
6.4 DISCUSSION 
Covalent incorporation of the immunosuppressive proteins TGF-β1 and IL-10 on 
the PEG hydrogel surfaces necessitated modification to introduce functional groups 
compatibile with covalent conjugation during polymerization. Initially, conventional 
amine/NHS-succinimide chemistry was employed in which acrylate-PEG-NHS was 
reacted with TGF-β1 to introduce acrylate groups onto proteins for co-polymerization 
[20]. Upon acrylation, however, soluble acryl-TGF-β1 was found to significantly increase 
DC IL-12 production (data not shown). Therefore, an alternative chemistry was 
employed: modification of the targeted protein with Traut’s reagent. Reaction with 
Traut’s reagent introduces thiols onto proteins by modification of free amines, as 
evidenced by the successful detection of proteins on hydrogel surfaces. Additionally, 
bioactivity towards PE-25 reporter cells and JAWSII DCs was preserved.  
For the hydrogel experiments reported here, thiolated proteins were added to the 
pre-polymer mixture for bulk polymerization into PEG hydrogels, utilizing a thiol-acrylate 
mixed-mode photoinitated polymerization. As a consequence, proteins were present 
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throughout the hydrogel as well as on the gel surface. The presence of accessible 
proteins on the hydrogel surfaces was verified by a modified ELISA, whereby 
functionalized gels were incubated with a detection antibody. As has been previously 
reported, antibodies (approx. 150 kDa) are unable to diffuse within PEGDA hydrogels 
[34], so protein was detectable only if immobilized and available for binding on the 
hydrogel surface. Results were verified via a visual confirmation that the color change of 
the cleaved TMB ELISA substrate occurred at the hydrogel surface, while the interior of 
the hydrogel remained clear (data not shown). Using this modified ELISA, significant 
protein was detectable, quantifiable, and found to be dependent upon the protein 
concentration added to the pre-polymer solution. Further, the bioactivity of tethered 
TGF-β1 was confirmed via a significant cell response upon seeding with PE-25 TGF-β 
reporter cells.   
JAWSII iDCs were seeded on the surfaces of hydrogels functionalized with TGF-
β1 and/or IL-10 to assess bioactivity towards these cells. When cultured atop these 
gels, IL-12 production was suppressed upon stimulation, as was MHCII expression. In 
fact, these markers were suppressed to a similar extent by either soluble or immobilized 
factors. Ultimately, this expression profile indicates decreased DC maturation and 
provides evidence that immobilized immunosuppressive factors remain bioactive to 
DCs. While the suppression of IL-12 production and MHCII expression was successfully 
provided by TGF-β1 and/or IL-10, CD86 co-stimulatory molecule was unaffected. This 
finding is in contrast to previous observations of decreased co-stimulatory marker 
expression on stimulated DCs that have been pre-treated with TGF-β1 and IL-10 [2]. 
Because this finding was consistent for pre-treatment with either soluble or immobilized 
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factors, it is likely that the reduced sensitivity of co-stimulatory expression to 
immunosuppressive signaling is an inherit property of the JAWSII cell line and not a 
result of signaling molecule immobilization. Therefore, JAWSII DCs serve as an 
imperfect model for the generation of tolerogenic DCs, but the reduction of IL-12 
production and MHCII expression by functionalized hydrogels provided evidence that 
immobilized TGF-β1 and IL-10 retained bioactivity and that DCs were permissive to 
their signaling.     
 The bioactivity of immunomodulatory hydrogels was further assessed via 
experimentation with primary BMDCs isolated from NOD mice. When BMDCs were 
treated with soluble, thiolated immunosuppressive proteins, a reduction in stimulatory 
(MHCII), co-stimulatory (CD80 & CD86) and cytokine (IL-12) production was observed. 
In contrast to the JAWSII DCs, the observed reduction in maturation markers agrees 
well with previous findings [2]. BMDCs from NOD mice are known to undergo defective 
maturation following immune stimulation [26, 27]. Thus, the maximum levels of 
activation marker expression observed for non-immunomodulation controls agrees with 
those previously reported for mature BMDCs from NOD mice [35]. 
Primary BMDCs were then seeded atop functionalized hydrogels in order to 
assess the capacity of the immobilized proteins of interest to signal DCs. Initially, it was 
observed that PEG hydrogels modified with immunosuppressive factors alone delivered 
limited signaling to seeded BMDCs, as equivalent IL-12 was produced for either case 
following stimulation with LPS. We hypothesized that this effect could be due to limited 
interaction between cells and PEG surface, as PEG hydrogels are previously known to 
resist cells adhesion. Many researchers have observed that the addition of adhesion 
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ligands to biomaterial surfaces promotes cell attachment and increased cell signaling 
[36]; for example, we recently reported that the addition of ICAM-1 to PEG surfaces 
promoted T cell signaling [20]. Therefore, we investigated two methods of introducing 
adhesion molecules within the PEG hydrogels: via the addition of poly-L-lysine PLL and 
via the incorporation of the ECM proteins, collagen and laminin.  
The ECM proteins laminin and fibronectin were incorporated into PEG hydrogels 
to promote DC adhesion.  ECM proteins are widely employed within the field of tissue 
engineering to promote cell attachment to surfaces [36]. When seeded upon ECM-
hydrogels, BMDCs secreted modestly elevated IL-12 in the absence of LPS stimulation, 
compared to cells seeded on blank hydrogels. The inherent ability of ECM-
functionalized materials to induce the maturation of iDCs has been previously reported 
[7, 35], so it is not surprising we observed this effect. It is encouraging, however, that 
the introduction of TGF-β1 and IL-10 to the ECM-tethered surfaces significantly reduced 
the production of IL-12 and expression of MHCII, CD80 and CD86 by BMDCs. The 
observations that immobilized immunosuppressive proteins have the capacity to 
suppress ECM-mediated iDC maturation, as well as resist maturation upon LPS 
stimulation, provide striking evidence of the bioactivity of immunomodulatory PEG 
hydrogels. 
Further, others have incorporated poly-L-lysine (PLL) onto surfaces to promote 
dendritic cell attachment [37], and it is well known that positively charged groups on PLL 
result in the rapid binding of serum proteins to material surfaces, enabling cell 
interactions [38, 39].  Additionally, serum coated surfaces (e.g., PLL-coated materials) 
have been used to limited the adjuvant effect [37, 40], and are therefore a suitable 
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platform for immunomodulation. BMDCs were seeded upon hydrogels functionalized 
with PLL and TGF-β1 and/or IL-10 and then stimulated. For PLL-hydrogels, an 
immunosuppressive effect was observed, as DC IL-12 production and surface marker 
expression on control and immunomodulatory hydrogels were decreased relative to 
controls. Further, T cell studies confirmed that PLL hydrogels functionalized with 
immunomodulatory factors significantly reduced dendritic cell maturation.  Ultimately, 
these findings indicated that decreased cell-material interactions were a likely reason for 
limited signaling on unmodified immunomodulatory gels. Further, the 
immunosuppressive activity of PLL/immunomodulatory hydrogels towards BMDCs from 
NOD mice provides evidence that this sort of surface has the potential to interact 
favorably with DCs from type I diabetes. 
 
6.5 CONCLUSIONS  
In summary, we have reported a strategy for the introduction of 
immunosuppressive proteins, TGF-β1 and IL-10, into PEG hydrogels in a manner that 
preserves bioactivity towards iDCs. While future work is required to demonstrate that 
the DCs created by these surfaces are, in fact, tolerogenic DCs capable of inducing 
TREG formation, we have demonstrated that the immunomodulatory hydrogels reported 
herein possess bioactivity that approaches that of the soluble immunosuppressive 
proteins when cultured in the presence of the immortalized JAWSII DC cell line or 
primary BMDCs isolated from NOD mice. This immunomodulatory biomaterial platform 
has the potential to serve as an in vitro culture platform for the generation of tolerogenic 
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DCs. Further, this technology suggest strategies for tissue engineering applications, 
such as a coating of cell-laden biomaterials where it is desirable to limit the maturation 
of local dendritic cells and subsequently ameliorate the adaptive immune response. 
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Chapter 7 
 
Conclusions and Recommendations 
 
 This thesis advances the understanding of bioactive and immunoactive 
modifications to encapsulation barriers for the purpose of improving their 
immunoisolation capability.   Throughout these studies, poly(ethylene glycol) (PEG) 
hydrogels were modified with various bioactive molecules and then investigated in 
relevant in vitro model systems.  Overall, these functionalized biomaterials provided 
significant spatially-controllable bioactivity to ameliorate inflammatory damage within 
capsules, reduce the local population of T cells in proximity to cell-laden capsule, or 
dampen dendritic cell maturation, towards eliciting transplant tolerance.       
 In studies related to Specific Aim 1 (Chapter 3), a polymerizable superoxide 
dismutase mimetic (SODm) was incorporated into β-cell laden PEG hydrogels to 
prevent superoxide-mediated damage.  During initial studies, the SODm was shown to 
be well-tolerated by encapsulated cells.  To explore the molecule’s potential protective 
benefits, superoxide was generated chemically via the reaction of xanthine with 
xanthine oxidase.   When generated in the presence of cells, this chemically generated 
superoxide results in significant cell death, observed via both reduced metabolic activity 
and through the visualization of fewer live cells via live/dead confocal imaging.   When 
SODm was incorporated in the cell-laden gels through copolymerization, however, a 
dose-response was observed whereby increased concentrations of SODm resulted in 
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increased cell survival as evidenced by greater metabolic activity following challenge 
with superoxide.  Finally, a longer-term study was performed in which β-cells were 
encapsulated within hydrogels with or without SODm and then treated with superoxide 
three times over the course of ten days.  This study confirmed the cytoprotective effect 
of SODm with multiple challenges, as cells within hydrogels functionalized with SODm 
demonstrated over 60% survival at the conclusion of the experiment, whereas 
essentially no metabolic activity remained for control gels. 
 Encouraged by the marked cytoprotective effect of polymerized SODm, we 
attempted an in vivo study in which murine islets were encapsulated in PEG hydrogel 
disks with or without SODm.  These studies were conducted as part of a fruitful 
collaboration with Prof. Kathryn Haskins and Brenda Bradley at National Jewish,.  
Functionalized hydrogels were implanted in the abdominal fat and kidney capsules of 
mice and then explanted 7 days later to assess cell survival.  Unfortunately, poor 
survival was observed for all implanted islets, regardless of the presence of SODm.  
High viability was observed, however, for control islet capsules cultured in vitro.   As a 
result of the poor survival observed for all implanted islets, these studies were 
inadequate to improve understanding about the in vivo protective benefits of 
incorporating SODm within PEG capsules.   Further investigations regarding the in vivo 
efficacy of polymerized SODm will likely yield important evidence supporting its use 
within cell-laden hydrogels, however, before further in vivo studies can be conducted, 
optimization of the encapsulation and transplantation systems to allow improved basal 
cell survival is required.  Among many potential explanations for poor in vivo islet 
survival, the most likely was the unavailability of oxygen and nutrients.  Thus, improved 
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small molecule transport could be achieved via the introduction of pores or channels 
within PEG hydrogel disks.  Conversely, the size of capsules could be reduced (the 
investigated disks were ~5 mm in diameter by ~2 mm thick).  Both approaches would 
reduce the diffusion distance between encapsulated cells and nutrients.  Upon 
improvement to encapsulated islet survival in vivo, further investigations would become 
possible with several of the immunoisolation materials described in this thesis. 
 Specific Aim 2 (Chapter 4) focused on the development and testing of a surface-
mediated photopolymerization for the formation of functionalized PEG chains.  Anti-fas 
was successfully incorporated within coatings at a high surface density.  When seeded 
with jurkat T cells, anti-fas-functionalized polymer surfaces induced significant 
apoptosis, which was increased by the incorporation of the ICAM-1 adhesion ligand.  
ICAM-1 is previously known to stabilize interactions between T cells and effector cells 
for the purpose of promoting cell-cell signaling, so it is likely that ICAM-1 stabilized the 
interaction between functionalized surfaces and T cells during fas signaling.  
 While the DTC-mediated functionalization strategy enabled the formation of 
surface-initiated coatings, it was not readily translatable to cell-laden hydrogels.  In its 
initial form, this surface-initiated chemistry was not compatible with aqueous conditions 
due to the insolubility of the DTC photoiniferter.  To improve solubility, a photoiniferter 
was tethered to either end of PEG chains to form the molecule DTC-PEG-DTC.  PEG is 
highly water-soluble, and therefore, PEGylation is a commonly used chemical 
modification to improve aqueous solubility.  While DTC-PEG-DTC was successfully 
synthesized, as confirmed by NMR, and was soluble in aqueous buffers, the reactivity of 
this molecule in aqueous conditions could not be demonstrated.  Perhaps further 
174 
 
experimentation with DTC-PEG-DTC would enable photoiniferter-mediated 
polymerization in aqueous conditions.  Alternatively, a living radical polymerization 
chemistry better-suited for aqueous conditions could be employed, such as reversible 
addition-fragmentation chain transfer (RAFT) polymerization, to form controlled anti-fas 
coatings. 
 While DTC was not adapted to fabricate coatings atop PEG hydrogels, surface-
initiated coatings mediated by the glucose oxidase (GOx) enzyme were successfully 
formed.  As explored in experiments related to Specific Aim 3 (Chapter 5), conformal, 
PEG-based polymer coatings were readily formed on the surfaces of hydrogels with a 
high incorporation of accessible signaling molecules.  Similar to the results obtained in 
Specific Aim 2, culturing jurkat T cells with these functionalized coating resulted in 
significant T cells apoptosis and cell death.  After 48 hrs of seeding atop coatings 
dually-functionalized with anti-fas and ICAM-1, over 60% of all T cells were either 
apoptotic or dead.   
GOx-mediated coatings were adapted for cell-laden hydrogels and eventually 
found to maintain high encapsulated cell viability.   Initially, low molecular weight PEG 
mono- and di-acrylates were employed for coatings.  Unfortunately, low molecular 
weight PEG acrylates were found to be highly toxic to encapsulated cells; to the extent 
that dipping a PEGDA hydrogel (4,600 Da, 10 wt%) containing β-cells into a 1 wt% PEG 
diacrylate (Mn=550 Da) in PBS for 10 seconds, followed by transfer to cell culture 
media, was adequate to kill virtually all encapsulated cells.  PEG methacrylates, 
however, were better-tolerated by encapsulated cells, as high encapsulated cell viability 
was maintained following 60s dippings into 25 wt% PEG methacrylate (Mn=525 Da).  
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Further, PEG methacrylates demonstrated comparable reactivity when employed in 
GOx-mediated dip-coatings.   Therefore, PEG methacrylates are considered a superior 
choice for coating cell-laden hydrogels.   While GOx-mediated coatings were utilized to 
provide anti-fas functionality on the surfaces of PEG hydrogels, GOx coatings should 
find broad appeal within the field of regenerative medicine.  One could envision 
numerous useful applications for functionalized, conformal coatings on cell-laden 
biomaterials, including fabricating multilayered hydrogels for tailorable therapeutic 
release, signaling additional immune cell types (e.g., macrophages), or for creating 
spatially and functionally-defined layered hydrogels for the co-encapsulation of multiple 
cell types.  
In its present form, the GOx-mediated reactive chemistry is versatile and should 
find many applications.  One limitation, however, seems to be that residual glucose 
oxidase enzyme is entrapped within polymer layers during formation, resulting in 
continued GOx activity after dip-coatings.  This activity was apparent due to the 
requirement for catalase in cell culture media following coating, but was also evident 
because freshly-coated hydrogels, when placed in cell culture media containing phenol-
red pH indicator, rapidly reduced the media pH.  This persistence necessitated that cell-
laden samples be transferred to fresh media approximately every half hour for the first 2 
to 3 hrs following coating.  The observed pH drop likely occurred as residual glucose 
oxidase in the coating reacted with glucose from cell media to form H2O2 and D-
glucono-1,5-lactone, the latter of which rapidly hydrolyzes in water to form gluconic acid.  
After the first 3 hrs following fabrication of the coating, the pH change was no longer 
observed, indicating that residual GOx likely loses activity after a relatively short amount 
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of time.  Ultimately, the addition of catalase to media and frequent media changes 
shortly after coating formation overcame the deleterious effects of residual GOx in 
coatings, but an orthogonal coating chemistry could eliminate these problems 
altogether.  For example, residual GOx enzyme continues to react with glucose in cell 
culture media, but if an alternate oxidase enzyme, one which reacts with a substrate 
absent from cell culture media, were employed, oxidase activity could be confined to the 
dipping reaction.  Towards this concept, preliminary experiments were carried out with 
galactose oxidase (GalOx), a commercially available enzyme which has been reported 
to generate H2O2 with a similar catalytic activity to GOx.  Hydrogels were swollen in 
solutions containing galactose, and coating of the gel was attempted in pre-polymer 
containing GalOx.  Unfortunately, initial studies failed to identify reaction conditions that 
enabled coating formation.  In the future, further experimentation with the GalOx 
enzyme, or an alternative oxidase, could result in reactive coatings with orthogonality 
and improved cytocompatibility.    
Throughout Specific Aim 4 (Chapter 6), PEG hydrogels were functionalized with 
immunosuppressive proteins to explore their potential for signaling nearby dendritic 
cells.   Towards this objective, TGF-β1 and IL-10 were rendered polymerizable via 
thiolation by Traut’s reagent and then successfully incorporated within PEG hydrogels.   
The presence of protein on hydrogel surfaces was confirmed via ELISA and by a 
reporter cell assay.   Initial dendritic cell experiments were performed with the JAWSII 
immature dendritic cell (iDC) line and treatment with either soluble or immobilized TGF-
β1 and / or IL-10 significantly reduced IL-12 secretion and MHCII expression following 
stimulation with LPS and cytokines.  This study offered encouraging evidence that 
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immunosuppressive hydrogels exhibit substantial bioactivity, and that iDCs are capable 
of receiving immunosuppression signals from biomaterial surfaces.   
While JAWSII DCs were successfully used to confirm the bioactivity of 
immunoactive hydrogels, this cell line was determined to be an imperfect cell type for 
the study of the immunosuppressive effects of TGF-β1 and IL-10.  JAWSII DCs were 
not entirely permissive to immunosuppressive signaling, since soluble and immobilized 
TGF-β1 and IL-10 were unable to reduce the expression of co-stimulatory markers (e.g., 
CD86), even though this effect is commonly observed with other primary DCs.   As a 
result, it was necessary to evaluate immunomodulatory hydrogels further with primary 
immature bone-marrow derived dendritic cells (BMDCs).  In collaboration with the 
Haskins’ group, primary DCs were cultured on immunosuppressive hydrogels, but only 
slight reductions in maturation were initially observed (e.g., reduced IL-12 production) 
following immune stimulation.   To improve signaling between immunosuppressive 
hydrogels and immature BMDCs, poly-L-lysine (PLL) and extracellular matrix proteins 
(ECM) were introduced to increase general adhesion.  With the introduction of 
adhesion, immunosuppressive hydrogels were observed to significantly reduce the 
production of IL-12 following stimulation, as well as reduce the expression of the CD80 
co-stimulatory molecule before and after immune stimulation.  These finding provided 
striking evidence that hydrogels modified with TGF-β1 and IL-10 have profound effects 
on nearby immature dendritic cells.  
The introduction of general adhesion was found to greatly improve the signaling 
capacity of immunomodulatory hydrogels.  In practice, however, implanting hydrogels 
which promote general adhesion could promote the attachment of undesirable cell 
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types, including macrophages and fibroblasts, which would likely result in fibrous 
capsule formation.   Thus, future efforts might focus on developing a methodology to 
specifically promote interactions between PEG hydrogels and DCs.  This selective 
adhesion could be achieved by incorporating ligands specific for dendritic cell surface 
markers (i.e., similar to the approach investigated in Specific Aim 2, in which ICAM-1 
was utilized to promote interactions with T cells).   Alternatively, the controlled release of 
specific, bioactive factors might be employed to attract DCs to PEG surfaces.  For 
example, granulocyte colony stimulating factor (G-CSF) has been previously 
demonstrated as a chemoattractant for dendritic cells able to be programmed for 
tolerance.  Ultimately, while surface adhesion greatly improved signaling towards 
immature BMDCs in vitro, it is possible that increased interactions between dendritic 
cells and PEG hydrogels could occur innately in the biologically-complex in vivo 
environment, rendering the introduction of adhesion prior to transplantation 
unnecessary. 
For the studies described in Specific Aim 4, the primary objective was to 
demonstrate that immunosuppressive PEG hydrogels were capable of reducing 
dendritic cell maturation via material-cell signaling.  In these studies, the DC maturation 
state was assessed because numerous reports have identified partially-mature dendritic 
cells as having the capability to form antigen specific tolerance via the formation of 
regulatory T cells (TREG) or through the induction of T cell anergy.   Therefore, while the 
studies detailed in this thesis highlight the capacity of immunomodulatory biomaterials 
to reduce DC maturation, further investigation is necessary to demonstrate that DCs 
primed by these materials are able to induce TREG formation.   If a sufficient in vitro 
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model were developed to test TREG formation, the next step would be to incubate 
immature DCs atop immunomodulatory hydrogels in the presence of soluble or 
immobilized antigen (e.g., insulin to model DCs responding to an islet transplant) and 
then assay to determine if antigen specific tolerance could be achieved via the 
formation of anti-insulin TREG cells.  Demonstrating antigen-specific tolerance requires 
the development of a complex model system, but the encouraging results presented in 
this thesis provide the motivation for such experiments.     
Overall, this thesis investigated strategies to introduce immunoactive 
modifications to PEG hydrogels for the purpose of improving their immunoisolation 
capacity.   In general, biologically-functionalized PEG surfaces are readily able to signal 
nearby cells of the adaptive immune response.  Further, increasing the interactions 
between immune cells and biomaterial surfaces via general or specific adhesions 
significantly improves signal delivery.   Specific Aim 1 highlighted the ability of 
polymerized superoxide dismutase enzyme to improve cellular survival in response to 
reactive oxygen species, one of the major inflammatory effectors of an immune 
response.   In Specific Aim 2, functionalized PEG surfaces signaled local T cell 
apoptosis, reducing the concentration of the primary responder cells responsible for 
maintaining the adaptive immune response.  In Specific Aim 3, a versatile reactive 
coating strategy was adapted to present immunoactive signals from the surfaces of cell-
laden hydrogels.   Finally, Specific Aim 4 introduced immunosuppressive hydrogels 
modified with TGF-β1 and IL-10 and highlighted their capacity to reduce dendritic cell 
maturation, towards preventing the development of deleterious adaptive immunity 
altogether.   Ultimately, the bioactive material platforms developed within this thesis 
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have great potential and suggest innovative strategies for the engineering of future 
immunoisolation barriers to provide localized and targeted protection of cells delivered 
in biomaterial carriers for implantation.  
181 
 
Chapter 8 
Bibliography 
 
8.1   Chapter 1 references 
1. Incidence and trends of childhood Type 1 diabetes worldwide 1990-1999. Diabet 
Med 2006 Aug;23(8):857-866. 
 
2. Prentki M, Tornheim K, Corkey BE. Signal transduction mechanisms in nutrient-
induced insulin secretion. Diabetologia 1997 Jul;40 Suppl 2:S32-41. 
 
3. Vanelli M, Chiarelli F. Treatment of diabetic ketoacidosis in children and 
adolescents. Acta Biomed 2003 Aug;74(2):59-68. 
 
4. Lawrence SE, Cummings EA, Gaboury I, Daneman D. Population-based study of 
incidence and risk factors for cerebral edema in pediatric diabetic ketoacidosis. The 
Journal of pediatrics 2005 May;146(5):688-692. 
 
5. Siafarikas A, O'Connell S. Type 1 diabetes in children - emergency management. 
Australian family physician  May;39(5):290-293. 
 
6. Gremizzi C, Vergani A, Paloschi V, Secchi A. Impact of pancreas transplantation 
on type 1 diabetes-related complications. Current opinion in organ transplantation 2010 
Feb;15(1):119-123. 
 
7. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects 
for diabetic complications. Jama 2002 Nov 27;288(20):2579-2588. 
 
8. Goh SY, Cooper ME. Clinical review: The role of advanced glycation end 
products in progression and complications of diabetes. The Journal of clinical 
endocrinology and metabolism 2008 Apr;93(4):1143-1152. 
 
9. The effect of intensive treatment of diabetes on the development and progression 
of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control 
and Complications Trial Research Group. The New England journal of medicine 1993 
Sep 30;329(14):977-986. 
 
10. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes care 2003 
Jun;26(6):1902-1912. 
 
11. Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes 
Control and Complications Trial Research Group. Diabetes 1997 Feb;46(2):271-286. 
 
182 
 
12. Boyle PJ, Kempers SF, O'Connor AM, Nagy RJ. Brain glucose uptake and 
unawareness of hypoglycemia in patients with insulin-dependent diabetes mellitus. The 
New England journal of medicine 1995 Dec 28;333(26):1726-1731. 
 
13. Jun HS, Yoon JW. Approaches for the cure of type 1 diabetes by cellular and 
gene therapy. Current gene therapy 2005 Apr;5(2):249-262. 
 
14. Yechoor V, Chan L. Gene therapy progress and prospects: gene therapy for 
diabetes mellitus. Gene therapy 2005 Jan;12(2):101-107. 
 
15. Aye T, Block J, Buckingham B. Toward closing the loop: an update on insulin 
pumps and continuous glucose monitoring systems. Endocrinology and metabolism 
clinics of North America 2010 Sep;39(3):609-624. 
 
16. Kumareswaran K, Evans ML, Hovorka R. Artificial pancreas: an emerging 
approach to treat Type 1 diabetes. Expert review of medical devices 2009 Jul;6(4):401-
410. 
 
17. Minkowski O. Untersuchungen über den Diabetes mellitus nach Extirpation des 
Pankreas. Berl Klin Wchnschr 1892;29:90. 
 
18. Watson-Williams P. Notes on Diabetes treated with extract and by grafts of 
sheep's pancreas. British Medical Journal 1894;2:1303-1304. 
 
19. Ballinger WF, Lacy PE. Transplantation of intact pancreatic islets in rats. Surgery 
1972 Aug;72(2):175-186. 
 
20. Ricordi C, Lacy PE, Finke EH, Olack BJ, Scharp DW. Automated method for 
isolation of human pancreatic islets. Diabetes 1988 Apr;37(4):413-420. 
 
21. Scharp DW, Lacy PE, Santiago JV, McCullough CS, Weide LG, Falqui L, et al. 
Insulin independence after islet transplantation into type I diabetic patient. Diabetes 
1990 Apr;39(4):515-518. 
 
22. Alesci S, De Martino MU, Ilias I, Gold PW, Chrousos GP. Glucocorticoid-induced 
osteoporosis: from basic mechanisms to clinical aspects. Neuroimmunomodulation 
2005;12(1):1-19. 
 
23. Qi D, Rodrigues B. Glucocorticoids produce whole body insulin resistance with 
changes in cardiac metabolism. American journal of physiology 2007 Mar;292(3):E654-
667. 
 
24. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, et al. Islet 
transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-
free immunosuppressive regimen. The New England journal of medicine 2000 Jul 
27;343(4):230-238. 
183 
 
 
25. Ryan EA, Lakey JR, Paty BW, Imes S, Korbutt GS, Kneteman NM, et al. 
Successful islet transplantation: continued insulin reserve provides long-term glycemic 
control. Diabetes 2002 Jul;51(7):2148-2157. 
 
26. Goss JA, Schock AP, Brunicardi FC, Goodpastor SE, Garber AJ, Soltes G, et al. 
Achievement of insulin independence in three consecutive type-1 diabetic patients via 
pancreatic islet transplantation using islets isolated at a remote islet isolation center. 
Transplantation 2002 Dec 27;74(12):1761-1766. 
 
27. Ricordi C. Islet transplantation: a brave new world. Diabetes 2003 
Jul;52(7):1595-1603. 
 
28. Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, et 
al. International trial of the Edmonton protocol for islet transplantation. The New 
England journal of medicine 2006 Sep 28;355(13):1318-1330. 
 
29. Bromberg JS, LeRoith D. Diabetes cure--is the glass half full? The New England 
journal of medicine 2006 Sep 28;355(13):1372-1374. 
 
30. Poggioli R, Faradji RN, Ponte G, Betancourt A, Messinger S, Baidal DA, et al. 
Quality of life after islet transplantation. Am J Transplant 2006 Feb;6(2):371-378. 
 
31. Gruessner AC, Sutherland DE. Pancreas transplant outcomes for United States 
(US) cases as reported to the United Network for Organ Sharing (UNOS) and the 
International Pancreas Transplant Registry (IPTR). Clinical transplants 2008:45-56. 
 
32. White SA, Shaw JA, Sutherland DE. Pancreas transplantation. Lancet 2009 May 
23;373(9677):1808-1817. 
 
33. Fiorina P, Venturini M, Folli F, Losio C, Maffi P, Placidi C, et al. Natural history of 
kidney graft survival, hypertrophy, and vascular function in end-stage renal disease type 
1 diabetic kidney-transplanted patients: beneficial impact of pancreas and successful 
islet cotransplantation. Diabetes care 2005 Jun;28(6):1303-1310. 
 
34. Lee TC, Barshes NR, O'Mahony CA, Nguyen L, Brunicardi FC, Ricordi C, et al. 
The effect of pancreatic islet transplantation on progression of diabetic retinopathy and 
neuropathy. Transplantation proceedings 2005 Jun;37(5):2263-2265. 
 
35. Fiorina P, Folli F, Zerbini G, Maffi P, Gremizzi C, Di Carlo V, et al. Islet 
transplantation is associated with improvement of renal function among uremic patients 
with type I diabetes mellitus and kidney transplants. J Am Soc Nephrol 2003 
Aug;14(8):2150-2158. 
 
184 
 
36. Wiseman AC. Simultaneous pancreas kidney transplantation: a critical appraisal 
of the risks and benefits compared with other treatment alternatives. Advances in 
chronic kidney disease 2009 Jul;16(4):278-287. 
 
37. Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, et al. Five-
year follow-up after clinical islet transplantation. Diabetes 2005 Jul;54(7):2060-2069. 
38. Leitao CB, Cure P, Tharavanij T, Baidal DA, Alejandro R. Current challenges in 
islet transplantation. Current diabetes reports 2008 Aug;8(4):324-331. 
 
39. Ryan EA, Bigam D, Shapiro AM. Current indications for pancreas or islet 
transplant. Diabetes, obesity & metabolism 2006 Jan;8(1):1-7. 
 
40. Babensee JE, McIntire LV, Anderson JM, Mikos AG. Host response to tissue 
engineered devices. Advanced drug delivery reviews 1998 Aug 3;33(1-2):111-139. 
 
41. Robitaille R, Dusseault J, Henley N, Desbiens K, Labrecque N, Halle JP. 
Inflammatory response to peritoneal implantation of alginate-poly-L-lysine 
microcapsules. Biomaterials 2005 Jul;26(19):4119-4127. 
 
42. Berney T, Molano RD, Cattan P, Pileggi A, Vizzardelli C, Oliver R, et al. 
Endotoxin-mediated delayed islet graft function is associated with increased intra-islet 
cytokine production and islet cell apoptosis. Transplantation 2001 Jan 15;71(1):125-
132. 
 
43. Matsuda T, Omori K, Vuong T, Pascual M, Valiente L, Ferreri K, et al. Inhibition 
of p38 pathway suppresses human islet production of pro-inflammatory cytokines and 
improves islet graft function. Am J Transplant 2005 Mar;5(3):484-493. 
 
44. Ehrnfelt C, Kumagai-Braesch M, Uzunel M, Holgersson J. Adult porcine islets 
produce MCP-1 and recruit human monocytes in vitro. Xenotransplantation 2004 
Mar;11(2):184-194. 
 
45. Chen MC, Proost P, Gysemans C, Mathieu C, Eizirik DL. Monocyte 
chemoattractant protein-1 is expressed in pancreatic islets from prediabetic NOD mice 
and in interleukin-1 beta-exposed human and rat islet cells. Diabetologia 2001 
Mar;44(3):325-332. 
 
46. Thomas HE, Darwiche R, Corbett JA, Kay TW. Interleukin-1 plus gamma-
interferon-induced pancreatic beta-cell dysfunction is mediated by beta-cell nitric oxide 
production. Diabetes 2002 Feb;51(2):311-316. 
 
47. Johansson U, Olsson A, Gabrielsson S, Nilsson B, Korsgren O. Inflammatory 
mediators expressed in human islets of Langerhans: implications for islet 
transplantation. Biochemical and biophysical research communications 2003 Aug 
29;308(3):474-479. 
 
185 
 
48. Anderson JM. Inflammatory response to implants. ASAIO transactions / 
American Society for Artificial Internal Organs 1988 Apr-Jun;34(2):101-107. 
 
49. Di Matteo MA, Loweth AC, Thomas S, Mabley JG, Morgan NG, Thorpe JR, et al. 
Superoxide, nitric oxide, peroxynitrite and cytokine combinations all cause functional 
impairment and morphological changes in rat islets of Langerhans and insulin secreting 
cell lines, but dictate cell death by different mechanisms. Apoptosis 1997;2(2):164-177. 
 
50. Rabinovitch A, Suarez-Pinzon WL. Cytokines and their roles in pancreatic islet 
beta-cell destruction and insulin-dependent diabetes mellitus. Biochemical 
pharmacology 1998 Apr 15;55(8):1139-1149. 
 
51. Jang JY, Lee DY, Park SJ, Byun Y. Immune reactions of lymphocytes and 
macrophages against PEG-grafted pancreatic islets. Biomaterials 2004 
Aug;25(17):3663-3669. 
 
52. Yoon JW, Jun HS, Santamaria P. Cellular and molecular mechanisms for the 
initiation and progression of beta cell destruction resulting from the collaboration 
between macrophages and T cells. Autoimmunity 1998;27(2):109-122. 
 
53. Wiegand F, Kroncke KD, Kolb-Bachofen V. Macrophage-generated nitric oxide 
as cytotoxic factor in destruction of alginate-encapsulated islets. Protection by arginine 
analogs and/or coencapsulated erythrocytes. Transplantation 1993 Nov;56(5):1206-
1212. 
 
54. Gill RG. Antigen presentation pathways for immunity to islet transplants. 
Relevance to immunoisolation. Annals of the New York Academy of Sciences 1999 Jun 
18;875:255-260. 
 
55. Gray DW. Encapsulated islet cells: the role of direct and indirect presentation and 
the relevance to xenotransplantation and autoimmune recurrence. British medical 
bulletin 1997;53(4):777-788. 
 
56. Wang Y, Pontesilli O, Gill RG, La Rosa FG, Lafferty KJ. The role of CD4+ and 
CD8+ T cells in the destruction of islet grafts by spontaneously diabetic mice. 
Proceedings of the National Academy of Sciences of the United States of America 1991 
Jan 15;88(2):527-531. 
 
57. Fulton B, Markham A. Mycophenolate mofetil. A review of its pharmacodynamic 
and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 1996 
Feb;51(2):278-298. 
 
58. Klintmalm GB, Goldstein R, Gonwa T, Wiesner RH, Krom RA, Shaw BW, Jr., et 
al. Prognostic factors for successful conversion from cyclosporine to FK 506-based 
immunosuppressive therapy for refractory rejection after liver transplantation. US 
186 
 
Multicenter FK 506 Liver Study Group. Transplantation proceedings 1993 Feb;25(1 Pt 
1):641-643. 
 
59. Faulds D, Goa KL, Benfield P. Cyclosporin. A review of its pharmacodynamic 
and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. 
Drugs 1993 Jun;45(6):953-1040. 
 
60. Stegall MD, Simon M, Wachs ME, Chan L, Nolan C, Kam I. Mycophenolate 
mofetil decreases rejection in simultaneous pancreas-kidney transplantation when 
combined with tacrolimus or cyclosporine. Transplantation 1997 Dec 27;64(12):1695-
1700. 
 
61. Cantarovich D, Vistoli F. Minimization protocols in pancreas transplantation. 
Transpl Int 2009 Jan;22(1):61-68. 
 
62. Algire GH. An adaption of the transparant chamber technique to the mouse. 
Journal of the National Cancer Institute 1943;4:1-11. 
 
63. Chick WL, Like AA, Lauris V. Beta cell culture on synthetic capillaries: an artificial 
endocrine pancreas. Science (New York, NY 1975 Mar 7;187(4179):847-849. 
 
64. Lim F, Sun AM. Microencapsulated islets as bioartificial endocrine pancreas. 
Science (New York, NY 1980 Nov 21;210(4472):908-910. 
 
65. de Vos P, Spasojevic M, Faas MM. Treatment of diabetes with encapsulated 
islets. Advances in experimental medicine and biology 2010;670:38-53. 
 
66. de Vos P, Marchetti P. Encapsulation of pancreatic islets for transplantation in 
diabetes: the untouchable islets. Trends Mol Med 2002 Aug;8(8):363-366. 
 
67. Sun AM, Parisius W, Healy GM, Vacek I, Macmorine HG. The use, in diabetic 
rats and monkeys, of artificial capillary units containing cultured islets of Langerhans 
(artificial endocrine pancreas). Diabetes 1977 Dec;26(12):1136-1139. 
 
68. Maki T, Lodge JP, Carretta M, Ohzato H, Borland KM, Sullivan SJ, et al. 
Treatment of severe diabetes mellitus for more than one year using a vascularized 
hybrid artificial pancreas. Transplantation 1993 Apr;55(4):713-717; discussion 717-718. 
 
69. Beck J, Angus R, Madsen B, Britt D, Vernon B, Nguyen KT. Islet encapsulation: 
strategies to enhance islet cell functions. Tissue Eng 2007 Mar;13(3):589-599. 
 
70. Wilson JT, Chaikof EL. Challenges and emerging technologies in the 
immunoisolation of cells and tissues. Advanced drug delivery reviews 2008 Jan 
14;60(2):124-145. 
 
187 
 
71. de Vos P, Hamel AF, Tatarkiewicz K. Considerations for successful 
transplantation of encapsulated pancreatic islets. Diabetologia 2002 Feb;45(2):159-173. 
 
72. Vandenbossche GM, Bracke ME, Cuvelier CA, Bortier HE, Mareel MM, Remon 
JP. Host reaction against empty alginate-polylysine microcapsules. Influence of 
preparation procedure. The Journal of pharmacy and pharmacology 1993 
Feb;45(2):115-120. 
73. Weber C, Ayres-Price J, Costanzo M, Becker A, Stall A. NOD mouse peritoneal 
cellular response to poly-L-lysine-alginate microencapsulated rat islets. Transplantation 
proceedings 1994 Jun;26(3):1116-1119. 
 
74. Trivedi N, Keegan M, Steil GM, Hollister-Lock J, Hasenkamp WM, Colton CK, et 
al. Islets in alginate macrobeads reverse diabetes despite minimal acute insulin 
secretory responses. Transplantation 2001 Jan 27;71(2):203-211. 
 
75. Soon-Shiong P, Feldman E, Nelson R, Heintz R, Yao Q, Yao Z, et al. Long-term 
reversal of diabetes by the injection of immunoprotected islets. Proceedings of the 
National Academy of Sciences of the United States of America 1993 Jun 
15;90(12):5843-5847. 
 
76. Sun Y, Ma X, Zhou D, Vacek I, Sun AM. Normalization of diabetes in 
spontaneously diabetic cynomologus monkeys by xenografts of microencapsulated 
porcine islets without immunosuppression. The Journal of clinical investigation 1996 
Sep 15;98(6):1417-1422. 
 
77. Leu FJ, Chen CF, Chiang WE, Chern HT, Shian LR, Chung TM, et al. 
Microencapsulated pancreatic islets: a pathologic study. Journal of the Formosan 
Medical Association = Taiwan yi zhi 1992 Sep;91(9):849-858. 
 
78. O'Shea GM, Goosen MF, Sun AM. Prolonged survival of transplanted islets of 
Langerhans encapsulated in a biocompatible membrane. Biochimica et biophysica acta 
1984 May 22;804(1):133-136. 
 
79. Strand BL, Ryan TL, In't Veld P, Kulseng B, Rokstad AM, Skjak-Brek G, et al. 
Poly-L-Lysine induces fibrosis on alginate microcapsules via the induction of cytokines. 
Cell transplantation 2001;10(3):263-275. 
 
80. Mallett AG, Korbutt GS. Alginate modification improves long-term survival and 
function of transplanted encapsulated islets. Tissue engineering 2009 Jun;15(6):1301-
1309. 
 
81. Langlois G, Dusseault J, Bilodeau S, Tam SK, Magassouba D, Halle JP. Direct 
effect of alginate purification on the survival of islets immobilized in alginate-based 
microcapsules. Acta biomaterialia 2009 Nov;5(9):3433-3440. 
 
188 
 
82. Hill RS, Cruise GM, Hager SR, Lamberti FV, Yu X, Garufis CL, et al. 
Immunoisolation of adult porcine islets for the treatment of diabetes mellitus. The use of 
photopolymerizable polyethylene glycol in the conformal coating of mass-isolated 
porcine islets. Annals of the New York Academy of Sciences 1997 Dec 31;831:332-343. 
 
83. Cruise GM, Hegre OD, Lamberti FV, Hager SR, Hill R, Scharp DS, et al. In vitro 
and in vivo performance of porcine islets encapsulated in interfacially photopolymerized 
poly(ethylene glycol) diacrylate membranes. Cell transplantation 1999 May-
Jun;8(3):293-306. 
 
84. Cruise GM, Hegre OD, Scharp DS, Hubbell JA. A sensitivity study of the key 
parameters in the interfacial photopolymerization of poly(ethylene glycol) diacrylate 
upon porcine islets. Biotechnology and bioengineering 1998 Mar 20;57(6):655-665. 
 
85. Cruise GM, Scharp DS, Hubbell JA. Characterization of permeability and network 
structure of interfacially photopolymerized poly(ethylene glycol) diacrylate hydrogels. 
Biomaterials 1998 Jul;19(14):1287-1294. 
 
86. Thrash M. Modeling oxygen transport in a cylindrical bioartificial pancreas. Asaio 
J 2010 Jul-Aug;56(4):338-343. 
 
87. Dufrane D, Goebbels RM, Gianello P. Alginate Macroencapsulation of Pig Islets 
Allows Correction of Streptozotocin-Induced Diabetes in Primates up to 6 Months 
Without Immunosuppression. Transplantation  Oct 22. 
 
88. Grundfest-Broniatowski SF, Tellioglu G, Rosenthal KS, Kang J, Erdodi G, Yalcin 
B, et al. A new bioartificial pancreas utilizing amphiphilic membranes for the 
immunoisolation of porcine islets: a pilot study in the canine. ASAIO J 2009 Jul-
Aug;55(4):400-405. 
 
89. Qi M, Gu Y, Sakata N, Kim D, Shirouzu Y, Yamamoto C, et al. PVA hydrogel 
sheet macroencapsulation for the bioartificial pancreas. Biomaterials 2004 
Dec;25(27):5885-5892. 
 
90. Weber LM, Anseth KS. Hydrogel encapsulation environments functionalized with 
extracellular matrix interactions increase islet insulin secretion. Matrix Biol 2008 
Oct;27(8):667-673. 
 
91. Weber LM, Hayda KN, Haskins K, Anseth KS. The effects of cell-matrix 
interactions on encapsulated beta-cell function within hydrogels functionalized with 
matrix-derived adhesive peptides. Biomaterials 2007 Jul;28(19):3004-3011. 
 
92. Weber LM, Hayda KN, Anseth KS. Cell-matrix interactions improve beta-cell 
survival and insulin secretion in three-dimensional culture. Tissue engineering 2008 
Dec;14(12):1959-1968. 
 
189 
 
93. Weber LM, Cheung CY, Anseth KS. Multifunctional pancreatic islet encapsulation 
barriers achieved via multilayer PEG hydrogels. Cell transplantation 2008;16(10):1049-
1057. 
 
94. Lin CC, Anseth KS. Glucagon-Like Peptide-1 Functionalized PEG Hydrogels 
Promote Survival and Function of Encapsulated Pancreatic beta-Cells. 
Biomacromolecules 2009 Sep;10(9):2460-2467. 
95. Hume PS. Polymerizable superoxide dismutase mimetic protects β-cells 
encapsulated in PEG hydrogels from reactive oxygen species-mediated damage. 
Tissue engineering 2011. 
 
96. Lin CC. Cell-cell communication mimicry with PEG hydrogels for enhancing Beta-
cell function. Proc Natl Acad Sci USA 2010 2010. 
 
97. Bryant SJ, Nuttelman CR, Anseth KS. Cytocompatibility of UV and visible light 
photoinitiating systems on cultured NIH/3T3 fibroblasts in vitro. J Biomater Sci Polym Ed 
2000;11(5):439-457. 
 
98. Lin CC, Metters AT, Anseth KS. Functional PEG-peptide hydrogels to modulate 
local inflammation induced by the pro-inflammatory cytokine TNFalpha. Biomaterials 
2009 Oct;30(28):4907-4914. 
 
99. Sun LT, Bencherif SA, Gilbert TW, Farkas AM, Lotze MT, Washburn NR. 
Biological activities of cytokine-neutralizing hyaluronic acid-antibody conjugates. Wound 
Repair Regen  May-Jun;18(3):302-310. 
 
100. Lin CC, Boyer PD, Aimetti AA, Anseth KS. Regulating MCP-1 diffusion in affinity 
hydrogels for enhancing immuno-isolation. J Control Release 2010 Mar 19;142(3):384-
391. 
 
101. Chae SY, Lee M, Kim SW, Bae YH. Protection of insulin secreting cells from 
nitric oxide induced cellular damage by crosslinked hemoglobin. Biomaterials 2004 
Feb;25(5):843-850. 
 
102. Cheung CY, McCartney SJ, Anseth K. Synthesis of Polymerizable Superoxide 
Dismutase Mimetics to Reduce Reactive Oxygen Species Damage in Transplanted 
Biomedical Devices. Advanced Functional Materials 2008;18:3119-3126. 
 
103. Bunger CM, Tiefenbach B, Jahnke A, Gerlach C, Freier T, Schmitz KP, et al. 
Deletion of the tissue response against alginate-pll capsules by temporary release of 
co-encapsulated steroids. Biomaterials 2005 May;26(15):2353-2360. 
 
104. Giovagnoli S, Blasi P, Luca G, Fallarino F, Calvitti M, Mancuso F, et al. Bioactive 
long-term release from biodegradable microspheres preserves implanted ALG-PLO-
ALG microcapsules from in vivo response to purified alginate. Pharmaceutical research 
2010 Feb;27(2):285-295. 
190 
 
 
105. Baruch L, Benny O, Gilert A, Ukobnik M, Ben Itzhak O, Machluf M. Alginate-PLL 
cell encapsulation system Co-entrapping PLGA-microspheres for the continuous 
release of anti-inflammatory drugs. Biomedical microdevices 2009 Jun 11. 
 
106. Yu DG, Branford-White C, Shen XX, Zhang XF, Zhu LM. Solid Dispersions of 
Ketoprofen in Drug-Loaded Electrospun Nanofibers. J Dispersion Sci Technol 
2010;31(7):902-908. 
 
107. Yu DG, Branford-White C, White K, Li XL, Zhu LM. Dissolution Improvement of 
Electrospun Nanofiber-Based Solid Dispersions for Acetaminophen. AAPS 
PharmSciTech  Jun;11(2):809-817. 
 
108. Aimetti AA, Tibbitt MW, Anseth KS. Human neutrophil elastase responsive 
delivery from poly(ethylene glycol) hydrogels. Biomacromolecules 2009 Jun 
8;10(6):1484-1489. 
 
109. Takeda Y, Gotoh M, Dono K, Nishihara M, Grochowiecki T, Kimura F, et al. 
Protection of islet allografts transplanted together with Fas ligand expressing testicular 
allografts. Diabetologia 1998 Mar;41(3):315-321. 
 
110. Korbutt GS, Elliott JF, Rajotte RV. Cotransplantation of allogeneic islets with 
allogeneic testicular cell aggregates allows long-term graft survival without systemic 
immunosuppression. Diabetes 1997 Feb;46(2):317-322. 
 
111. Dufour JM, Rajotte RV, Kin T, Korbutt GS. Immunoprotection of rat islet 
xenografts by cotransplantation with sertoli cells and a single injection of antilymphocyte 
serum. Transplantation 2003 May 15;75(9):1594-1596. 
 
112. Valdes-Gonzalez RA, Dorantes LM, Garibay GN, Bracho-Blanchet E, Mendez 
AJ, Davila-Perez R, et al. Xenotransplantation of porcine neonatal islets of Langerhans 
and Sertoli cells: a 4-year study. Eur J Endocrinol 2005 Sep;153(3):419-427. 
 
113. Dufour JM, Rajotte RV, Korbutt GS, Emerich DF. Harnessing the 
immunomodulatory properties of Sertoli cells to enable xenotransplantation in type I 
diabetes. Immunol Invest 2003 Nov;32(4):275-297. 
 
114. Suarez-Pinzon W, Korbutt GS, Power R, Hooton J, Rajotte RV, Rabinovitch A. 
Testicular sertoli cells protect islet beta-cells from autoimmune destruction in NOD mice 
by a transforming growth factor-beta1-dependent mechanism. Diabetes 2000 
Nov;49(11):1810-1818. 
 
115. Abdi R, Fiorina P, Adra CN, Atkinson M, Sayegh MH. Immunomodulation by 
mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes 
2008 Jul;57(7):1759-1767. 
 
191 
 
116. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal 
stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses 
independently of the major histocompatibility complex. Scand J Immunol 2003 
Jan;57(1):11-20. 
 
117. Tyndall A, Walker UA, Cope A, Dazzi F, De Bari C, Fibbe W, et al. 
Immunomodulatory properties of mesenchymal stem cells: a review based on an 
interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, 
London, UK, 31 October 2005. Arthritis Res Ther 2007;9(1):301. 
 
118. Tibbitt MW, Anseth KS. Hydrogels as extracellular matrix mimics for 3D cell 
culture. Biotechnology and bioengineering 2009 Jul 1;103(4):655-663. 
 
119. Ito Y. Surface micropatterning to regulate cell functions. Biomaterials 1999 
Dec;20(23-24):2333-2342. 
 
120. Lynn AD, Kyriakides TR, Bryant SJ. Characterization of the in vitro macrophage 
response and in vivo host response to poly(ethylene glycol)-based hydrogels. Journal of 
biomedical materials research 2010 Jun 1;93(3):941-953. 
 
121. Kou PM, Babensee JE. Macrophage and dendritic cell phenotypic diversity in the 
context of biomaterials. Journal of biomedical materials research 2010 Jan;96(1):239-
260. 
 
122. Babensee JE. Interaction of dendritic cells with biomaterials. Seminars in 
immunology 2008 Apr;20(2):101-108. 
 
123. Acharya AP, Dolgova NV, Moore NM, Xia CQ, Clare-Salzler MJ, Becker ML, et 
al. The modulation of dendritic cell integrin binding and activation by RGD-peptide 
density gradient substrates. Biomaterials 2011 Oct;31(29):7444-7454. 
 
124. Cheung CY, Anseth KS. Synthesis of immunoisolation barriers that provide 
localized immunosuppression for encapsulated pancreatic islets. Bioconjug Chem 2006 
Jul-Aug;17(4):1036-1042. 
 
125. Leclerc C, Brose C, Nouze C, Leonard F, Majlessi L, Becker S, et al. Immobilized 
cytokines as biomaterials for manufacturing immune cell based vaccines. Journal of 
biomedical materials research 2008 Sep 15;86(4):1033-1040. 
 
 
8.2   Chapter 2 references 
1. Cheung CY, McCartney SJ, Anseth K. Synthesis of Polymerizable Superoxide 
Dismutase Mimetics to Reduce Reactive Oxygen Species Damage in Transplanted 
Biomedical Devices. Advanced Functional Materials 2008;18:3119-3126. 
 
192 
 
2. Sebra RP, Masters KS, Bowman CN, Anseth KS. Surface grafted antibodies: 
controlled architecture permits enhanced antigen detection. Langmuir 2005 Nov 
22;21(24):10907-10911. 
 
3. Sebra RP, Masters KS, Cheung CY, Bowman CN, Anseth KS. Detection of 
antigens in biologically complex fluids with photografted whole antibodies. Anal Chem 
2006 May 1;78(9):3144-3151. 
 
4. Johnson LM, Fairbanks BD, Anseth KS, Bowman CN. Enzyme-mediated redox 
initiation for hydrogel generation and cellular encapsulation. Biomacromolecules 2009 
Nov 9;10(11):3114-3121. 
 
5. Johnson LM, Deforest CA, Pendurti A, Anseth KS, Bowman CN. Formation of 
three-dimensional hydrogel multilayers using enzyme-mediated redox chain initiation. 
ACS applied materials & interfaces 2010 Jul;2(7):1963-1972. 
 
 
8.3   Chapter 3 references 
1. Kelly WD, Lillehei RC, Merkel FK, Idezuki Y, Goetz FC. Allotransplantation of the 
pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery 1967 
Jun;61(6):827-837. 
 
2. Scharp DW, Lacy PE, Santiago JV, McCullough CS, Weide LG, Falqui L, et al. 
Insulin independence after islet transplantation into type I diabetic patient. Diabetes 
1990 Apr;39(4):515-518. 
 
3. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, et al. Islet 
transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-
free immunosuppressive regimen. The New England journal of medicine 2000 Jul 
27;343(4):230-238. 
 
4. Pavlakis M, Khwaja K. Pancreas and islet cell transplantation in diabetes. 
Current opinion in endocrinology, diabetes, and obesity 2007 Apr;14(2):146-150. 
 
5. White SA, Shaw JA, Sutherland DE. Pancreas transplantation. Lancet 2009 May 
23;373(9677):1808-1817. 
 
6. Gremizzi C, Vergani A, Paloschi V, Secchi A. Impact of pancreas transplantation 
on type 1 diabetes-related complications. Current opinion in organ transplantation 2010 
Feb;15(1):119-123. 
 
7. Tyden G, Reinholt FP, Sundkvist G, Bolinder J. Recurrence of autoimmune 
diabetes mellitus in recipients of cadaveric pancreatic grafts. The New England journal 
of medicine 1996 Sep 19;335(12):860-863. 
193 
 
 
8. Bertuzzi F, Ricordi C. Beta-cell replacement in immunosuppressed recipients: old 
and new clinical indications. Acta diabetologica 2007 Dec;44(4):171-176. 
 
9. Ryan EA, Bigam D, Shapiro AM. Current indications for pancreas or islet 
transplant. Diabetes, obesity & metabolism 2006 Jan;8(1):1-7. 
 
10. Chick WL, Like AA, Lauris V. Beta cell culture on synthetic capillaries: an artificial 
endocrine pancreas. Science (New York, NY 1975 Mar 7;187(4179):847-849. 
 
11. Wilson JT, Chaikof EL. Challenges and emerging technologies in the 
immunoisolation of cells and tissues. Advanced drug delivery reviews 2008 Jan 
14;60(2):124-145. 
 
12. de Vos P, Hamel AF, Tatarkiewicz K. Considerations for successful 
transplantation of encapsulated pancreatic islets. Diabetologia 2002 Feb;45(2):159-173. 
 
13. Cui H, Tucker-Burden C, Cauffiel SM, Barry AK, Iwakoshi NN, Weber CJ, et al. 
Long-term metabolic control of autoimmune diabetes in spontaneously diabetic 
nonobese diabetic mice by nonvascularized microencapsulated adult porcine islets. 
Transplantation 2009 Jul 27;88(2):160-169. 
 
14. Cruise GM, Hegre OD, Lamberti FV, Hager SR, Hill R, Scharp DS, et al. In vitro 
and in vivo performance of porcine islets encapsulated in interfacially photopolymerized 
poly(ethylene glycol) diacrylate membranes. Cell transplantation 1999 May-
Jun;8(3):293-306. 
 
15. Weber LM, Hayda KN, Anseth KS. Cell-matrix interactions improve beta-cell 
survival and insulin secretion in three-dimensional culture. Tissue engineering 2008 
Dec;14(12):1959-1968. 
 
16. Weber LM, Anseth KS. Hydrogel encapsulation environments functionalized with 
extracellular matrix interactions increase islet insulin secretion. Matrix Biol 2008 
Oct;27(8):667-673. 
 
17. Lin CC, Anseth KS. Glucagon-Like Peptide-1 Functionalized PEG Hydrogels 
Promote Survival and Function of Encapsulated Pancreatic beta-Cells. 
Biomacromolecules 2009 Sep;10(9):2460-2467. 
 
18. Jang JY, Lee DY, Park SJ, Byun Y. Immune reactions of lymphocytes and 
macrophages against PEG-grafted pancreatic islets. Biomaterials 2004 
Aug;25(17):3663-3669. 
 
19. de Vos P, Marchetti P. Encapsulation of pancreatic islets for transplantation in 
diabetes: the untouchable islets. Trends Mol Med 2002 Aug;8(8):363-366. 
 
194 
 
20. Mohseni Salehi Monfared SS, Larijani B, Abdollahi M. Islet transplantation and 
antioxidant management: a comprehensive review. World J Gastroenterol 2009 Mar 
14;15(10):1153-1161. 
 
21. Hadjivassiliou V, Green MH, James RF, Swift SM, Clayton HA, Green IC. Insulin 
secretion, DNA damage, and apoptosis in human and rat islets of Langerhans following 
exposure to nitric oxide, peroxynitrite, and cytokines. Nitric Oxide 1998;2(6):429-441. 
 
22. Di Matteo MA, Loweth AC, Thomas S, Mabley JG, Morgan NG, Thorpe JR, et al. 
Superoxide, nitric oxide, peroxynitrite and cytokine combinations all cause functional 
impairment and morphological changes in rat islets of Langerhans and insulin secreting 
cell lines, but dictate cell death by different mechanisms. Apoptosis 1997;2(2):164-177. 
 
23. Delaney CA, Tyrberg B, Bouwens L, Vaghef H, Hellman B, Eizirik DL. Sensitivity 
of human pancreatic islets to peroxynitrite-induced cell dysfunction and death. FEBS 
letters 1996 Oct 7;394(3):300-306. 
 
24. Muscoli C, Cuzzocrea S, Riley DP, Zweier JL, Thiemermann C, Wang ZQ, et al. 
On the selectivity of superoxide dismutase mimetics and its importance in 
pharmacological studies. British journal of pharmacology 2003 Oct;140(3):445-460. 
 
25. Weringer EJ, Like AA. Diabetes mellitus in the BB/W rat. Insulitis in pancreatic 
islet grafts after transplantation in diabetic recipients. The American journal of pathology 
1986 Oct;125(1):107-112. 
 
26. Yoon JW, Jun HS, Santamaria P. Cellular and molecular mechanisms for the 
initiation and progression of beta cell destruction resulting from the collaboration 
between macrophages and T cells. Autoimmunity 1998;27(2):109-122. 
 
27. Haskins K, Bradley B, Powers K, Fadok V, Flores S, Ling X, et al. Oxidative 
stress in type 1 diabetes. Annals of the New York Academy of Sciences 2003 
Nov;1005:43-54. 
 
28. Lenzen S, Drinkgern J, Tiedge M. Low antioxidant enzyme gene expression in 
pancreatic islets compared with various other mouse tissues. Free radical biology & 
medicine 1996;20(3):463-466. 
 
29. Ho E, Bray TM. Antioxidants, NFkappaB activation, and diabetogenesis. 
Proceedings of the Society for Experimental Biology and Medicine Society for 
Experimental Biology and Medicine (New York, NY 1999 Dec;222(3):205-213. 
 
30. Tyrberg B, Eizirik DL, Marklund SL, Olejnicka B, Madsen OD, Andersson A. 
Human islets in mixed islet grafts protect mouse pancreatic beta-cells from alloxan 
toxicity. Pharmacology & toxicology 1999 Dec;85(6):269-275. 
 
195 
 
31. Grankvist K, Marklund S, Taljedal IB. Superoxide dismutase is a prophylactic 
against alloxan diabetes. Nature 1981 Nov 12;294(5837):158-160. 
 
32. Piganelli JD, Flores SC, Cruz C, Koepp J, Batinic-Haberle I, Crapo J, et al. A 
metalloporphyrin-based superoxide dismutase mimic inhibits adoptive transfer of 
autoimmune diabetes by a diabetogenic T-cell clone. Diabetes 2002 Feb;51(2):347-355. 
 
33. Nomikos IN, Wang Y, Lafferty KJ. Involvement of O2 radicals in 'autoimmune' 
diabetes. Immunology and cell biology 1989 Feb;67 ( Pt 1):85-87. 
 
34. Salvemini D, Riley DP, Cuzzocrea S. SOD mimetics are coming of age. Nature 
reviews 2002 May;1(5):367-374. 
 
35. Pasternack RF, Banth A, Pasternack JM, Johnson CS. Catalysis of the 
disproportionation of superoxide by metalloporphyrins. III. Journal of inorganic 
biochemistry 1981 Nov;15(3):261-267. 
 
36. Benov L, Batinic-Haberle I. A manganese porphyrin suppresses oxidative stress 
and extends the life span of streptozotocin-diabetic rats. Free radical research 2005 
Jan;39(1):81-88. 
 
37. Szabo C, Day BJ, Salzman AL. Evaluation of the relative contribution of nitric 
oxide and peroxynitrite to the suppression of mitochondrial respiration in 
immunostimulated macrophages using a manganese mesoporphyrin superoxide 
dismutase mimetic and peroxynitrite scavenger. FEBS letters 1996 Feb 26;381(1-2):82-
86. 
 
38. Day BJ, Fridovich I, Crapo JD. Manganic porphyrins possess catalase activity 
and protect endothelial cells against hydrogen peroxide-mediated injury. Archives of 
biochemistry and biophysics 1997 Nov 15;347(2):256-262. 
 
39. Nakaoka R, Tabata Y, Yamaoka T, Ikada Y. Prolongation of the serum half-life 
period of superoxide dismutase by poly(ethylene glycol) modification. J Control Release 
1997 Jun;46(3):253-261. 
 
40. Kojima Y, Akaike T, Sato K, Maeda H, Hirano T. Polymer conjugation to Cu,Zn-
SOD and suppression of hydroxyl radical generation on exposure to H2O2: Improved 
stability of SOD in vitro and in vivo. J Bioact Compat Polym 1996 Jul;11(3):169-190. 
 
41. Li Z, Wang F, Roy S, Sen CK, Guan J. Injectable, highly flexible, and 
thermosensitive hydrogels capable of delivering superoxide dismutase. 
Biomacromolecules 2009 Dec 14;10(12):3306-3316. 
 
42. Chiumiento A, Dominguez A, Lamponi S, Villalonga R, Barbucci R. Anti-
inflammatory properties of superoxide dismutase modified with carboxymetil-cellulose 
polymer and hydrogel. Journal of materials science 2006 May;17(5):427-435. 
196 
 
 
43. Chiumiento A, Lamponi S, Barbucci R, Dominguez A, Perez Y, Villalonga R. 
Immobilizing Cu,Zn-superoxide dismutase in hydrogels of carboxymethylcellulose 
improves its stability and wound healing properties. Biochemistry (Mosc) 2006 
Dec;71(12):1324-1328. 
 
44. Cheung CY, McCartney SJ, Anseth KS. Synthesis of Polymerizable Superoxide 
Dismutase Mimetics to Reduce Reactive Oxygen Species Damage in Transplanted 
Biomedical Devices. Advanced Functional Materials 2008 Oct;18(20):3119-3126. 
 
45. McCord JM, Fridovich I. Superoxide dismutase. An enzymic function for 
erythrocuprein (hemocuprein). J Biol Chem 1969 Nov 25;244(22):6049-6055. 
 
46. Cohen HJ, Chovaniec ME. Superoxide generation by digitonin-stimulated guinea 
pig granulocytes. A basis for a continuous assay for monitoring superoxide production 
and for the study of the activation of the generating system. The Journal of clinical 
investigation 1978 Apr;61(4):1081-1087. 
 
47. Choi SY, Ha H, Kim KT. Capsaicin inhibits platelet-activating factor-induced 
cytosolic Ca2+ rise and superoxide production. J Immunol 2000 Oct 1;165(7):3992-
3998. 
 
48. Cruise GM, Scharp DS, Hubbell JA. Characterization of permeability and network 
structure of interfacially photopolymerized poly(ethylene glycol) diacrylate hydrogels. 
Biomaterials 1998 Jul;19(14):1287-1294. 
 
49. Lin CC, Boyer PD, Aimetti AA, Anseth KS. Regulating MCP-1 diffusion in affinity 
hydrogels for enhancing immuno-isolation. J Control Release 2010 Mar 19;142(3):384-
391. 
 
50. Su J, Hu BH, Lowe WL, Jr., Kaufman DB, Messersmith PB. Anti-inflammatory 
peptide-functionalized hydrogels for insulin-secreting cell encapsulation. Biomaterials  
Jan;31(2):308-314. 
 
51. Weber LM, Hayda KN, Haskins K, Anseth KS. The effects of cell-matrix 
interactions on encapsulated beta-cell function within hydrogels functionalized with 
matrix-derived adhesive peptides. Biomaterials 2007 Jul;28(19):3004-3011. 
 
52. Gabler WL, Creamer HR, Bullock WW. Modulation of the kinetics of induced 
neutrophil superoxide generation by fluoride. Journal of dental research 1986 
Sep;65(9):1159-1165. 
 
53. Luther MJ, Davies E, Muller D, Harrison M, Bone AJ, Persaud SJ, et al. Cell-to-
cell contact influences proliferative marker expression and apoptosis in MIN6 cells 
grown in islet-like structures. American journal of physiology 2005 Mar;288(3):E502-
509. 
197 
 
 
54. Hauge-Evans AC, Squires PE, Persaud SJ, Jones PM. Pancreatic beta-cell-to-
beta-cell interactions are required for integrated responses to nutrient stimuli: enhanced 
Ca2+ and insulin secretory responses of MIN6 pseudoislets. Diabetes 1999 
Jul;48(7):1402-1408. 
 
55. Konstantinova I, Nikolova G, Ohara-Imaizumi M, Meda P, Kucera T, Zarbalis K, 
et al. EphA-Ephrin-A-mediated beta cell communication regulates insulin secretion from 
pancreatic islets. Cell 2007 Apr 20;129(2):359-370. 
 
56. Lin CC. Cell-cell communication mimicry with PEG hydrogels for enhancing Beta-
cell function. Proc Natl Acad Sci USA 2010 2010. 
 
57. Kavdia M, Lewis RS. Free radical profiles in an encapsulated pancreatic cell 
matrix model. Annals of biomedical engineering 2002 May;30(5):721-730. 
58. Uchiyama T, Kiritoshi Y, Watanabe J, Ishihara K. Degradation of phospholipid 
polymer hydrogel by hydrogen peroxide aiming at insulin release device. Biomaterials 
2003 Dec;24(28):5183-5190. 
 
59. Lin CC, Metters AT, Anseth KS. Functional PEG-peptide hydrogels to modulate 
local inflammation induced by the pro-inflammatory cytokine TNFalpha. Biomaterials 
2009 Oct;30(28):4907-4914. 
 
60. Cheung CY, Anseth KS. Synthesis of immunoisolation barriers that provide 
localized immunosuppression for encapsulated pancreatic islets. Bioconjug Chem 2006 
Jul-Aug;17(4):1036-1042. 
 
61. Hume PS, Anseth KS. Inducing local T cell apoptosis with anti-Fas-functionalized 
polymeric coatings fabricated via surface-initiated photopolymerizations. Biomaterials 
2010 Apr;31(12):3166-3174. 
 
 
8.4   Chapter 4 references  
1. Wollert KC, Drexler H. Cell-based therapy for heart failure. Curr Opin Cardiol 
2006;21(3):234-239. 
 
2. Emerich DF, Winn SR. Immunoisolation cell therapy for CNS diseases. Crit Rev 
Ther Drug Carrier Syst 2001;18(3):265-298. 
 
3. Lee MK, Bae YH. Cell transplantation for endocrine disorders. Adv Drug Deliv 
Rev 2000;42(1-2):103-120. 
 
4. Wilson JT, Chaikof EL. Challenges and emerging technologies in the 
immunoisolation of cells and tissues. Adv Drug Deliv Rev 2008;60(2):124-145. 
 
198 
 
5. Lim F, Sun AM. Microencapsulated islets as bioartificial endocrine pancreas. 
Science 1980;210(4472):908-910. 
 
6. Kabelitz D, Geissler EK, Soria B, Schroeder IS, Fandrich F, Chatenoud L. 
Toward cell-based therapy of type I diabetes. Trends Immunol 2008;29(2):68-74. 
 
7. de Vos P, Marchetti P. Encapsulation of pancreatic islets for transplantation in 
diabetes: the untouchable islets. Trends Mol Med 2002;8(8):363-366. 
 
8. Mandrup-Poulsen T, Zumsteg U, Reimers J, Pociot F, Morch L, Helqvist S, et al. 
Involvement of interleukin 1 and interleukin 1 antagonist in pancreatic beta-cell 
destruction in insulin-dependent diabetes mellitus. Cytokine 1993;5(3):185-191. 
 
9. Jang JY, Lee DY, Park SJ, Byun Y. Immune reactions of lymphocytes and 
macrophages against PEG-grafted pancreatic islets. Biomaterials 2004;25(17):3663-
3669. 
 
10. Lee DY, Park SJ, Lee S, Nam JH, Byun Y. Highly poly(ethylene) glycolylated 
islets improve long-term islet allograft survival without immunosuppressive medication. 
Tissue Eng 2007;13(8):2133-2141. 
 
11. Cui H, Tucker-Burden C, Cauffiel SM, Barry AK, Iwakoshi NN, Weber CJ, et al. 
Long-term metabolic control of autoimmune diabetes in spontaneously diabetic 
nonobese diabetic mice by nonvascularized microencapsulated adult porcine islets. 
Transplantation 2009;88(2):160-169. 
 
12. Yun Lee D, Hee Nam J, Byun Y. Functional and histological evaluation of 
transplanted pancreatic islets immunoprotected by PEGylation and cyclosporine for 1 
year. Biomaterials 2007;28(11):1957-1966. 
 
13. Cheung CY, McCartney SJ, Anseth K. Synthesis of Polymerizable Superoxide 
Dismutase Mimetics to Reduce Reactive Oxygen Species Damage in Transplanted 
Biomedical Devices. Adv Funct Mater 2008;18:3119-3126. 
 
14. Leung A, Lawrie G, Nielsen LK, Trau M. Synthesis and characterization of 
alginate/poly-L-ornithine/alginate microcapsules for local immunosuppression. J 
Microencapsul 2008;25(6):387-398. 
 
15. Lin CC, Metters AT, Anseth KS. Functional PEG-peptide hydrogels to modulate 
local inflammation induced by the pro-inflammatory cytokine TNFalpha. Biomaterials 
2009;30(28):4907-4914. 
 
16. Cheung CY, Anseth KS. Synthesis of immunoisolation barriers that provide 
localized immunosuppression for encapsulated pancreatic islets. Bioconjug Chem 
2006;17(4):1036-1042. 
 
199 
 
17. Palmer E. Negative selection--clearing out the bad apples from the T-cell 
repertoire. Nat Rev Immunol 2003;3(5):383-391. 
 
18. Nagata S, Golstein P. The Fas death factor. Science 1995;267(5203):1449-1456. 
 
19. Siegel RM, Frederiksen JK, Zacharias DA, Chan FK, Johnson M, Lynch D, et al. 
Fas preassociation required for apoptosis signaling and dominant inhibition by 
pathogenic mutations. Science 2000;288(5475):2354-2357. 
 
20. Holler N, Tardivel A, Kovacsovics-Bankowski M, Hertig S, Gaide O, Martinon F, 
et al. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a 
death-inducing signaling complex. Mol Cell Biol 2003;23(4):1428-1440. 
 
21. Cifone MG, De Maria R, Roncaioli P, Rippo MR, Azuma M, Lanier LL, et al. 
Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase. J 
Exp Med 1994;180(4):1547-1552. 
 
22. Moreno JB, Margraf S, Schuller AM, Simon A, Moritz A, Scholz M. Inhibition of 
neutrophil activity in cardiac surgery with cardiopulmonary bypass: a novel strategy with 
the leukocyte inhibition module. Perfusion 2004;19(1):11-16. 
 
23. Scholz M, Simon A, Berg M, Schuller AM, Hacibayramoglu M, Margraf S, et al. In 
vivo inhibition of neutrophil activity by a FAS (CD95) stimulating module: arterial in-line 
application in a porcine cardiac surgery model. J Thorac Cardiovasc Surg 
2004;127(6):1735-1742. 
 
24. Otsu T. Iniferter concept and living radical polymerization. J Polym Sci Pol Chem 
2000;38(12):2121-2136. 
 
25. Sebra RP, Masters KS, Bowman CN, Anseth KS. Surface grafted antibodies: 
controlled architecture permits enhanced antigen detection. Langmuir 
2005;21(24):10907-10911. 
 
26. Sebra RP, Masters KS, Cheung CY, Bowman CN, Anseth KS. Detection of 
antigens in biologically complex fluids with photografted whole antibodies. Anal Chem 
2006;78(9):3144-3151. 
 
27. Juo P, Kuo CJ, Yuan J, Blenis J. Essential requirement for caspase-8/FLICE in 
the initiation of the Fas-induced apoptotic cascade. Curr Biol 1998;8(18):1001-1008. 
 
28. Juo P, Woo MS, Kuo CJ, Signorelli P, Biemann HP, Hannun YA, et al. FADD is 
required for multiple signaling events downstream of the receptor Fas. Cell Growth 
Differ 1999;10(12):797-804. 
 
29. Dustin ML, Bivona TG, Philips MR. Membranes as messengers in T cell 
adhesion signaling. Nat Immunol 2004;5(4):363-372. 
200 
 
 
30. Sieg S, Smith D, Kaplan D. Differential activity of soluble versus cellular Fas 
ligand: regulation by an accessory molecule. Cell Immunol 1999;195(2):89-95. 
 
31. Somersalo K, Anikeeva N, Sims TN, Thomas VK, Strong RK, Spies T, et al. 
Cytotoxic T lymphocytes form an antigen-independent ring junction. J Clin Invest 
2004;113(1):49-57. 
 
32. Weis M, Schlegel J, Kass GE, Holmstrom TH, Peters I, Eriksson J, et al. Cellular 
events in Fas/APO-1-mediated apoptosis in JURKAT T lymphocytes. Exp Cell Res 
1995;219(2):699-708. 
 
33. Yang L, Froio RM, Sciuto TE, Dvorak AM, Alon R, Luscinskas FW. ICAM-1 
regulates neutrophil adhesion and transcellular migration of TNF-alpha-activated 
vascular endothelium under flow. Blood 2005;106(2):584-592. 
 
34. Smith CW, Marlin SD, Rothlein R, Toman C, Anderson DC. Cooperative 
interactions of LFA-1 and Mac-1 with intercellular adhesion molecule-1 in facilitating 
adherence and transendothelial migration of human neutrophils in vitro. J Clin Invest 
1989;83(6):2008-2017. 
 
35. Simms MG, Walley KR. Activated macrophages decrease rat cardiac myocyte 
contractility: importance of ICAM-1-dependent adhesion. Am J Physiol 1999;277(1 Pt 
2):H253-260. 
 
36. Patel SS, Thiagarajan R, Willerson JT, Yeh ET. Inhibition of alpha4 integrin and 
ICAM-1 markedly attenuate macrophage homing to atherosclerotic plaques in ApoE-
deficient mice. Circulation 1998;97(1):75-81. 
 
37. Brown SB, Savill J. Phagocytosis triggers macrophage release of Fas ligand and 
induces apoptosis of bystander leukocytes. J Immunol 1999;162(1):480-485. 
 
38. Liles WC, Kiener PA, Ledbetter JA, Aruffo A, Klebanoff SJ. Differential 
expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for 
the regulation of apoptosis in neutrophils. J Exp Med 1996;184(2):429-440. 
 
39. Richardson BC, Lalwani ND, Johnson KJ, Marks RM. Fas ligation triggers 
apoptosis in macrophages but not endothelial cells. Eur J Immunol 1994;24(11):2640-
2645. 
 
 
  
201 
 
8.5   Chapter 5 references 
 
1. Wilson JT, Chaikof EL. Challenges and emerging technologies in the 
immunoisolation of cells and tissues. Advanced drug delivery reviews 2008 Jan 
14;60(2):124-145. 
 
2. White SA, Shaw JA, Sutherland DE. Pancreas transplantation. Lancet 2009 May 
23;373(9677):1808-1817. 
 
3. Pavlakis M, Khwaja K. Pancreas and islet cell transplantation in diabetes. 
Current opinion in endocrinology, diabetes, and obesity 2007 Apr;14(2):146-150. 
 
4. Gremizzi C, Vergani A, Paloschi V, Secchi A. Impact of pancreas transplantation 
on type 1 diabetes-related complications. Current opinion in organ transplantation 2010 
Feb;15(1):119-123. 
 
5. de Vos P, Marchetti P. Encapsulation of pancreatic islets for transplantation in 
diabetes: the untouchable islets. Trends Mol Med 2002 Aug;8(8):363-366. 
 
6. de Vos P, Hamel AF, Tatarkiewicz K. Considerations for successful 
transplantation of encapsulated pancreatic islets. Diabetologia 2002 Feb;45(2):159-173. 
 
7. Jang JY, Lee DY, Park SJ, Byun Y. Immune reactions of lymphocytes and 
macrophages against PEG-grafted pancreatic islets. Biomaterials 2004 
Aug;25(17):3663-3669. 
 
8. Kulseng B, Thu B, Espevik T, Skjak-Braek G. Alginate polylysine microcapsules 
as immune barrier: permeability of cytokines and immunoglobulins over the capsule 
membrane. Cell transplantation 1997 Jul-Aug;6(4):387-394. 
 
9. Lin CC, Metters AT, Anseth KS. Functional PEG-peptide hydrogels to modulate 
local inflammation induced by the pro-inflammatory cytokine TNFalpha. Biomaterials 
2009 Oct;30(28):4907-4914. 
 
10. Leung A, Lawrie G, Nielsen LK, Trau M. Synthesis and characterization of 
alginate/poly-L-ornithine/alginate microcapsules for local immunosuppression. J 
Microencapsul 2008 Sep;25(6):387-398. 
 
202 
 
11. Cheung CY, McCartney SJ, Anseth K. Synthesis of Polymerizable Superoxide 
Dismutase Mimetics to Reduce Reactive Oxygen Species Damage in Transplanted 
Biomedical Devices. Advanced Functional Materials 2008;18:3119-3126. 
 
12. Chiumiento A, Lamponi S, Barbucci R, Dominguez A, Perez Y, Villalonga R. 
Immobilizing Cu,Zn-superoxide dismutase in hydrogels of carboxymethylcellulose 
improves its stability and wound healing properties. Biochemistry (Mosc) 2006 
Dec;71(12):1324-1328. 
 
13. Li Z, Wang F, Roy S, Sen CK, Guan J. Injectable, highly flexible, and 
thermosensitive hydrogels capable of delivering superoxide dismutase. 
Biomacromolecules 2009 Dec 14;10(12):3306-3316. 
 
14. Giovagnoli S, Blasi P, Luca G, Fallarino F, Calvitti M, Mancuso F, et al. Bioactive 
long-term release from biodegradable microspheres preserves implanted ALG-PLO-
ALG microcapsules from in vivo response to purified alginate. Pharmaceutical research 
2010 Feb;27(2):285-295. 
 
15. Aimetti AA, Tibbitt MW, Anseth KS. Human neutrophil elastase responsive 
delivery from poly(ethylene glycol) hydrogels. Biomacromolecules 2009 Jun 
8;10(6):1484-1489. 
 
16. Ricci M, Blasi P, Giovagnoli S, Rossi C, Macchiarulo G, Luca G, et al. Ketoprofen 
controlled release from composite microcapsules for cell encapsulation: effect on post-
transplant acute inflammation. J Control Release 2005 Oct 20;107(3):395-407. 
 
17. Bunger CM, Tiefenbach B, Jahnke A, Gerlach C, Freier T, Schmitz KP, et al. 
Deletion of the tissue response against alginate-pll capsules by temporary release of 
co-encapsulated steroids. Biomaterials 2005 May;26(15):2353-2360. 
 
18. Hume PS, Anseth KS. Inducing local T cell apoptosis with anti-Fas-functionalized 
polymeric coatings fabricated via surface-initiated photopolymerizations. Biomaterials 
2010 Apr;31(12):3166-3174. 
 
19. Cheung CY, Anseth KS. Synthesis of immunoisolation barriers that provide 
localized immunosuppression for encapsulated pancreatic islets. Bioconjug Chem 2006 
Jul-Aug;17(4):1036-1042. 
 
20. Kabelitz D, Geissler EK, Soria B, Schroeder IS, Fandrich F, Chatenoud L. 
Toward cell-based therapy of type I diabetes. Trends Immunol 2008 Feb;29(2):68-74. 
203 
 
 
21. Cifone MG, De Maria R, Roncaioli P, Rippo MR, Azuma M, Lanier LL, et al. 
Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase. J 
Exp Med 1994 Oct 1;180(4):1547-1552. 
 
22. van de Stolpe A, van der Saag PT. Intercellular adhesion molecule-1. J Mol Med 
1996 Jan;74(1):13-33. 
 
23. Sebra RP, Masters KS, Bowman CN, Anseth KS. Surface grafted antibodies: 
controlled architecture permits enhanced antigen detection. Langmuir 2005 Nov 
22;21(24):10907-10911. 
 
24. Cruise GM, Hegre OD, Lamberti FV, Hager SR, Hill R, Scharp DS, et al. In vitro 
and in vivo performance of porcine islets encapsulated in interfacially photopolymerized 
poly(ethylene glycol) diacrylate membranes. Cell transplantation 1999 May-
Jun;8(3):293-306. 
 
25. Weber LM, Anseth KS. Hydrogel encapsulation environments functionalized with 
extracellular matrix interactions increase islet insulin secretion. Matrix Biol 2008 
Oct;27(8):667-673. 
 
26. Lin CC, Anseth KS. Glucagon-Like Peptide-1 Functionalized PEG Hydrogels 
Promote Survival and Function of Encapsulated Pancreatic beta-Cells. 
Biomacromolecules 2009 Sep;10(9):2460-2467. 
 
27. Pearl-Yafe M, Yolcu ES, Yaniv I, Stein J, Shirwan H, Askenasy N. The dual role 
of Fas-ligand as an injury effector and defense strategy in diabetes and islet 
transplantation. Bioessays 2006 Feb;28(2):211-222. 
 
28. Weber LM, Cheung CY, Anseth KS. Multifunctional pancreatic islet encapsulation 
barriers achieved via multilayer PEG hydrogels. Cell transplantation 2008;16(10):1049-
1057. 
 
29. Hahn MS, Taite LJ, Moon JJ, Rowland MC, Ruffino KA, West JL. 
Photolithographic patterning of polyethylene glycol hydrogels. Biomaterials 2006 
Apr;27(12):2519-2524. 
 
30. Hynd MR, Frampton JP, Burnham MR, Martin DL, Dowell-Mesfin NM, Turner JN, 
et al. Functionalized hydrogel surfaces for the patterning of multiple biomolecules. 
Journal of biomedical materials research 2007 May;81(2):347-354. 
204 
 
 
31. Zhang HB, Shepherd JNH, Nuzzo RG. Microfluidic contact printing: a versatile 
printing platform for patterning biomolecules on hydrogel substrates. Soft 
Matter;6(10):2238-2245. 
 
32. Johnson LM, Deforest CA, Pendurti A, Anseth KS, Bowman CN. Formation of 
three-dimensional hydrogel multilayers using enzyme-mediated redox chain initiation. 
ACS applied materials & interfaces 2010 Jul;2(7):1963-1972. 
 
33. Johnson LM, Fairbanks BD, Anseth KS, Bowman CN. Enzyme-mediated redox 
initiation for hydrogel generation and cellular encapsulation. Biomacromolecules 2009 
Nov 9;10(11):3114-3121. 
 
34. Hume PS. Polymerizable superoxide dismutase mimetic protects β-cells 
encapsulated in PEG hydrogels from reactive oxygen species-mediated damage. 
Tissue engineering 2011. 
 
35. Salinas CN, Anseth KS. Mixed mode thiol-acrylate photopolymerizations for the 
synthesis of PEG-peptide hydrogels. Macromolecules 2008 Aug;41(16):6019-6026. 
 
36. Lin CC. Cell-cell communication mimicry with PEG hydrogels for enhancing Beta-
cell function. Proc Natl Acad Sci USA 2010 2011. 
 
37. Dustin ML, Bivona TG, Philips MR. Membranes as messengers in T cell 
adhesion signaling. Nat Immunol 2004 Apr;5(4):363-372. 
 
38. Sieg S, Smith D, Kaplan D. Differential activity of soluble versus cellular Fas 
ligand: regulation by an accessory molecule. Cell Immunol 1999 Aug 1;195(2):89-95. 
 
39. Tsuge H, Natsuaki O, Ohashi K. Purification, properties, and molecular features 
of glucose oxidase from Aspergillus niger. Journal of biochemistry 1975 Oct;78(4):835-
843. 
 
40. Cruise GM, Scharp DS, Hubbell JA. Characterization of permeability and network 
structure of interfacially photopolymerized poly(ethylene glycol) diacrylate hydrogels. 
Biomaterials 1998 Jul;19(14):1287-1294. 
 
  
205 
 
8.6   Chapter 6 references 
1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 
1998 Mar 19;392(6673):245-252. 
 
2. Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant 
tolerance. Nat Rev Immunol 2007 Aug;7(8):610-621. 
 
3. Matzinger P. An innate sense of danger. Seminars in immunology 1998 
Oct;10(5):399-415. 
 
4. van Kooten C, Lombardi G, Gelderman KA, Sagoo P, Buckland M, Lechler R, et 
al. Dendritic Cells as a Tool to Induce Transplantation Tolerance: Obstacles and 
Opportunities. Transplantation 2011 Jan;91(1):2-7. 
 
5. Babensee JE. Interaction of dendritic cells with biomaterials. Seminars in 
immunology 2008 Apr;20(2):101-108. 
 
6. Babensee JE, Paranjpe A. Differential levels of dendritic cell maturation on 
different biomaterials used in combination products. Journal of biomedical materials 
research 2005 Sep 15;74(4):503-510. 
 
7. Acharya AP, Dolgova NV, Clare-Salzler MJ, Keselowsky BG. Adhesive 
substrate-modulation of adaptive immune responses. Biomaterials 2008 
Dec;29(36):4736-4750. 
 
8. Rogers TH, Babensee JE. The role of integrins in the recognition and response 
of dendritic cells to biomaterials. Biomaterials 2011 Feb;32(5):1270-1279. 
 
9. Hubbell JA, Thomas SN, Swartz MA. Materials engineering for 
immunomodulation. Nature 2009 Nov 26;462(7272):449-460. 
 
10. Norton LW, Park J, Babensee JE. Biomaterial adjuvant effect is attenuated by 
anti-inflammatory drug delivery or material selection. J Control Release 2010 Sep 
15;146(3):341-348. 
 
11. Hackstein H, Thomson AW. Dendritic cells: emerging pharmacological targets of 
immunosuppressive drugs. Nat Rev Immunol 2004 Jan;4(1):24-34. 
 
12. Kosiewicz MM, Alard P. Tolerogenic antigen-presenting cells: regulation of the 
immune response by TGF-beta-treated antigen-presenting cells. Immunologic research 
2004;30(2):155-170. 
 
13. Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH. Induction of tolerance by IL-
10-treated dendritic cells. J Immunol 1997 Nov 15;159(10):4772-4780. 
14. Sato K, Nagayama H, Tadokoro K, Juji T, Takahashi TA. Extracellular signal-
regulated kinase, stress-activated protein kinase/c-Jun N-terminal kinase, and p38mapk 
206 
 
are involved in IL-10-mediated selective repression of TNF-alpha-induced activation and 
maturation of human peripheral blood monocyte-derived dendritic cells. J Immunol 1999 
Apr 1;162(7):3865-3872. 
 
15. Torres-Aguilar H, Aguilar-Ruiz SR, Gonzalez-Perez G, Munguia R, Bajana S, 
Meraz-Rios MA, et al. Tolerogenic dendritic cells generated with different 
immunosuppressive cytokines induce antigen-specific anergy and regulatory properties 
in memory CD4+ T cells. J Immunol  Feb 15;184(4):1765-1775. 
 
16. Ito Y. Surface micropatterning to regulate cell functions. Biomaterials 1999 
Dec;20(23-24):2333-2342. 
 
17. Hirano Y, Mooney DJ. Peptide and protein presenting materials for tissue 
engineering. Adv Mater 2004 Jan;16(1):17-25. 
 
18. Mann BK, Schmedlen RH, West JL. Tethered-TGF-beta increases extracellular 
matrix production of vascular smooth muscle cells. Biomaterials 2001 Mar;22(5):439-
444. 
 
19. Cheung CY, Anseth KS. Synthesis of immunoisolation barriers that provide 
localized immunosuppression for encapsulated pancreatic islets. Bioconjug Chem 2006 
Jul-Aug;17(4):1036-1042. 
 
20. Hume PS, Anseth KS. Inducing local T cell apoptosis with anti-Fas-functionalized 
polymeric coatings fabricated via surface-initiated photopolymerizations. Biomaterials 
2010 Apr;31(12):3166-3174. 
 
21. Leclerc C, Brose C, Nouze C, Leonard F, Majlessi L, Becker S, et al. Immobilized 
cytokines as biomaterials for manufacturing immune cell based vaccines. Journal of 
biomedical materials research 2008 Sep 15;86(4):1033-1040. 
 
22. Jiang X, Shen C, Rey-Ladino J, Yu H, Brunham RC. Characterization of murine 
dendritic cell line JAWS II and primary bone marrow-derived dendritic cells in Chlamydia 
muridarum antigen presentation and induction of protective immunity. Infection and 
immunity 2008 Jun;76(6):2392-2401. 
 
23. Jorgensen TN, Haase C, Michelsen BK. Treatment of an immortalized APC cell 
line with both cytokines and LPS ensures effective T-cell activation in vitro. Scand J 
Immunol 2002 Nov;56(5):492-503. 
 
24. Otsu S, Gotoh K, Yamashiro T, Yamagata J, Shin K, Fujioka T, et al. Transfer of 
antigen-pulsed dendritic cells induces specific T-Cell proliferation and a therapeutic 
effect against long-term Helicobacter pylori infection in mice. Infection and immunity 
2006 Feb;74(2):984-993. 
207 
 
25. Pinchuk LM, Lee SR, Filipov NM. In vitro atrazine exposure affects the 
phenotypic and functional maturation of dendritic cells. Toxicol Appl Pharmacol 2007 
Sep 15;223(3):206-217. 
 
26. Langmuir PB, Bridgett MM, Bothwell AL, Crispe IN. Bone marrow abnormalities 
in the non-obese diabetic mouse. Int Immunol 1993 Feb;5(2):169-177. 
 
27. Peng R, Bathjat K, Li Y, Clare-Salzler MJ. Defective maturation of myeloid 
dendritic cell (DC) in NOD mice is controlled by IDD10/17/18. Annals of the New York 
Academy of Sciences 2003 Nov;1005:184-186. 
 
28. Lin CC, Anseth KS. Controlling Affinity Binding with Peptide-Functionalized 
Poly(ethylene glycol) Hydrogels. Adv Funct Mater 2009 Jul 24;19(14):2325. 
 
29. Clarke DC, Brown ML, Erickson RA, Shi Y, Liu X. Transforming growth factor 
beta depletion is the primary determinant of Smad signaling kinetics. Molecular and 
cellular biology 2009 May;29(9):2443-2455. 
 
30. He J, Haskins K. Pathogenicity of T helper 2 T-cell clones from T-cell receptor 
transgenic non-obese diabetic mice is determined by tumour necrosis factor-alpha. 
Immunology 2008 Jan;123(1):108-117. 
 
31. Poulin M, Haskins K. Induction of diabetes in nonobese diabetic mice by Th2 T 
cell clones from a TCR transgenic mouse. J Immunol 2000 Mar 15;164(6):3072-3078. 
 
32. Traut RR, Bollen A, Sun TT, Hershey JWB, Sundberg J, Pierce LR. METHYL 4-
MERCAPTOBUTYRIMIDATE AS A CLEAVABLE CROSSLINKING REAGENT AND ITS 
APPLICATION TO ESCHERICHIA-COLI 30S RIBOSOME. Biochemistry 
1973;12(17):3266-3273. 
 
33. Salinas CN, Anseth KS. Mixed mode thiol-acrylate photopolymerizations for the 
synthesis of PEG-peptide hydrogels. Macromolecules 2008 Aug;41(16):6019-6026. 
 
34. Cruise GM, Scharp DS, Hubbell JA. Characterization of permeability and network 
structure of interfacially photopolymerized poly(ethylene glycol) diacrylate hydrogels. 
Biomaterials 1998 Jul;19(14):1287-1294. 
 
35. Acharya AP, Dolgova NV, Xia CQ, Clare-Salzler MJ, Keselowsky BG. Adhesive 
substrates modulate the activation and stimulatory capacity of non-obese diabetic 
mouse-derived dendritic cells. Acta biomaterialia 2010 Jan;7(1):180-192. 
 
36. Zhu J. Bioactive modification of poly(ethylene glycol) hydrogels for tissue 
engineering. Biomaterials 2010 Jun;31(17):4639-4656. 
 
208 
 
37. Mant A, Tourniaire G, Diaz-Mochon JJ, Elliott TJ, Williams AP, Bradley M. 
Polymer microarrays: identification of substrates for phagocytosis assays. Biomaterials 
2006 Oct;27(30):5299-5306. 
 
38. Jenney CR, Anderson JM. Adsorbed serum proteins responsible for surface 
dependent human macrophage behavior. J Biomed Mater Res 2000 Mar 15;49(4):435-
447. 
 
39. Wang GX, Deng XY, Tang CJ, Liu LS, Xiao L, Xiang LH, et al. The adhesive 
properties of endothelial cells on endovascular stent coated by substrates of poly-l-
lysine and fibronectin. Artificial cells, blood substitutes, and immobilization 
biotechnology 2006;34(1):11-25. 
 
40. Kou PM, Babensee JE. Macrophage and dendritic cell phenotypic diversity in the 
context of biomaterials. Journal of biomedical materials research 2010 Jan;96(1):239-
260. 
 
 
